

1 DR. GILMAN: Well, the dosing regimen was  
2 different. We are told it was in the ball park of 12.

3 DR. KATZ: But it was given every month. It's a  
4 much shorter--

5 DR. GILMAN: That's right, that's right.

6 DR. WOLINSKY: If I could come back and reiterate  
7 what I said before, I think it is conceivable--but we don't  
8 have this data--it is conceivable with the aggressive dosing  
9 that was done in the French study, possibly for a less long  
10 period of time, that one conceivably could get the same  
11 results, but we just don't know that. So in that sense,  
12 voting or not voting, I think the data we have before us  
13 certainly gives us some feeling for what the limits of  
14 dosing ought to be.

15 DR. GILMAN: Does anybody else--voting members--  
16 want to make a comment about that question that Dr. Katz has  
17 posed?

18 Dr. Kawas?

19 DR. KAWAS: I just want to say I wouldn't have a  
20 clue what would be the best dose to give a patient of this  
21 drug or the frequency with which to give it. And even  
22 though I am convinced that there is probably a clinical  
23 effect of this drug, I think there is a lot of question  
24 about the dosing and the frequency--a lot of question.

25 DR. GILMAN: Dr. Temple?

1 DR. TEMPLE: There is no doubt about that. I  
2 can't imagine that by the time people who haven't yet been  
3 treated roll around to the end of their 2 years, we can't  
4 have reasonable data on what happens if you continue  
5 therapy, and I'm sure we'll make sure that those data are  
6 collected. So that at least ought to be known. Either you  
7 do really have to stop at 140, or you don't, and we don't  
8 know the answer to that yet. And it's not exactly  
9 undiscoverable. There are people who must be approaching  
10 that dose now who can be studied.

11 DR. PENN: It sounds like the usual FDA thing of  
12 wanting to kill the dog to make sure you know where the  
13 toxicity is, and I'm not sure that the company will be  
14 overjoyed at running studies over 140, so I'm not sure  
15 that's going to really get done.

16 The question of the exact dose, we can never  
17 answer. It would take many studies to try to do that.  
18 That's why they had their Phase I and II, to make a guess.

19 DR. GILMAN: Dr. Grundman?

20 DR. GRUNDMAN: Just going back to the EDSS scores  
21 on M-38, you know, the Mitoxantrone at 5 mg had a more rapid  
22 and more consistent effect than the Mitoxantrone at 12 mg,  
23 and we don't have data on the MRI on the Mito-5 in the  
24 second study.

25 DR. GILMAN: That is absolutely correct. Again,

1 the sponsor's aim was to use 12, and they wanted to use 5  
2 just to see whether there was a greater effect at 12 than at  
3 5.

4 DR. GRUNDMAN: There was.

5 DR. GILMAN: Well, for that one marker, there was  
6 not.

7 DR. GRUNDMAN: The other markers were unblinded.

8 DR. GILMAN: Correct. But we've dealt with that.  
9 We simply don't know the answer to that.

10 DR. TEMPLE: No--there was a better effect on two  
11 of the other blinded markers--somewhat better. It wasn't  
12 all that different, but it was leaning.

13 Just as an observation, the third-year data from  
14 24 to 36 months, if I read it correctly, showed that people  
15 began to get worse again; they didn't lose the entire  
16 effect, but the trend lines if you were to draw them showed  
17 that the disease started to recur, progression started to  
18 recur, or whatever the right word is.

19 It is hard for me to imagine that people won't be  
20 interested in knowing whether they could prevent that. We  
21 don't know the answer yet, but wouldn't that be interesting?

22 DR. WEINER: I think that what you're going to see  
23 happening is that one will try to prevent that by using  
24 other drugs at that time rather than by using more of the  
25 Mitoxantrone is what I would predict.

1 DR. GILMAN: Dr. Grotta?

2 DR. GROTTA: Well, in struggling to try to compare  
3 the two studies, if you look at Table M-40 and Table M-64,  
4 they both look at the same--admittedly, the patients are  
5 different in the two studies--but they look at the  
6 percentage of patients who change more than or equal to one  
7 point on the EDSS, which to me is the most understandable  
8 outcome. That is Number 40 and 64. And to me, what you are  
9 trying to prevent is worsening, so if you look at the  
10 percentage of patients who worsened in the Mito-12 category  
11 in 901, it was 8 percent compared to 25 percent in placebo,  
12 and in 902, it was 5 percent in the Mito plus  
13 methylprednisolone versus 29 percent in placebo.

14 Clinically, at least, they are roughly comparable,  
15 and I don't think we have enough information to say that one  
16 is better than the other--although you are quite right--  
17 maybe it is better to front-end-load it, but again, that's  
18 not the question we're being asked, and I don't really see  
19 that much of a difference to say that we shouldn't be at  
20 this point approving the dose that is requested.

21 DR. WOLINSKY: Those two tables, of course, have  
22 very different time lines.

23 DR. GILMAN: Exactly. One was monthly dosing, the  
24 other was three-monthly dosing. Six months versus 2 to 3  
25 years total duration of study. So I'm not sure they are

1 comparable at all. All right.

2 Again, I have to ask Dr. Temple, Dr. Katz, are  
3 there any other question you want us to address, because we  
4 are going to come to the question about requested approval.

5 DR. KATZ: One more which has to do with the fact  
6 that all the studies were done in Europe, and there were no  
7 domestic studies. I'd just like to know if people think  
8 that's okay, if patients are the same, the standard of care  
9 is pretty much the same, and the results in these studies  
10 would be relevant and transferrable to the domestic  
11 population.

12 DR. GILMAN: I don't personally see a problem with  
13 that. It appears that Study 901 was well-designed. There  
14 was some unblinding that I think could have been done a bit  
15 better, that is, inappropriately unblinded aspects to the  
16 study, but it looks as if the scales used were the scales  
17 that would be used in this country, except for SNS. We did  
18 not hear about validation of that scale. I can't really  
19 comment on it, but it has been used in Germany for 10 years,  
20 we hear. I don't think any of us around this table has a  
21 bit of experience with it, anyway--or do we? Does anybody  
22 have experience with the SNS?

23 [No response.]

24 DR. GILMAN: No. But to answer your question, I  
25 am pretty comfortable with it.

1           Anybody else?

2           DR. WEINER: I would echo that. I am comfortable  
3 with it.

4           DR. GILMAN: Anything else, then? Dr. Katz, Dr.  
5 Temple, anything else?

6           DR. KATZ: No. Thank you.

7           DR. TEMPLE: No.

8           DR. GILMAN: All right.

9           The sponsor now requests approval for the  
10 following: To slow progression of neurological disability  
11 and reduce the relapse rate in patient with progressive  
12 forms of multiple sclerosis, excluding primary progressive  
13 multiple sclerosis.

14           So the question that we are asked--that is, the  
15 voting members of the Committee--is: Has the sponsor  
16 submitted substantial evidence of effectiveness to support  
17 their proposed indication?

18           Members of the Committee who are going to vote on  
19 this are Drs. Kawas, Penn, Van Belle, Grotta, Lacey, Penix  
20 and Gilman.

21           I think there ought to be a bit of discussion to  
22 lay the groundwork for our vote.

23           Dr. Grotta?

24           DR. GROTTA: I assume that our vote does not  
25 necessarily endorse this exact wording, but rather the

1 spirit of the wording according to the discussions we have  
2 had?

3 DR. GILMAN: Precisely, yes. They will alter the  
4 wording for the package insert if we are in approval, but  
5 there are two points to this. One is the relapse, and the  
6 second is disability, slowing the progression of  
7 neurological disability. We could take them separately if  
8 anybody wishes to; I think we could take them together  
9 myself.

10 DR. KAWAS: Just in terms of the spirit, I planned  
11 on voting no for that question, because as it is worded, I  
12 feel very uncomfortable with it. As a neurologist who  
13 doesn't take care of MS patients, but I think the average  
14 neurologist would interpret it as it is worded right now for  
15 a different form the disease to do something for patients  
16 differently than the drugs that are currently available, and  
17 although I do believe there is evidence of effectiveness of  
18 this drug, it is not clear to me personally that it does  
19 anything or provides anything other than an additional  
20 armamentarium to the neurologist.

21 So how this is worded is very important to how I  
22 would vote, and maybe I need to have a better idea than what  
23 we are really being asked now with Question Number 1 as  
24 opposed to Question Number 2.

25 DR. GILMAN: Would it help you if we separated the

1 two parts--to slow the progression of neurological  
2 disability, talk about that, and then talk about reducing  
3 the relapse rate?

4 DR. KAWAS: No. Probably the two parts that  
5 bother me the most are I don't like "slow the progression of  
6 neurologic disability," but I also don't like the  
7 "progressive multiple sclerosis" term. As you have heard  
8 today, I think a lot of people interpret that as a different  
9 form of disease that provides a completely new indication,  
10 whereas the drugs that are available don't do that.

11 DR. GILMAN: How would it sit with you if we said  
12 "to slow worsening of neurological disability," et cetera,  
13 "with worsening forms of multiple sclerosis"?

14 DR. KAWAS: That's getting better.

15 DR. PENN: I like it as it is for the reasons I  
16 have said, but I don't know how everybody else feels about  
17 it.

18 DR. GILMAN: We could go around the table and see  
19 what people think.

20 DR. GROTTA: I'd recommend we take a vote on how  
21 it is, and if it doesn't pass, then maybe we can wrestle  
22 with amendments.

23 DR. GILMAN: Yes. It's going to be wordsmithing,  
24 then, which I am a little bit uncomfortable with here.

25 Dr. Temple?

1 DR. TEMPLE: Obviously, people think the term  
2 "progression" carries extra freight, and we don't have to  
3 use that term. "Worsening" is fine, if that general idea  
4 sounds better to people. And I think we are totally  
5 convinced that the term "progressive multiple sclerosis" is  
6 ambiguous, so we could substitute "worsening" and put in  
7 parentheses the two subtypes, which as I understand it--tell  
8 me where I am wrong--are secondary progressive MS or  
9 relapsing remitting with worsening, or something like that.

10 That describes the population. It doesn't carry  
11 any implication about what you are doing at the micro or  
12 histologic level; it just says, I would have thought, what  
13 was shown, if that's in fact what you think has been shown.

14 DR. GILMAN: I tend to agree with that. It is  
15 close to the data, so I like that wording.

16 Dr. Grotta?

17 DR. GROTTA: In that case, I had written up a  
18 slight amendment if you want me to read it.

19 DR. GILMAN: Go ahead.

20 DR. GROTTA: "To slow accumulated neurological  
21 disability and reduce the relapse rate in patients with  
22 clinically worsening, secondary progressive or relapsing  
23 multiple sclerosis."

24 DR. GILMAN: It should be "relapsing remitting";  
25 right?

1 DR. GROTTA: All right. Close, but no cigar.

2 DR. GILMAN: Right. We are wordsmithing. Could  
3 we have that again?

4 DR. GROTTA: "To slow accumulated neurological  
5 disability and reduce the relapse rate in patients with  
6 clinically worsening, secondary progressive or relapsing  
7 remitting multiple sclerosis."

8 DR. TEMPLE: The only thing wrong with that is  
9 that relapsing remitting comes in two flavors.

10 DR. GROTTA: Well, "clinically worsening,  
11 secondary progressive or relapsing remitting multiple  
12 sclerosis."

13 DR. TEMPLE: Gotcha.

14 DR. WOLINSKY: What I think was studied in these  
15 trials are patients with relapsing remitting and secondary  
16 progressive disease with rapidly accumulating deficits.

17 DR. GILMAN: How rapid is "rapid"?

18 DR. WOLINSKY: The trials actually define that.

19 DR. KATZ: Again, my view would be that the use of  
20 a modifier like "rapidly" is really open to interpretation,  
21 even if in the clinical trials section of labeling we  
22 actually say what the data are. My personal view would be  
23 to stay away from that sort of language.

24 DR. PENIX: I like this modification. It does  
25 help clarify the point somewhat. But there should be some

1 leeway. Physicians and patients should have some--we can't  
2 characterize the intensity of the disease, so I think that  
3 if we got rid of that "rapidly progressing," or did not  
4 include that--in other words, I support Dr. Grotta's  
5 amendment.

6 DR. GILMAN: Yes, I think it helps very much  
7 myself.

8 Are there any other comments about that?

9 Dr. Temple?

10 DR. TEMPLE: Just to get your words right, would  
11 you say the very first part of the sentence again?

12 DR. GROTTA: "To slow accumulated neurological  
13 disability"--

14 DR. TEMPLE: Okay. I have a question. Do you  
15 slow accumulated neurological disability, or do you reduce  
16 it? You slow worsening--

17 DR. GROTTA: I'll defer to the group.

18 DR. WEINER: You could say "slow the accumulation  
19 of"--that's what you're saying.

20 DR. TEMPLE: Well, it starts to get a little  
21 complicated, but I think we could work on that.

22 You like the term "accumulated neurological  
23 disability" in preference to "worsening neurological  
24 disability"--there is a preference there?

25 DR. GROTTA: We are using "worsening" later in the

1 definition because we're seeing clinical worsening, and Dr.  
2 Wolinsky proposed that what we are really doing--it's the  
3 amount of neurologic disability that accumulates as a result  
4 of their disease that we are either slowing or preventing.  
5 I think the drug does seem to slow it. The rate of  
6 development of the neurological deficit seems to be  
7 retarded. Now, the question is it permanently retarded or  
8 not, we don't need to address in this, but it does seem to  
9 slow it.

10 DR. TEMPLE: Okay. I'm just checking. You like  
11 the concept of "accumulated neurological disability" as  
12 opposed to "worsening neurological disability"--I realize  
13 the inelegance of using the same word twice in the same  
14 sentence.

15 DR. GILMAN: What does "accumulated" mean, though?

16 DR. TEMPLE: Don't ask me.

17 DR. GILMAN: That's a serious question.

18 DR. GROTTA: Well, again, if somebody has visual  
19 loss, hemipareses and ataxia, they are accumulating a number  
20 of different neurological deficits, so it doesn't prevent  
21 any one of them. In total, your score tests the global  
22 function of the patient, and you are preventing their  
23 disability. That's obviously only one way to say it, and if  
24 someone has a better suggestion--but it seems to me  
25 "accumulated neurological"--

1 DR. GILMAN: I think the problem is that you're  
2 saying there is an accumulation of different systems into  
3 the mix. But what about the patient who simply has a  
4 worsening EDSS because the gait becomes worse and worse and  
5 worse--is that still "accumulating"? Why not just  
6 "worsening," so that you can get around this equivocation or  
7 lack of clarity?

8 Dr. Katz?

9 DR. KATZ: Yes. I have a pretty good sense, I  
10 believe, even though no vote has been taken yet, of what the  
11 Committee thinks the drug does and what the data don't speak  
12 to. I have worded the question this way to get the  
13 Committee's sense of what you think the drug does, and I  
14 think I have that sense--I think we have that sense.

15 If you would permit us, we can work on language  
16 with the company and I'm sure we can come to some mutual  
17 agreement, incorporating your views about what you think the  
18 drug does. So if you just want to vote to say if there is  
19 substantial evidence for a reasonable claim for MS or some  
20 generic language, I'd be happy with a vote on that, and  
21 we'll work on the language, the specifics, if that meets  
22 with your approval.

23 DR. GILMAN: Approved.

24 DR. WEINER: I would just like to make a comment.  
25 I don't know the name of the doctor sitting right next to

1 you--

2 DR. GILMAN: Dr. Kawas.

3 DR. WEINER: --yes--I would also support some of  
4 the comments that you made in the fact that this is not  
5 something unique to progressive MS that has never been shown  
6 before per se, but I support some of your comments.

7 DR. GILMAN: Well, all the same, I think we should  
8 take a vote. If the voting members of the Committee are  
9 comfortable with what we just heard from Dr. Katz, it will  
10 be something close to what Dr. Grotta said. I would prefer  
11 not to have the word "accumulating" in there, because that's  
12 not clear to me, but if it is "worsening," all right.

13 Is there any further discussion, or shall we vote?

14 [No response.]

15 DR. GILMAN: All those in favor--there should be  
16 seven votes--the question is has the sponsor submitted  
17 substantial evidence of effectiveness to support their  
18 proposed indication, and the proposed indication is as  
19 modified, as we have discussed--"worsening of neurological  
20 disability," et cetera. All right?

21 All those who say yes, the sponsor has submitted  
22 evidence, please raise your hands.

23 [A show of hands.]

24 DR. GILMAN: So it is unanimous.

25 Let's move on, then. If not, then--well, we have,

1 so we can drop Question 2.

2                   Question 3: Has the sponsor submitted sufficient  
3 safety data?

4                   In my view, yes, but let me hear from the rest of  
5 the Committee and from our consultants.

6                   DR. WEINER: I would say yes.

7                   DR. WOLINSKY: Yes. I think they have convinced  
8 me that they will do a good job in limiting us.

9                   DR. GILMAN: Committee members, any discussion of  
10 this?

11                  DR. KAWAS: Once again for me, at least, the  
12 wording is very important. I think it is crucial that  
13 additional data is collected even if this drug were approved  
14 and available, in post-marketing and other ways. I feel  
15 that there are a lot of questions that haven't been answered  
16 yet in terms of safety in the long run and maintaining  
17 dosage.

18                  This drug looks to me like it does what other  
19 drugs available for MS do, but the toxicity looks to me like  
20 it has the potential to be greater in the long run, and we  
21 won't know that without looking further.

22                  DR. GILMAN: Can you elaborate a little on some of  
23 your concerns? You said long-term safety data--is that what  
24 you are referring to--say, 5 years' experience. We did hear  
25 about some accumulated data over 10 years or so.

1 DR. KAWAS: Primarily my concern would be over a  
2 long duration and high-dose usage, yes.

3 DR. GILMAN: Could you define "long duration"?

4 DR. KAWAS: We have seen data when this was  
5 administered over 2 years, and I guess, presumably, that's  
6 what would be recommended. And I guess, presumably, it  
7 would also be recommended that nobody get another course of  
8 this ever again. I mean, people with MS have MS when they  
9 are 20, and they still have it when they are 40 and when  
10 they are 60 and when they are 80, and we don't have any way  
11 of knowing whether or not additional dosage regimens or  
12 anything like that is appropriate. Everybody knows that  
13 physicians kind of so whatever they want, in spite of what  
14 is on the package insert, and I think it would be very  
15 useful to have an idea of what would happen if they gave  
16 another dosage to this.

17 The one patient who received two regimens of this  
18 of 155 mg cumulative and 120 mg was a 40-year-old who were  
19 are told died.

20 DR. GILMAN: Dr. Penix?

21 DR. PENIX: The representatives of Immunex have  
22 indicated that they would, but I would certainly like to see  
23 a specific cap set and also some guidelines about patient  
24 monitoring, in specific, both in regard to the cardiac  
25 function and in regard to the hematologic monitoring.

1 DR. GILMAN: Are we ready for the vote? All  
2 right.

3 All those who believe the sponsor has submitted  
4 sufficient safety data of the voting members, please raise  
5 your hands.

6 [A show of hands.]

7 DR. GILMAN: Six.

8 All those who do not believe that sufficient data  
9 on safety has been submitted?

10 [One hand raised.]

11 DR. GILMAN: One. One opposes that notion.

12 Now, are there any other questions that the  
13 Division wants us to address? Dr. Katz?

14 Dr. Kawas?

15 DR. KAWAS: Actually, maybe it's an extension of  
16 the safety issue, but I thought the Division also asked us  
17 to consider whether there should be restrictions on the way  
18 the drug was given out and by whom.

19 DR. GILMAN: Thank you. Yes, they did. The  
20 question is whether this drug should be administered by  
21 oncologists only, or should neurologists who have license,  
22 essentially, have the capacity to give it.

23 Dr. Penn?

24 DR. PENN: I was hoping you would include  
25 neurosurgeons in this category. I think it is a danger to

1 give specific information like that, to restrict the drug in  
2 that way, and it depends on the education of the doctors who  
3 do it. I think that if the company puts an emphasis on  
4 education, then there are a great number of people who could  
5 potentially use this safely--even nurse practitioners, if  
6 you don't mind my saying so.

7 DR. GILMAN: I would tend to agree that, really,  
8 it depends upon the education, sensitivity, knowledge base,  
9 and care of the treating physician, not necessarily how that  
10 person has been boarded, as it were, but let me hear the  
11 other members of the Committee talk about that.

12 Dr. Penix?

13 DR. PENIX: I agree. I think that perhaps people  
14 are concerned about the lack of treatable diseases that  
15 neurologists have taken care of. But clearly, in our  
16 experience, the MS physicians are dedicated and have a great  
17 deal of experience in taking care of these patients and also  
18 will be primarily responsible for following their clinical  
19 outcome. So I think there should not be any restrictions.

20 DR. GILMAN: Is that unanimous?

21 Dr. Kawas?

22 DR. KAWAS: I think it's a mistake to say that  
23 this is going to be given out by MS physicians. I mean,  
24 most of us around this table come from academic centers, so  
25 we get into this notion of thinking that every doctor takes

1 care of only one disease. But the majority of this is going  
2 to be given out by people who are a little more broad than  
3 that, including internists and other doctors.

4 I'm not so sure that I would suggest a restriction  
5 based on specialty, however, but how about some kind of  
6 registry restriction? I believe, for example, there is a  
7 precedent with Clozaril where anybody who goes through the  
8 paperwork or whatever potentially can distribute the drug,  
9 but going through the paperwork ensures an education  
10 process. Is that an option that perhaps we should be  
11 considering?

12 DR. GILMAN: Dr. Temple--that's something that the  
13 FDA will address, I suspect.

14 DR. TEMPLE: Yes, we'll explore that. A recently  
15 approved anti-arrhythmic drug that has to be started in the  
16 hospital is available only to people who have taken the  
17 training program. One of the difficulties is that this is a  
18 drug that is out there for other uses, and it is not so easy  
19 to do that, because it can be prescribed through those other  
20 forums.

21 But we would certainly think about what kind of  
22 training, special packaging, et cetera, would be appropriate  
23 here.

24 DR. PENIX: My impression is that with Clozaril  
25 and maybe some of the other anti-arrhythmics, the concern

1 there is because of the potential fatal outcomes, and it  
2 appears that there is no increase in fatal outcome with this  
3 particular drug. That may require--my vote would be not to  
4 limit it, and I hope I didn't imply before that there should  
5 be specialty limitations, because I don't think so.

6 DR. GILMAN: Dr. Lacey, please.

7 DR. LACEY: I would like to speak against limiting  
8 the administration of the drug by specialty, based on the  
9 geographic area in which I live as an illustration of many  
10 areas of this country. In one-third of the State of  
11 Illinois, the southern part of Illinois, there is often not  
12 a single neurologist practicing.

13 DR. PENIX: Nor oncologist, probably.

14 DR. LACEY: No. We have oncologists sometimes,  
15 but not a neurologist. So if you were restricted on the  
16 side of neurologists--

17 DR. GILMAN: Dr. Kawas, do you want to comment  
18 further.

19 DR. KAWAS: I guess I just wanted to say in part  
20 the reason I voted no on do we have enough safety data is  
21 because there were no fatalities in people who just got one  
22 course under careful clinical observation. There was a  
23 fatality of an individual who got two courses. The average  
24 patient and his doctor--I mean, patients who live a block  
25 from the hospital are told on a regular basis that they

1 cannot come and see me anymore. So I think we don't know  
2 whether two courses of this disease will kill people or not.  
3 So I guess all I want to put a plea in for is some mechanism  
4 where that could be controlled.

5 DR. PENIX: Would not the cap on the total dosage-  
6 -because the dose that the patient got who died, didn't it  
7 exceed 140 mg?

8 DR. GILMAN: The patient got 275 mg.

9 DR. KATZ: I don't think--270 mg per meter  
10 squared--but in any event, theoretically, in an ideal world,  
11 the cap of 140, if that's what we ultimately decide on,  
12 would do it. But as Claudia points out, people go to  
13 different doctors; people move around, they want more, and  
14 they will try to get more, and they aren't necessarily going  
15 to tell their history. I don't know if this is going to  
16 happen, but this is certainly one thing that presumably you  
17 could be reasonably concerned about given what we think we  
18 know about the toxicity at even minimally higher doses than  
19 140.

20 DR. GILMAN: Dr. Grotta, then Dr. Penix.

21 DR. GROTTA: Well, my experience is that if you  
22 put all these warnings and so on about side effects on the  
23 package insert, physicians in this country, where there is a  
24 lawyer on every corner, are not going to be prescribing this  
25 drug unless they are very careful and cautious about it.

1 You can never totally safeguard against misuse of a drug if  
2 someone doesn't pay attention, and I don't think we can do  
3 that, so I think we just put the warnings and the side  
4 effects on the package insert and the limitations of dose,  
5 and that should be sufficient.

6 DR. GILMAN: Dr. Penix?

7 DR. PENIX: I agree with that. As a stroke  
8 neurologist, in my experience, I have never seen anyone  
9 exceed the recommended dose of Ticlopidine [ph.] nor TPA.  
10 So I think if we put it on the package insert and make it  
11 very clear, physicians would tend not to do that. But  
12 you're right, there is a complication of patients not  
13 reporting it to the physicians, and I think that that is  
14 going to be impossible to regulate.

15 DR. GILMAN: Do you want a vote on this question,  
16 Dr. Katz, or have you heard enough--

17 DR. KATZ: I have heard enough.

18 DR. GILMAN: Would you like to hear anymore about  
19 anything else--Dr. Temple, Dr. Katz?

20 DR. KATZ: No. The only thing I have left to say  
21 is to thank everybody. It has been a long day, with a lot  
22 of difficult issues, and I think everybody really  
23 contributed, and I want to thank you very much.

24 I particularly want to publicly thank Drs. Kawas  
25 and Gilman, whose last meeting this is, at least for a

1 while. They are rotating off the Committee. You have both  
2 been tremendous assets to the Division and to the Committee-  
3 -it goes without saying, but it is worth saying--you have  
4 been courageous at times under very stressful conditions,  
5 publicly, and I want to thank you very much. The Committee  
6 will miss you, the Division will miss you, and I personally  
7 will miss you. Thank you very much for your work.

8 [Applause.]

9 DR. GILMAN: Thank you, Dr. Katz, and let me thank  
10 the Committee and consultants. It has been an interesting  
11 day.


12 We will adjourn now.

13 [Whereupon, at 5:27 p.m., the proceedings were  
14 concluded.]

15 - - -

## C E R T I F I C A T E

I, ANNIE HAYES the Official Court Reporter for Miller Reporting Company, Inc., hereby certify that I recorded the foregoing proceedings; that the proceedings have been reduced to typewriting by me, or under my direction and that the foregoing transcript is a correct and accurate record of the proceedings to the best of my knowledge, ability and belief.



\_\_\_\_\_  
ANNIE HAYES

## **Lawyer's Notes**

---



112:11; 113:12, 14, 19;  
120:14, 25; 123:16, 16;  
128:13; 139:2; 141:5, 22,  
143:17; 172:19;  
173:23, 25; 222:20; 290:8,  
10; 298:9; 299:11  
**6-the** 44:4  
**6-month** 113:16; 117:17;  
119:23; 120:18; 135:2  
**6.1.2.a** 223:6  
**60** 47:3; 49:6; 89:20;  
316:10  
**600** 10:7  
**603** 42:13; 168:11  
**62** 290:18  
**63** 75:19; 192:2  
**64** 49:5; 53:11; 196:20;  
215:4; 304:8  
**67** 120:19  
**689** 42:12  
**69** 52:4; 104:20; 215:5

## 7

**7** 38:1; 44:7; 86:1; 212:8,  
21; 283:3  
**70** 89:21; 200:6; 214:15  
**700** 180:10  
**73** 49:11; 60:20  
12:14  
85:1; 87:4  
**76.8** 52:7  
**77** 215:12

## 8

**8** 8:11; 31:22; 41:19;  
44:19; 87:17; 176:5;  
280:5; 304:11  
**80** 32:3; 49:13; 103:12;  
176:7; 316:10  
**81** 196:20  
**83** 215:11  
**84** 49:12  
**85** 109:2; 196:20  
**86** 104:22; 187:9; 215:14  
**89** 196:20

## 9

**9** 164:2; 176:5  
**90** 47:3; 177:5  
**901** 42:4, 19, 21; 56:7;  
121:21; 128:10, 13, 18;  
142:24; 143:2, 5, 7; 167:1,  
16; 168:12, 12; 172:10;  
1:8; 181:25; 186:13;  
7:11, 14; 188:8; 189:4;  
196:16; 197:19; 215:1, 10,  
25; 221:17; 222:14, 15, 20;  
225:12; 239:3; 241:10;  
261:1; 268:11; 269:2, 5,  
14, 22; 279:25; 299:18;

304:11; 305:13  
**902** 42:5; 59:3; 61:4; 62:9;  
84:9; 96:3, 6; 120:23;  
121:20; 134:19; 138:2, 6,  
6; 139:10; 141:9; 143:3, 6,  
11; 167:1, 22; 172:6, 9;  
187:13; 188:5, 9, 13;  
191:9; 197:20; 205:24;  
212:6, 7; 215:9; 216:10,  
21; 217:11; 222:9, 14, 15,  
19; 225:7, 25; 231:22;  
232:23; 237:16, 21; 238:1,  
9, 14; 239:3; 254:1, 9;  
258:19; 259:8; 260:2;  
268:12, 12; 269:3; 275:23;  
277:11, 16; 282:17, 23;  
300:23; 304:12  
**902-to** 216:24  
**903** 42:9; 174:17; 197:11;  
215:15  
**99-point** 48:6

## A

**A-12-in** 68:19  
**ABC** 159:21  
**ability** 31:10; 58:21  
**ablation** 275:23  
**able** 65:8; 92:25; 108:21;  
126:20; 130:8; 150:17;  
168:4; 195:18; 200:25;  
203:2; 226:3; 241:25;  
245:10; 249:6; 252:17;  
277:19; 300:14  
**abnormal** 260:12  
**abnormalities** 142:22;  
257:24  
**abnormality** 69:20; 70:7,  
10; 277:23  
**abnormality--in** 70:4  
**above** 170:13; 171:24;  
204:6, 12; 206:22; 214:15  
**absence** 70:23  
**absolute** 299:4  
**absolutely** 136:11;  
150:5; 199:14; 232:14;  
236:2, 11, 18; 302:25  
**abstracted** 253:19  
**Academic** 174:18;  
318:24  
**accelerate** 193:18  
**accelerated** 20:17  
**accept** 93:5; 263:25;  
279:8  
**acceptable** 26:2; 31:11  
**accepted** 80:22; 161:15;  
162:2; 288:17  
**access** 28:9, 10; 62:1;  
63:7; 100:22; 118:24;  
119:2  
**acclivities** 33:5  
**accompanies** 207:4  
**according** 43:8; 75:15;  
115:22, 25; 307:1  
**accordingly** 69:13

**account** 20:5; 60:8;  
67:18; 77:9; 99:24; 131:9;  
175:19; 186:22  
**Accounting** 161:2  
**accrual** 227:5; 235:22  
**accruing** 140:23; 230:8;  
231:16; 232:6; 234:19  
**accumulate** 208:5; 277:6  
**accumulated** 230:21, 22;  
235:6; 257:23; 259:9;  
260:11; 284:17; 288:21;  
292:6, 11; 309:20; 310:4;  
311:12, 15, 22; 312:11, 15,  
25; 315:25  
**accumulates** 312:3  
**accumulating** 135:7;  
136:19; 231:23; 232:12,  
20; 233:19; 276:25;  
310:16; 312:19; 313:5;  
314:11  
**accumulation** 259:24;  
260:3; 264:1; 290:21;  
311:18; 313:2  
**accumulative** 233:21  
**accuracy** 175:12  
**accurate** 22:13  
**accurately** 22:20  
**ACE** 123:3, 10, 15, 18;  
268:2  
**acetate** 229:14; 230:19;  
288:25  
**achieved** 53:21; 175:22;  
261:3  
**acknowledge** 7:2  
**across** 14:19; 136:21;  
150:7; 154:2; 271:1; 289:2  
**act** 33:6  
**action** 32:25; 33:13;  
136:8, 9; 278:7  
**active** 12:9; 33:10; 43:18;  
88:2, 3, 8, 17; 90:19;  
96:17, 20; 97:9, 12, 13;  
108:21, 24; 121:3; 140:6;  
210:1, 1; 232:2; 241:16,  
17, 21; 242:1; 243:5;  
257:8; 287:5  
**actively** 175:8; 187:24;  
295:16  
**activity** 44:21; 50:4;  
56:21; 88:20; 104:4;  
125:6; 144:23; 153:3;  
222:16; 224:11; 256:5, 11;  
257:21; 260:14; 272:18,  
19; 275:24  
**actual** 32:6; 65:2; 86:9;  
115:9; 186:16; 208:16;  
243:4; 268:5  
**actual-assuming** 262:15  
**Actually** 12:13, 14; 22:1;  
31:24; 38:22, 24; 39:17;  
68:7, 12; 72:14, 23; 73:5,  
6, 13; 74:13; 85:4; 105:14;  
113:3; 114:2; 118:22;  
121:12; 125:5, 8, 10, 12,  
15; 126:18; 128:2; 141:4;  
144:24; 145:22; 181:7;

**admitted** 182:14; 195:13  
**ADR** 173:8  
**adult** 97:22  
**advanced** 14:20; 176:19  
**advantages** 62:17  
**adverse** 45:24; 168:13,  
21, 25; 169:1, 6, 8; 172:2,  
8, 11, 13, 25; 173:2;  
175:20; 176:22; 181:16;  
182:1; 183:14, 15; 194:9;  
195:19, 21; 206:11; 211:3,  
13  
**adversity** 167:11  
**advisory** 243:22  
**advocate** 161:11  
**advocated** 260:9  
**affairs** 161:8  
**affect** 38:24; 39:14; 79:7,  
13; 80:5, 16; 84:4, 8;  
100:16; 126:8; 163:12;  
287:10; 288:9  
**affected** 67:8; 158:11;  
231:13; 272:14  
**affecting** 21:13; 286:15;  
287:23; 288:7, 7; 294:11  
**affects** 32:19; 39:15, 20;  
266:23; 267:18; 292:10;  
293:7; 295:2  
**affirmative** 258:8  
**affirming** 158:13  
**afflicts** 33:19  
**afternoon** 157:7; 226:7  
**AFTERNOON SESSION**  
157:1  
**afterward** 264:24  
**again** 8:22; 9:24; 12:20;  
15:8; 18:13; 19:13; 23:7;  
26:14, 19; 28:21; 43:10;  
47:20; 50:8, 17; 51:13, 14,  
19, 22; 52:10, 21; 53:11,  
21; 54:11; 55:8, 21; 61:10;  
63:12; 66:4, 18; 69:15;  
74:19; 77:15; 78:24;  
79:14; 80:3; 87:25; 88:1;  
89:15; 94:10; 99:5, 10;  
100:19; 101:13; 103:10;  
104:7; 105:3, 6, 9; 106:9;  
107:4; 108:9; 109:15, 25;  
110:1; 113:10, 11, 24;  
115:17; 116:2, 11, 23;  
117:17; 119:17, 23; 120:3,  
18; 122:21; 129:13;  
131:13, 16; 132:14, 17;  
133:8; 135:2, 19; 137:11,  
17; 138:7; 144:2; 145:6;  
147:14; 149:10; 166:23;  
169:7; 172:1, 2; 174:10;  
175:16; 179:5; 182:23;  
185:25; 187:23; 190:2;  
192:16; 213:15; 215:21;  
218:24; 223:8, 22; 225:8,  
24; 231:13, 25; 233:1, 2;  
234:23; 236:13; 240:25;  
241:22; 242:3, 16; 245:4;  
249:9; 253:17; 261:22;  
262:6, 8, 21; 265:1;  
285:12; 287:15, 24; 291:3;



aspects 305:15  
assertion 231:21; 232:9,  
17, 18  
  sess 48:5; 98:16  
assessed 11:18; 18:21;  
19:24; 46:7; 11; 52:2;  
61:20; 67:1, 2; 82:10;  
89:16, 20; 248:9; 271:21  
assessing 72:23  
assessment 28:22;  
40:24; 45:8, 23, 25; 61:23,  
24, 24; 62:4, 22, 23; 64:1;  
65:7; 66:3; 67:5; 73:3;  
79:8, 13; 90:15; 91:7;  
98:11, 12; 120:3; 132:13;  
182:6; 199:10; 210:25;  
217:7; 219:19; 270:20;  
271:23; 300:16  
assessments 65:9; 66:8;  
263:23  
assessor 11:22; 64:6;  
67:21; 90:11; 131:21  
asset 270:5  
assets 323:2  
assign 89:9  
assigned 89:1; 177:22  
assignment 12:22;  
18:24; 89:9; 268:13  
assistance 44:7; 50:5  
associated 25:16; 49:9;  
4:21; 58:22; 24; 102:7;  
1:23; 183:11; 208:25  
association 154:23;  
186:4  
assuaged 277:16  
assume 92:14, 21;  
105:16; 125:16; 209:16,  
25; 306:24  
assume--so 83:9  
assumed 100:11  
assumption 23:20;  
106:18  
assumptions 136:13;  
265:12  
assure 92:16  
assures 272:17  
astonishing 86:10  
astrocytosis 149:23  
ataxia 272:7; 312:19  
atherosclerosis 124:12  
athiol 248:23; 249:14, 23;  
250:12  
athlete 157:17  
attached 47:7  
attack 43:14; 70:24;  
123:15; 210:14; 256:5;  
260:1  
attacks 73:5; 75:3, 5;  
6:21; 210:15; 227:9, 11;  
8:17; 232:3, 13; 234:18;  
235:1, 7, 16; 237:8, 12;  
239:12; 257:22; 260:15;  
261:4, 6; 272:10, 13;  
278:18; 287:20; 288:3  
attempt 223:18; 272:15

attempting 214:21  
attempts 80:17  
attention 322:2  
attitude 139:4, 21  
attitudes 139:19  
audit 64:22; 69:7, 8;  
220:6  
auditors 69:4, 5, 6  
audits 69:3, 13  
August 34:8  
author 225:19  
authorities 270:15  
automatically 46:25  
available 27:10; 81:23,  
25; 100:1; 102:3; 106:2, 8,  
22; 108:1, 10; 109:1;  
121:21; 127:8; 132:1, 3;  
143:14; 150:1; 155:1;  
163:7; 165:24; 170:11;  
177:21; 178:8; 179:7, 10,  
13, 16; 180:15; 181:13;  
184:3; 192:21; 220:21;  
246:19; 247:13; 248:3;  
255:23; 256:13; 271:2;  
286:9; 307:16; 308:10;  
315:14, 19; 319:16  
Avanex 18:9; 230:18;  
231:9; 239:13; 288:12  
average 49:23; 97:22;  
103:25; 107:23; 114:8;  
307:13; 320:23  
avoid 131:4; 234:3  
avoided 240:11  
aware 7:23; 33:18; 63:18;  
79:18; 201:15; 255:25;  
268:13; 290:17  
away 164:2; 234:22;  
249:8; 292:20, 25; 310:23

## B

B 113:6; 259:16  
B-109 195:22  
B-129 143:14  
B-130 114:20  
B-131 113:7; 114:2  
B-135 117:8  
B-25 133:5  
B-28 77:6  
B-77 65:18; 73:8  
B-89 59:16  
B-cells 33:3  
B-lymphocytes 127:12,  
13  
babies 163:8  
back 8:22; 18:5; 28:6;  
47:7; 69:15; 71:8; 72:3;  
73:7; 84:20; 85:23; 90:2;  
95:11; 100:6; 112:17;  
120:2; 122:7; 124:4;  
125:22; 130:18; 131:13;  
134:13; 140:3; 141:11;  
142:11; 145:10; 149:11;  
161:6; 165:3; 168:3;  
187:24; 188:16; 225:22;

229:24; 234:9; 235:4;  
239:5; 251:16, 25; 253:14,  
19; 258:16; 260:1; 265:20;  
266:7; 267:20; 269:8;  
274:22; 279:23; 281:9;  
284:7; 292:20; 301:6;  
302:20  
background 88:12;  
163:23  
baclofen 134:2  
bad 110:5, 13; 148:22;  
149:6, 13; 261:3  
bag 289:21  
balance 74:16; 88:25  
ball 301:2  
Baltimore 157:10  
bank—at 275:22  
bar 55:11; 293:15  
barely 165:9  
barrier 125:15, 17; 126:3,  
11; 149:19; 281:24  
base 59:6; 60:6; 250:24;  
258:18; 318:8  
Based 6:19; 16:17; 20:2,  
8; 21:1; 31:10; 34:4; 36:6;  
44:25; 47:13, 15, 17; 60:9;  
61:1; 63:13; 69:13; 76:24;  
78:2, 25; 80:8; 88:3; 91:7;  
97:2, 13; 99:10; 103:14;  
110:1; 113:25; 124:19;  
128:12, 16; 135:25;  
136:12; 137:3; 154:2, 19;  
168:8; 170:1; 175:16;  
179:1, 8, 10; 181:12;  
198:9; 199:8; 200:25;  
206:4; 212:5, 10; 213:19;  
218:6; 220:18; 221:19;  
223:22; 224:1; 225:12;  
238:5; 240:22; 242:20;  
246:8, 15; 248:7; 265:7;  
287:14, 16; 319:5; 320:8  
baseline 36:6; 37:1; 50:2;  
51:2, 14, 21; 53:2; 54:11;  
55:20; 57:7, 22; 59:10, 18,  
23; 60:12; 78:2, 19, 24;  
96:20; 99:25; 102:16;  
103:10, 12; 104:2; 107:1;  
120:7; 122:4; 124:5;  
129:12; 136:23; 143:16;  
169:15; 172:19; 176:5;  
213:10, 16; 214:3; 221:19;  
223:11, 22; 224:1; 227:9,  
10; 234:17, 19; 235:20;  
237:12; 258:21, 25; 271:2  
basic 121:12  
basically 165:7; 256:3;  
266:15; 276:13; 295:24  
basis 13:21; 16:5, 11;  
18:12; 19:24; 20:9; 23:21;  
24:24; 36:16; 42:7; 54:20;  
83:12; 88:25; 119:3;  
124:20; 132:12; 169:14;  
172:7; 188:6, 14; 209:6;  
212:7; 213:22; 214:4;  
243:23; 263:13; 293:24;  
320:25  
basketball 157:19  
batches 101:10

bathed 166:6  
bear 36:19; 126:17;  
292:22  
bearing 29:13; 130:16  
bears 124:23  
beat 116:18  
beautiful 160:20  
became 104:11; 160:20  
become 66:4; 86:12, 21;  
111:19; 148:12; 150:9;  
164:14; 175:24; 193:13;  
214:21  
becomes 71:19; 95:3, 8;  
106:6; 163:6; 277:11;  
313:4  
becoming 142:10; 151:5;  
178:4; 192:17; 194:25;  
243:24  
bedrock 13:14  
began 157:20, 25;  
161:24; 178:2; 303:15  
begin 42:18; 50:16;  
63:12; 121:20; 168:12;  
214:14; 236:4  
beginning 17:25; 46:20;  
96:4; 104:7; 106:25;  
131:16; 164:8; 206:16;  
243:13; 270:16; 277:6;  
284:18  
beginning-to 80:18  
begins 30:7  
behalf 160:1  
behind 108:20  
belabor 261:22  
Belgium 24:20; 42:25;  
89:5, 5, 6  
belief 280:18  
believes 7:1; 163:10  
BELLE 5:3, 3; 83:15, 17;  
107:12, 13; 204:23;  
208:18, 19, 24; 209:16;  
253:6, 7, 8; 306:19  
belongs 169:10  
below 76:2; 169:23;  
171:7  
beneficial 21:21; 138:21;  
248:23; 295:4  
benefit 21:9; 22:2, 9;  
23:10, 11; 31:2; 35:1;  
53:21; 124:1, 14; 145:22;  
148:20; 152:4; 182:5;  
199:9; 205:1; 210:23, 25;  
228:10; 229:8; 237:15, 16;  
243:3; 246:18; 261:22;  
262:1; 276:10; 280:24, 25;  
282:11; 300:25  
benefit-and-risk 40:24  
benefits 20:24; 205:2;  
211:9; 213:23; 214:25;  
256:12; 264:24  
benefitted 241:23  
benign 44:11  
best 75:6; 133:23;  
142:21; 145:14; 150:14;  
154:22; 202:22; 203:8;  
251:24; 252:24; 285:21;  
301:20  
beta 229:14; 255:12  
Beta-Interferon 242:24;  
243:2, 10; 255:10  
Beta-Interferons 289:18  
Betaferon 256:3  
betaseron 20:2; 138:25;  
201:22; 202:8; 230:17, 24;  
231:8; 239:13; 256:4;  
287:10; 288:12, 20  
Betaseron-1 287:11  
Bethlehem 158:1  
better 22:22; 52:18, 22;  
56:16; 77:16; 93:24, 24;  
123:5, 11; 141:7; 145:21;  
152:10; 155:15, 15; 162:4;  
166:10; 205:10, 12, 13, 15,  
17, 21; 219:5; 225:5;  
228:6; 241:2; 264:22;  
267:2; 276:22; 296:22;  
297:22, 22; 299:12;  
303:10, 11; 304:16, 17;  
305:15; 307:22; 308:14;  
309:4; 312:24  
between-we 143:20  
beyond 36:13; 85:22;  
87:21; 115:11; 131:24, 25;  
143:4; 197:22, 23; 198:10,  
22; 203:3, 7; 204:19;  
206:17; 213:20; 248:21;  
250:1, 11; 259:4; 278:5;  
280:18  
BfArM 42:25  
bias 45:7; 82:17, 22;  
148:21; 217:5; 271:22;  
290:20  
bias-have 257:23  
biased 78:20; 81:6;  
218:19  
biased--allegedly 83:9  
big 116:13; 278:15  
bilirubin 191:7, 16  
Bill 5:14; 300:3  
Biogen 8:9  
biologic 56:21; 222:5;  
228:2; 296:9  
biological 292:2, 12;  
297:14  
biologically 240:13;  
294:2  
Biologics--we 20:10  
biology 292:17; 293:20,  
22  
biostatistician 5:4  
birth 178:5  
bit 10:10; 14:13; 23:15;  
45:17; 55:5; 76:16; 79:23;  
86:10; 92:18; 112:16;  
117:20; 118:23; 124:8;  
154:17; 163:23; 167:12;  
191:1; 226:22; 234:23;  
242:8; 265:4; 286:1;  
305:14, 21; 306:21;  
308:24  
black 39:21  
bladder 79:5, 16; 92:6

bleeding 189:22	bothers 142:17; 244:23	C-37 191:10	315:1, 22; 319:8, 19;	239:21; 244:13; 251:15;
blind 12:16; 62:19; 68:8; 116:11; 152:21; 238:5; 269:18; 274:16	bothersome 92:19	C-40 192:6	322:1, 2	262:23; 263:16; 264:16;
blind-breaking 82:14, 18, 23	bottom 85:22; 182:24; 190:6; 192:24	C-42 79:24	can-respond 6:8	279:3; 309:17
blinded 11:18, 22; 12:19, 19; 57:15; 61:16; 64:5; 65:9, 10; 67:1; 81:5; 83:1, 21; 89:10, 15, 23; 90:11; 102:25; 136:4; 139:5, 6; 141:15; 145:19; 209:6; 217:6; 221:1; 263:22; 264:3, 5; 268:11, 18, 19, 22; 270:20; 273:8, 11, 19; 274:24, 25; 282:17; 293:17; 303:11	bought 163:25	canadian 158:3; 256:2	cases 19:22; 62:10;	
blinded-so 294:9	bowel 92:6	Call 5:11, 15; 7:6; 10:1; 19:23; 31:9; 32:8; 35:19; 36:1, 5; 39:1; 40:22; 41:23; 60:21; 64:14; 88:8, 10, 14; 126:21; 179:1, 9; 180:25; 181:1; 188:6; 189:1; 197:15; 198:10, 16;	139:5; 171:18; 190:10;	
blinded-the 66:8; 269:15	box 39:21; 82:4; 220:20	call 14:14; 15:24; 28:23; 73:25; 89:8; 140:18; 169:22; 173:2; 190:14; 232:11; 237:24; 238:3; 258:19; 262:12; 267:11; 289:19	206:4; 211:15; 212:24; 213:8; 224:22, 25; 225:1, 10; 296:12; 300:12	
blinding 89:19; 217:22; 268:23; 269:1, 2, 6; 270:3; 272:14, 16, 23; 274:12; 277:12, 15; 293:12	boxed 27:20	called 10:21; 12:8; 13:22; 20:17; 47:14; 82:3; 109:6; 111:12; 123:17; 172:15; 173:13; 183:14; 220:7; 233:23; 234:20, 21; 254:9; 258:20; 261:25; 272:10	cancer-and 273:11	
block 320:24	brain 22:20; 23:3; 125:2, 14, 14, 16, 20; 126:3, 11, 23; 148:22; 149:13, 19; 150:15; 151:7, 8; 152:13; 277:22, 24; 281:21, 24; 283:13, 17, 19	calling 136:15; 158:17; 177:18	cancers 10:2	
blood 37:17, 22; 38:4, 10, 14; 125:14, 16; 126:3, 11; 128:3; 149:19; 164:23; 170:4; 183:7, 11; 184:13; 281:24	brainstem 92:4	came 30:1; 62:3; 124:4; 125:9; 188:16, 20; 191:17; 266:6, 15; 278:17	candidate 155:6; 162:25;	
bloodstream 128:1	Branch 5:15	can 6:11; 7:3; 16:15, 20; 17:2; 19:8; 21:22; 22:7; 29:11, 18; 31:2; 33:6, 19; 36:17, 25; 50:20, 24;	249:11, 15	
blue 45:10, 11; 53:4; 63:22, 23; 91:3, 4; 103:1; 234:25; 238:23; 239:1; 240:1; 247:24	breaks 269:17	52:17; 53:21; 56:1, 2, 12; 58:15, 22; 59:4; 61:7, 13; 63:4; 64:11; 67:11; 68:22;	cane 158:2	
blue-so 63:20	breast 7:6; 181:1	74:23; 75:6, 16, 21; 77:5, 14; 78:7, 10, 22; 79:14, 25; 80:3, 4; 82:20; 85:9; 88:3, 7; 90:23; 91:4, 6, 25;	cap 90:1; 199:14; 202:15;	
blurred 157:15	brevity 57:3	95:10; 100:5; 101:19; 104:12; 105:4, 11; 112:16, 19; 115:17; 120:4, 8, 9;	204:5; 236:5; 246:16;	
boarded 318:10	brief 30:19; 33:24	122:7; 125:1, 4; 126:22; 128:7; 129:15; 131:10, 12, 13; 132:4; 141:5; 143:9;	247:2; 316:23; 321:5, 11	
Bob 30:1, 3; 88:18	briefing 12:25; 24:1; 34:12; 47:8; 52:16; 58:14; 132:15; 169:5; 172:11; 174:11; 179:15; 180:7; 248:12	145:7; 147:2, 13, 14; 148:4; 153:21; 154:19;	capacity 317:22	
BOEHM 4:11, 11	briefly 10:5; 13:1; 15:7; 62:19; 138:4, 9; 204:16; 249:24	158:18; 159:13; 160:2, 6; 162:14; 163:12; 165:9, 10,	Capital 160:22	
bona 19:1	Brigham 7:13; 95:21	12, 13, 13, 16, 22, 24;	capping 199:21; 202:19	
bonafide 269:10; 272:15	bring 26:15; 149:16; 162:19; 191:8; 197:18; 202:22	166:8, 9, 9, 13, 24; 167:4; 169:25; 171:9; 173:4;	capsule 140:9	
bone 32:3; 164:23	brings 140:3	179:17; 184:21; 185:4;	car 162:18	
book 141:5; 298:5	broad 257:11; 319:2	186:21; 188:23; 189:22;	Carbondale 5:8	
book-if 24:1	brochures 162:12	190:5, 24; 191:8; 193:13;	cardiac 36:6, 7, 14, 20;	
booklet 11:20	broken 128:14	196:20; 197:1, 9, 9; 198:3,	38:17; 169:10; 178:11, 16,	
borderline 68:13	brought 34:23; 158:15	23, 202:22; 203:8; 208:3;	20:18; 182:15; 198:1; 200:5,	
Boston 95:22	bugs 267:19, 20	21:11:23; 212:7; 219:13;	17:21; 213:2, 24; 214:14;	
both 6:2; 18:20, 21; 32:2, 19; 33:14; 34:8; 36:18; 54:10; 61:14; 63:23; 67:9, 13; 84:10, 16, 18; 97:13; 98:1, 7; 105:25; 123:21; 127:8; 142:18; 150:25; 153:1, 18; 154:11; 155:13; 162:6; 164:1; 202:16; 205:11; 217:8; 218:9, 25; 222:14; 230:2; 241:16; 254:24; 258:13; 268:19, 22; 269:10; 272:20; 275:13; 285:8; 295:20; 297:7; 304:4; 316:24; 323:1	burdening 277:4	220:14; 221:10; 223:1, 6, 10; 226:17; 227:3; 234:14,	247:5; 250:3, 8, 20, 23;	
bother 308:5	burdens 257:19	23; 235:13; 236:12, 18;	300:12; 316:24	
bothered 142:15; 154:6; 268:22; 300:4	busy 52:15; 169:4	239:23; 241:15; 242:5;	cardiologist 178:17	
	Butan 209:19, 20; 210:2, 5, 18	244:3, 9, 14; 245:16;	Cardiologists 170:5	
	buttressed 274:14	246:14; 247:5, 7; 249:4, 7;	cardiototoxicity 32:13;	
	buy 173:5	250:18, 24; 252:1; 253:5;	38:25; 39:2, 4, 11; 172:17;	
		260:19; 262:14, 16; 265:2, 13; 266:4, 23; 271:21;	200:1, 7, 9; 204:12, 19;	
		272:13; 273:17, 19; 275:8, 21; 277:7; 278:6; 279:8,	249:4	
		11, 24; 280:16; 281:12;	cardiovascular 123:1	
		282:10, 20; 283:15;	care 21:13; 25:6; 68:5;	
		285:16; 294:12, 24; 296:7;	175:1; 292:13, 14; 293:3;	
		298:11; 302:10, 16;	300:5; 305:8; 307:13;	
		308:21; 313:6, 15, 16;	318:9, 15, 17; 319:1	
			career 158:8; 160:24;	
			161:9	
			careful 290:3; 295:21;	
			320:22; 321:25	
			carefully 169:12; 181:8;	
			190:12; 197:24; 201:8;	
			263:10; 274:3, 4	
			cariogenic 182:14	
			carried 105:17, 18;	
			106:6; 107:7; 153:6	
			carries 309:2	
			carry 309:10	
			carrying 153:4	
			case 16:8; 19:8, 11;	
			20:22; 21:23, 24; 22:7;	
			71:2; 74:12; 81:24; 100:7;	
			123:17; 152:22; 154:21;	
			172:14, 14, 15; 175:5, 12;	
			177:11; 180:18; 183:17,	
			20; 190:9, 10; 191:23;	
			195:10; 220:9; 231:9;	
			243:9; 244:23; 245:4;	

249:2; 252:8, 19; 266:21;  
279:19; 290:22; 301:13;  
316:22; 319:21; 321:16  
certified 164:14; 236:8  
cessation 262:24; 263:3  
cetera 47:12; 64:17;  
76:20; 86:2; 90:16; 127:5,  
25; 153:17; 277:2, 4;  
278:18; 294:25; 308:12;  
314:20; 319:22  
chair 4:3; 110:2  
chaired 42:24; 96:9  
chairs 91:11  
challenge 267:23  
chance 165:19; 200:8;  
249:25; 264:23; 280:3, 6;  
284:12  
change 23:18, 23; 51:1;  
53:1, 17; 58:11; 69:20;  
70:2, 5; 76:15, 20; 77:20;  
80:19; 93:14, 16; 94:5, 6,  
11, 16, 24; 117:6; 118:11;  
119:14; 121:12, 14; 123:7,  
8; 128:4; 133:12, 13;  
134:8; 143:20; 153:13;  
192:22; 207:23; 245:6, 11;  
264:11; 279:10; 284:15,  
25; 290:19; 292:3, 4, 21;  
304:6  
changed 123:12; 143:16;  
158:9; 180:17  
anges 94:18; 106:18;  
16:12, 13; 125:4; 143:1;  
148:22, 23; 151:12;  
153:18; 203:18; 257:2;  
268:5; 276:9; 278:23;  
282:16  
changing 123:22; 236:22  
Chapter 158:21; 159:1, 4;  
160:22; 162:9  
characteristics 78:2  
characterize 311:2  
characterized 228:16  
charge 66:19  
chart-as 92:5  
check 78:9; 219:24  
checked 38:4; 72:19;  
82:4  
checking 312:10  
chemistries 171:24;  
174:9; 191:9  
chemistry 212:15  
chemokyne 257:3  
chemotherapy 32:2;  
63:14, 18; 85:9, 11; 90:5,  
12, 14, 24; 103:1; 127:23;  
179:4, 23; 181:22; 193:15;  
294:24  
chest 179:24; 200:4;  
4:15; 250:4  
CF 199:20  
CHFs 180:4  
chief 164:13  
child 164:3; 171:4; 178:6  
child-bearing 170:23

children 160:16; 166:4;  
179:25  
choice 85:5; 162:4;  
204:8, 8; 242:13, 14  
choose 67:2; 205:4;  
209:7  
Chris 161:15  
chronic 25:24; 161:24;  
255:7, 13, 17  
chronic-progressive 240:4  
chronically 26:3  
cigar 310:1  
circuitous 160:24  
claim 16:7; 17:11; 18:10,  
11; 123:21, 25; 131:3;  
239:17; 254:22; 258:12;  
265:6; 267:10; 270:9;  
284:8, 15; 289:15, 17, 18,  
23; 291:11, 12; 292:7;  
313:19  
claim--a 16:15  
claim--as 16:15  
claim--so 291:13  
claim--that 253:23  
claimed 24:16  
claims 17:14; 163:11;  
245:2  
clarification 61:15;  
234:8, 24; 254:14  
clarify 87:8; 170:3;  
217:17; 220:14; 239:1;  
310:25  
clarifying 91:21  
clarity 313:7  
class 169:10; 289:7  
classification 43:11;  
109:16, 24; 112:20;  
128:16; 140:19; 225:20;  
233:3  
classified 128:18;  
130:20; 137:24; 143:18;  
183:2; 240:24  
classify 112:1  
Claudia 4:24; 321:12  
clear 53:10, 65:6; 70:13;  
103:4; 131:2; 187:16;  
203:9; 206:24; 221:24;  
233:13; 243:24; 262:17;  
272:5, 8; 284:22; 291:5;  
307:18; 314:12; 322:11  
clear-cut 138:19; 139:3;  
227:20; 263:12  
cleared 160:5  
clearer 114:1; 238:18  
clearly 39:1; 64:18; 69:1;  
99:23; 107:13; 109:8;  
115:5; 121:23; 124:18;  
134:23; 142:6; 144:4;  
150:9; 159:11; 192:14;  
217:22; 224:24; 230:1;  
244:18; 245:7; 263:9;  
277:23; 282:16; 318:15  
clinic 35:11, 13; 71:3;  
174:18, 22; 175:1, 8, 14;  
176:24; 177:6; 178:18;  
182:11; 184:2; 188:16;  
207:12, 14; 208:1; 212:22;  
219:3  
clinical 11:12; 12:20;  
13:10, 11; 14:22; 19:10,  
11; 20:7, 15, 24; 21:3, 9;  
22:2, 9; 23:7, 10, 11, 16,  
18; 24:6; 31:2, 18; 33:15;  
36:7; 41:7; 45:18; 57:16;  
17; 59:1; 80:11; 93:21;  
97:2, 13; 98:2, 8, 99:6;  
106:24; 107:14; 113:5;  
114:16; 119:3; 137:3;  
138:11; 142:11; 147:20;  
148:9, 17, 20; 149:4;  
150:5, 10, 13, 18; 151:15,  
22; 152:4; 154:4, 15, 23;  
160:3; 167:18, 20, 23, 24;  
168:21; 169:13; 172:17,  
19; 174:25; 180:12;  
215:16; 216:13; 217:11;  
219:17; 221:21; 222:3, 4,  
10, 12; 226:18; 228:5;  
229:3, 8; 243:25; 245:23,  
25; 246:18; 248:16;  
257:19, 22; 268:20; 269:1,  
3; 270:13, 18; 271:9, 25;  
272:2; 274:24, 24; 275:8,  
15, 18, 19; 277:12, 14;  
278:5, 12, 23; 279:5, 20;  
280:9; 281:7, 11, 16, 18;  
282:11; 286:2, 4, 11;  
287:5; 292:3, 11; 293:9,  
13; 298:10; 301:22;  
310:21; 312:1; 318:18;  
320:22  
clinically 23:20; 24:3;  
82:7; 93:17; 94:17;  
106:11, 14; 115:12;  
155:15; 178:20; 272:23;  
276:23; 279:3, 10; 290:10;  
295:4; 304:14; 309:22;  
310:6, 10  
clinician 12:22; 61:17  
clinicians 18:24; 229:10  
close 17:2; 18:11; 71:3;  
130:21; 193:17; 247:4;  
258:8; 284:3; 289:17;  
309:15; 310:1; 314:10  
closed 96:12  
closely 236:20; 244:8;  
270:16  
closely--and 270:15  
closer 137:10; 188:14  
closest 126:22  
clouded 40:2, 8  
Clozaril 319:7, 24  
clue 86:23; 90:8; 301:20  
CNS 98:17; 125:11;  
126:17; 222:6  
co 42:23  
coding 101:15  
coffee 92:2  
cognitive 151:12;  
152:12, 13; 165:13  
cohort 10:9, 11; 183:1;  
186:10  
coincidence 217:5  
cold 8:23; 38:3  
colithiasis 191:19  
collaborators 132:8  
colleagues 235:11;  
243:18; 294:14  
collect 81:22; 175:6, 7;  
177:14, 19; 183:16, 17;  
203:1; 248:14, 16; 249:6  
collected 81:19, 20, 24;  
100:23; 130:7; 174:15;  
175:10; 181:1; 184:1;  
241:15; 242:18; 249:16;  
302:6; 315:13  
collection 175:5; 178:7,  
9  
Collectively 42:14  
college 157:18  
color 45:10  
Columns 75:16  
combination 32:6, 7, 8;  
67:15, 18; 97:4; 143:19;  
179:22; 219:6; 296:9, 13  
combine 67:2  
combined 10:19; 54:10;  
143:5; 202:12  
comfort 29:3  
comfortable 199:20;  
263:8; 273:24; 292:10;  
298:10; 305:25; 306:2;  
314:9  
comfortably 165:1  
coming 8:23; 19:11;  
100:6; 122:1; 134:12;  
137:1; 144:20; 150:21;  
160:12; 260:1; 274:22  
coming--Dr 8:25  
comment 6:11; 8:4;  
60:17; 64:9; 68:3; 74:20;  
75:11; 78:22; 79:10; 80:5,  
8; 85:20; 86:3; 91:9, 10,  
11; 94:21; 110:3; 112:16;  
122:25; 125:18, 22;  
133:18; 138:4; 144:8;  
183:21; 187:4; 188:17, 19;  
190:24; 193:6; 199:24;  
201:22; 202:5; 203:12, 13;  
204:3, 4; 206:15; 209:19;  
224:3; 225:24; 249:22;  
250:7; 251:5; 252:8;  
278:4; 280:16; 281:10;  
282:15; 284:14; 290:5;  
301:16; 305:19; 313:24;  
320:17  
comment--the 155:3  
comments 7:10; 8:16;  
240:6, 7; 245:17; 252:5;  
253:4; 273:5; 280:20;  
281:24; 294:17; 296:16;  
311:8; 314:4, 6  
committee 4:3, 21; 8:22;  
17:8; 20:4; 25:3; 26:5;  
28:9; 30:6; 114:16;  
122:21; 128:11; 131:2;  
155:17; 156:4, 7; 160:17;  
189:14; 206:19; 207:2;  
230:16; 243:22; 251:14,  
19, 21, 25; 252:10; 254:6,  
12; 255:1; 257:25; 258:7,  
13; 263:19; 270:8; 281:4;  
284:14; 291:2, 4; 292:16;  
306:18; 313:11; 314:8;  
315:5, 9; 318:11; 323:1, 2,  
5, 10  
Committee's 282:13;  
313:13  
Committee--ls 306:15  
committee--this 20:4  
committees 288:17  
common 136:23; 194:10;  
227:18; 235:18  
commonest 226:25  
commonly 10:20; 47:20;  
48:12; 53:16; 63:9; 80:14;  
88:8  
community 22:12;  
148:13; 161:13; 162:10  
Company 8:9; 26:10, 12;  
28:6, 19; 125:18; 179:11;  
198:11, 13; 199:21, 25;  
201:4; 202:22; 203:8;  
204:3, 9; 213:25; 214:9;  
238:24; 248:13; 249:2;  
295:20; 302:13; 313:16;  
318:3  
company's 199:11  
comparability 223:9  
comparable 294:5;  
304:14; 305:1  
comparative 153:6  
comparator 274:5  
compare 120:7; 129:5;  
132:24; 287:7; 304:2  
compared 11:4; 49:14;  
52:6, 12; 53:14; 54:11;  
55:16; 56:4; 57:25; 58:4;  
66:1; 99:25; 100:4;  
104:18, 19; 107:24; 111:3;  
119:19; 120:5; 135:4;  
168:22; 186:2; 196:11;  
205:16; 213:8; 215:4, 5,  
11, 14; 223:13; 225:1, 6;  
287:2; 293:10; 304:11  
comparing 10:16; 51:13,  
21; 57:22; 65:11; 66:4;  
209:12; 287:18  
comparison 46:14; 50:9,  
11; 59:25; 60:1; 67:22, 23;  
98:21; 99:2; 101:18;  
107:9; 120:16; 208:10;  
287:8; 288:2  
comparisons 46:22  
compelling 95:4  
compilation 180:6, 11  
complementary 46:8  
complete 90:4; 134:16;  
194:18; 207:24; 227:3;  
255:19, 20, 21; 275:23;  
298:18  
completed 8:12; 54:21;  
83:2; 102:6; 122:1; 180:5;  
248:18  
completely 20:22; 90:17;  
183:23; 184:12; 260:13;  
308:9

completing 49:8; 54:17; 102:11	confess 138:22	consistently 52:18; 210:9	272:10; 297:14; 301:22; 309:5; 315:7	count 37:17, 22; 38:5; 64:16; 128:3; 171:13, 15, 16; 184:22, 25; 187:7; 189:21; 190:15; 203:19; 272:11
complex 55:5; 249:5	confidence 66:3; 67:4; 94:8; 274:6	consisting 28:24	convinces 293:1	counted 18:20
complicated 10:18; 28:23; 275:21; 283:10; 285:23; 311:21	confident 65:2; 69:11; 209:14; 220:15; 231:14; 259:7	consists 212:2	convincing 95:8; 142:23; 294:10	countries 10:2; 42:23; 47:22; 89:3
complicated--I'll 28:23	confidently 277:7	constant 14:18; 44:6	convincingly 154:5	country 25:5, 7; 159:6; 244:12; 305:17; 320:10; 321:23
complicated-plus 237:10	confirmatory 13:22; 14:1, 5, 7, 15, 24; 142:13	constitute 14:14; 19:14	cooperating 91:13	counts 23:17; 37:20, 23; 38:1, 4, 10; 68:6; 128:7; 183:7, 11; 184:2, 4, 14, 20
complication 76:10; 322:12	confirmed 53:9, 13; 58:21; 72:9; 73:5; 74:3; 75:6; 94:11	constitutes 255:8	cooperative 179:14	couple 28:11, 11; 78:13; 81:10; 117:25; 160:24; 161:3; 190:22; 239:8
complications 196:6	Conflict 6:14, 16, 23	consultant 7:12, 17; 144:8; 201:16; 252:10; 258:1; 298:16	coordinate 164:8	courage 167:10
compliments 192:20	confronted 229:10; 295:7	consultants 5:24; 6:25; 30:21; 80:4; 253:5; 263:6; 273:4; 284:13, 14; 315:5; 323:10	coordinating 158:21	courageous 323:4
component 259:8	confused 111:7; 136:14; 172:21; 233:17; 272:12	consultation 8:11; 178:17	coordinator 159:10; 164:5	course 6:2; 9:10, 10; 18:7; 20:24; 21:16; 22:23; 23:5; 25:12; 30:11; 36:10; 37:4, 18, 20, 23; 38:12; 86:7; 97:19; 102:1; 141:19, 23; 148:8, 20; 152:12; 154:2; 165:6; 171:2; 174:2, 5; 179:3; 185:15; 187:15; 198:13, 21; 206:25; 211:19; 212:16, 18; 214:1, 6; 226:18, 22, 25; 229:22; 244:15; 250:5; 253:21; 260:11; 264:11; 272:3; 275:24; 277:25; 289:10; 296:5; 304:21; 316:7; 320:22
compound 251:6	confusing 234:5	consumer 5:8	Copaxone 7:12, 15; 231:13; 239:13; 286:19; 289:15; 295:10	course-and 149:15
computer 88:24; 165:10; 166:8	confusion 87:9; 111:6; 237:1; 262:3	contact 8:14; 61:25; 72:17; 172:16, 22; 176:7; 184:1	copies 47:7	courses 37:24; 38:13; 41:20; 44:19, 24; 97:7, 8, 24; 102:12; 117:16, 18, 19; 141:24; 142:2; 146:19, 20; 172:7; 173:23; 175:18; 176:9, 11, 12; 177:8, 16, 22; 191:25; 197:19, 20, 22; 211:23; 320:23; 321:2
conceivable 301:8	confusion--obviously 262:2	contains 10:4	copyright 161:12	cover 300:14
conceivable--but 301:7	confusions 142:9	contaminated 76:5	corner 321:24	covered 121:8
conceivably 280:23, 25; 301:10	congestive 169:19; 179:19; 180:19; 181:18; 199:18; 213:4, 7; 266:13	contemporaneous 23:14; 276:19; 277:14; 284:15	cornucopia 246:24	Craig 35:15
conceive 100:5	conjunction 27:24; 40:4	contemporaneously 23:9	coronary 124:9; 267:14, 16	create 162:8; 277:23; 295:14
concentrates 190:25	connect 263:3	context 95:6; 206:12; 241:20; 281:6	correctly 91:20; 114:23; 130:20; 189:3; 245:15; 299:20; 303:14	creative 161:13
concept 276:19; 284:19, 23; 312:11	Connecticut 161:15	continue 87:25; 96:1, 2; 97:15; 119:9; 139:25; 175:25; 179:5; 214:8; 224:17; 249:14, 14; 255:5; 296:21; 299:15; 302:4	correctly--you 219:10	credible 274:12
conceptual 260:18	connection 272:18	continued 67:23; 87:21; 177:7; 202:8; 264:25; 299:19	correlate 65:8, 13; 150:14, 18; 152:7; 221:20; 270:17; 275:25; 279:20	CRF 220:20
concern 83:14; 87:2, 6; 138:13; 189:13; 245:5; 254:1; 316:1; 319:25	consensus 226:19	continues 207:13	correlation 66:11; 107:15, 19, 22, 25; 113:8, 19; 114:2, 6, 9; 151:2; 154:20; 155:4, 9; 271:5, 9, 10, 11, 14; 282:24, 25	criteria 12:2, 13; 19:13, 16; 43:8, 18; 44:10; 46:3; 47:16; 50:17; 60:24; 61:1, 6; 65:7; 72:19; 81:11; 96:14, 23; 97:13; 115:25; 116:7, 9, 19; 133:24; 137:3; 144:4; 172:25; 173:17; 191:13; 216:2, 11; 219:13, 15, 24, 24; 220:19; 221:2; 233:4; 237:17; 238:19
concerned 203:6; 254:20; 258:15; 263:11; 300:20; 318:14; 321:17	consent 92:21, 22; 156:1	continuing 97:16; 171:23; 213:21, 23; 214:1	correlations 149:1, 8; 151:11; 153:7; 271:5; 277:3	criteria--meaning 97:2
concerning 35:7, 21; 59:5; 224:5	consequence 39:24; 282:12	continuum 17:5; 43:16; 225:17; 255:8; 256:21	contract 150:21	criterion 46:3, 4; 81:18,
concerns 34:22; 277:15; 315:23	consequences 115:23, 24; 117:4, 5	contraception 170:24	contrary 118:21	
conclude 34:25; 40:25; 90:13; 225:23	conservative 106:4; 131:19; 198:19; 213:9	contract 150:21	contrast 266:25; 268:1	
concluded 43:3; 245:18; 323:14	conservatively 198:11	contrary 118:21	contribute 75:5	
concluding 273:25	conserve 158:5	contrary 118:21	contributed 223:17; 322:23	
conclusion 41:22; 56:7; 58:20; 108:5, 10; 112:23; 120:23; 155:11; 181:15; 258:18; 279:5; 286:2	consider 53:9; 131:7; 146:13; 166:18; 170:5; 243:6, 8; 317:17	contribution 177:9	correspond 50:11; 229:18	
conclusions 33:12	considerable 148:14	contributor 228:20	corresponding 195:8	
concomitant 79:2, 11; 84:20	considerably 39:6; 279:14	control 119:19; 181:20; 215:12, 14; 247:18; 293:10	corroboration 13:15; 24:12	
concurrent/concomitant 80:9	considerations 25:11	controlled 10:5, 8, 15; 11:4; 14:7; 41:25; 42:6, 22; 102:22; 168:23; 198:6; 216:1, 10; 217:22; 247:22, 25; 253:22; 287:18; 321:4	corticospinal 150:8	
concurrently 57:13	considered 64:20; 65:1; 75:14; 76:13; 92:3; 100:7; 103:13, 17, 19; 117:5; 178:20; 203:25; 228:20; 243:14	conversations 231:25	corticosteroid 42:6; 52:2; 100:15; 117:9, 15; 145:4	
condition 17:24; 21:20; 62:3; 123:3	considering 64:13; 202:16; 319:11	convert 226:15; 227:7	corticosteroid--and 117:17	
conditions 16:19; 136:6; 323:4	consist 40:23; 96:15	convince 147:22, 23	corticosteroid-controlled 96:7	
conditions--if 214:10	consisted 43:18; 216:4; 225:25	convinced 125:4; 142:10; 151:5; 153:5;	corticosteroid-treated 117:10, 22	
conduct 41:11; 43:1; 274:3	consistency 65:25	counseling 161:25; 162:2	corticosteroids 218:18	
conducted 42:22; 69:4; 82:24; 84:10; 85:7; 96:7; 224:2; 246:5; 247:13, 17; 293:16	consistent 19:16; 57:17; 59:20; 64:25; 65:17; 72:14; 210:12; 217:6; 218:23; 222:2, 12; 230:5; 302:22	counselor 160:22	counselor 160:22	
conducted--study 42:4				
Conducting 98:5; 146:18				
confer 300:25				

18:294:8  
**critical** 71:19; 75:14;  
49  
IO 82:25  
**crucial** 75:14; 315:12  
**crutch** 44:7  
**crutches** 158:3  
**cumulative** 25:16, 19;  
26:2; 32:13; 39:7; 146:8;  
169:11; 179:17; 181:19;  
182:11; 202:15; 214:11;  
316:18  
**curious** 29:21  
**current** 8:2; 35:2; 109:23;  
110:21; 225:16; 231:5;  
286:24; 300:5  
**currently** 31:6; 33:21;  
41:8; 146:16, 18; 201:9;  
226:12; 229:13; 247:8, 11,  
14; 248:3, 11; 249:18;  
264:20; 282:2; 307:16  
**Currently-approved**  
228:8  
**Curry** 209:9  
**curve** 55:21; 76:4; 210:20  
**curves** 131:6; 141:25;  
142:6; 210:16; 231:17;  
266:15  
**cut** 150:7; 235:15  
**cycle** 90:15; 105:21;  
22:22; 193:2, 3  
**clophosphamide**  
40:9; 127:24  
**cystoly** 170:5  
**cytokine** 127:11, 17  
**cytokines** 33:8; 127:5  
**cytosine** 32:7; 40:10

## D

**d** 247:15  
**DAHUT** 5:14, 14:9:1;  
89:18; 92:11; 93:12, 13,  
21; 266:1, 2; 273:9, 10;  
290:4, 5  
**daily** 31:20; 61:11;  
115:23; 117:4, 6  
**damage** 24:2; 283:14  
**danger** 317:25  
**dangerous** 173:10  
**danger** 204:11  
**dark** 161:22  
**data** 10:7; 19:11; 21:1;  
22:15; 24:25; 27:4, 10;  
30:25; 33:25; 34:11, 21,  
23; 40:18; 19; 41:7, 15;  
42:12, 14; 43:3; 44:22, 25;  
49:1; 50:13; 52:24, 24;  
18; 56:12; 58:7; 59:13;  
8; 69:7; 74:20; 75:7, 24;  
79:24; 81:19, 19, 22;  
82:24; 83:8, 10; 84:11;  
94:12; 95:2, 5; 96:3; 99:10;  
101:19, 20, 22; 103:8;  
105:14, 21; 106:8, 22;

107:6; 108:10; 113:22;  
114:8, 16, 17; 115:1, 2;  
117:1, 7; 119:3; 121:5, 8,  
21, 25; 122:22; 125:12, 20;  
126:7, 17; 127:3, 7, 8, 9,  
11, 15; 129:25; 130:4, 7,  
23; 131:5, 5, 8, 12, 23, 25;  
132:18; 133:23; 134:17,  
18, 23, 25; 135:20, 21;  
137:18, 20, 23, 24; 138:7;  
140:25; 141:14; 142:12;  
143:5, 8, 11, 13, 15; 144:2;  
145:2; 146:11; 147:8, 21;  
149:6; 151:10, 25; 152:1,  
6, 8; 153:15, 24; 154:4, 5,  
6, 7; 155:1, 18; 168:10;  
170:11; 174:15; 175:4, 6;  
177:15; 178:6; 180:18;  
181:20; 184:3, 18, 20;  
185:8; 186:14, 20; 187:13;  
188:10; 192:6, 21; 193:9,  
23; 195:23; 196:2; 197:14;  
15, 23; 198:5; 199:16;  
200:20; 201:9; 206:13;  
209:5; 210:24; 216:23;  
218:7, 10; 219:6, 8;  
220:15, 21; 222:11; 223:2,  
24, 25; 230:5; 238:1;  
241:11, 15; 242:18, 20;  
243:19, 22; 245:19, 24, 25;  
246:8, 24; 247:12, 15;  
248:6, 14; 259:5; 263:9;  
270:24; 274:15; 275:23;  
276:2, 25; 277:6; 279:5, 6;  
281:2; 287:4; 289:3;  
290:20; 292:22, 25;  
294:21; 298:7, 9, 10, 18;  
299:19; 300:9, 12; 301:12;  
302:4, 5, 23; 303:13;  
309:15; 310:22; 313:11;  
315:3, 13, 25; 316:4;  
317:4, 8; 320:20  
**data-clinical** 216:23  
**data-for** 114:5  
**data-is** 315:23  
**data-it** 301:8  
**data-other** 152:1  
**data-the** 26:10; 168:8  
**data-was** 56:18  
**database** 10:12; 75:5;  
105:22; 180:4, 23; 181:25;  
229:24  
**databases** 179:11;  
180:7; 201:23; 202:25  
**databases-Lederle**  
179:11  
**datasets** 271:1  
**date** 118:11  
**daunting** 236:11  
**David** 35:18  
**day** 85:10, 22, 24; 86:1;  
90:14; 118:17; 144:11;  
156:12; 158:16; 162:14,  
16; 164:2; 174:6; 187:23;  
211:21; 212:9, 21; 226:22;  
278:20; 322:21; 323:11  
**days** 38:1; 61:12; 86:1;  
116:15; 118:13; 131:25;  
145:2; 188:24; 195:11;  
196:7, 12; 212:8  
**dead** 116:18  
**deal** 29:3; 270:1; 272:25;  
318:17  
**dealing** 27:19; 64:13;  
269:20; 293:23  
**deals** 296:2  
**dealt** 285:15; 303:8  
**dean's** 164:15  
**death** 176:15, 18; 177:10  
**deaths** 170:21; 172:16;  
176:20  
**debatable** 254:12  
**debate** 131:9; 148:1;  
271:13; 275:1; 278:19;  
279:21  
**debating** 147:18  
**debilitating** 33:19  
**December** 130:6  
**decide** 117:6; 199:3;  
321:11  
**decided** 44:25; 48:24;  
64:9; 66:19; 67:13; 76:12;  
85:15; 94:1; 103:7; 119:3;  
139:25; 161:23; 164:1, 22,  
23; 165:4; 173:2; 219:23;  
246:16  
**decides** 202:21  
**deciding** 20:5; 21:7;  
45:25; 62:6; 118:5;  
151:18; 214:7; 293:24  
**decision** 11:24; 18:22;  
29:24; 36:11; 62:16; 63:2,  
8, 12; 84:25; 85:11, 12;  
88:4; 199:10; 221:19  
**decisions** 199:8; 241:12  
**declared** 46:25; 119:1  
**declaring** 118:5, 24  
**declined** 105:5; 170:13;  
214:2, 5, 10  
**decrease** 104:22;  
118:17; 127:12, 13, 13, 17,  
19, 24; 171:16; 249:3  
**decreased** 121:2; 170:6;  
178:23, 24; 179:20; 183:7;  
192:11; 215:12, 13; 218:5  
**decreases** 33:3; 56:9;  
195:8; 215:4, 6  
**decreasing** 33:7, 7;  
286:21, 21, 22; 287:23  
**dedicated** 318:16  
**deduce** 75:6  
**deep** 161:22  
**defer** 38:20; 311:17  
**deficit** 43:14; 231:23;  
232:12, 20; 235:22;  
283:21; 292:11; 312:6  
**deficits** 70:22; 232:6;  
283:22; 310:16; 312:20  
**define** 70:19; 72:15;  
244:9; 259:8; 284:20;  
289:6; 294:12; 310:18;  
316:3  
**defined** 12:9; 43:19; 46:2;  
116:15; 118:13; 131:25;  
13, 19; 48:13; 50:8; 52:17;  
70:15; 76:24; 77:1; 81:17,  
23; 96:16, 17; 98:20; 99:1;  
109:14, 17, 22, 25; 115:5,  
18, 20, 22; 118:4; 128:22;  
137:25; 138:1; 216:3, 7;  
272:4, 5, 285:22  
**described** 13:8; 25:22;  
50:20; 71:12; 99:7; 141:9  
**describes** 43:25; 117:8;  
168:20; 169:5; 309:10  
**description** 11:3; 43:24;  
68:12; 179:15; 220:12  
**descriptions** 219:11  
**design** 17:21; 42:17;  
43:1; 48:13; 94:1, 3; 96:4;  
97:1; 99:11; 122:13;  
216:12; 219:18; 222:9;  
262:21; 263:11; 265:11;  
274:3  
**designated** 42:4; 174:17  
**designation** 34:8  
**designations** 228:6  
**designed** 17:19; 18:7;  
43:10; 96:9; 108:19, 20;  
109:16; 140:12; 175:5;  
183:17; 187:12; 201:8;  
223:21; 224:2; 245:23;  
250:12; 258:9  
**designing** 108:20  
**despite** 161:19; 217:2;  
218:10; 221:23; 229:5;  
293:14  
**destructive** 39:6  
**detail** 10:6; 32:15  
**detailed** 59:15  
**details** 26:14; 28:20  
**detect** 194:23  
**detected** 97:10; 171:19;  
198:1  
**deteriorated** 53:24;  
144:17  
**deteriorating** 96:20;  
121:4; 260:21; 280:3, 6  
**deterioration** 69:17;  
70:17; 102:14; 113:12, 13,  
15; 119:13; 229:11, 20;  
241:18; 290:8, 10  
**deterioration-not**  
114:24  
**determination** 69:24;  
113:11, 25; 274:16  
**determine** 20:20; 47:16;  
72:7, 8; 82:20; 126:20;  
177:17; 195:19; 209:9;  
220:7; 263:1; 297:22  
**determined** 6:20; 62:11;  
65:21; 66:10, 14; 115:7;  
214:3  
**determining** 8:13  
**devastating** 229:6  
**develop** 161:16; 185:16;  
199:18, 19; 212:12;  
273:16  
**developed** 48:3; 169:19;  
179:12  
**developing** 93:2; 163:1  
**Development** 30:15;  
282:6; 312:6  
**develops** 38:3, 12  
**deviation** 223:11  
**dexrazoxene** 38:17





ECG 203:19	8, 15; 24:16; 29:11; 31:11; 33:6; 39:7; 45:4; 46:8, 11; 50:14; 52:2; 54:3, 12; 56:21; 66:2; 76:17; 80:6, 15; 86:1, 1; 87:3; 94:8; 98:17; 108:23; 122:14; 123:19; 124:4, 10, 11, 19, 25; 125:3, 6, 23, 24; 126:12; 127:11; 128:4; 129:13; 138:19; 139:1; 140:11, 14; 141:10; 142:11, 19; 144:6, 9, 14; 145:16; 151:21; 152:2, 3; 169:11; 193:8; 209:9, 13; 217:4, 8; 218:17, 24; 222:5; 229:1; 254:8, 15; 262:22; 263:5; 264:13; 265:15, 22, 23; 266:19; 267:1, 11, 19; 268:14; 269:7, 8, 10, 16, 20; 272:9; 273:25; 275:7, 8, 17, 19, 19; 276:5; 278:12, 12; 279:24; 282:10; 285:2, 5, 13, 17; 286:3, 4, 7, 9; 289:1, 25; 292:2, 16, 18, 19; 293:1; 296:9, 14; 297:14, 16; 299:16, 17, 18; 301:23; 302:22; 303:2, 10, 16	eight 176:9, 11, 12; 197:19	ended 122:1; 231:16	entered 137:14; 229:11
<b>echo</b> 37:15; 111:21; 306:2	<b>eighties</b> 127:10; 181:1	<b>ending</b> 240:15	<b>entire</b> 303:15	
<b>echocardiogram</b> 178:12; 198:12, 21; 298:23; 299:5	<b>Eighty</b> 112:6, 8	<b>endometritis</b> 190:11	<b>entirely</b> 24:19, 25	
<b>echocardiograms</b> 172:18; 178:14, 18	<b>Eighty-six</b> 183:2	<b>endorse</b> 306:25	<b>entities</b> 17:7; 256:16	
<b>echocardiography</b> 203:20	<b>Einstein</b> 4:16	<b>endothelial</b> 39:15	<b>entitled</b> 25:1; 268:2; 270:8	
<b>echochardiograms</b> 169:14	<b>either</b> 11:14; 19:1; 23:9, 25; 28:1; 31:24; 36:6; 67:11; 81:12; 84:6; 87:19; 94:25; 97:15; 110:15; 112:2; 134:14; 146:20; 147:22; 150:1; 154:2; 164:24; 177:18; 179:22; 188:2; 200:17; 223:19; 227:3, 15; 243:2; 245:6; 256:24; 260:20; 302:6; 312:4	<b>endpoint</b> 29:22; 65:24; 67:5, 14; 81:6, 7; 94:2; 98:20; 99:1, 3; 104:7; 105:2, 9; 129:7, 11; 154:18; 167:18; 216:25; 224:6, 14; 245:25; 279:4; 290:11	<b>environment</b> 91:4	
<b>Edan</b> 35:9; 96:9; 110:2, 4, 22; 111:2; 112:5, 8, 12; 115:15, 19, 22; 116:4, 14; 117:2, 11; 118:8, 9; 119:2, 7; 134:24; 137:20; 138:4, 9, 10; 139:7, 12, 17; 146:17; 224:2, 4; 232:1, 25; 233:4, 6, 21, 25; 234:5, 10, 13; 238:20; 242:11	<b>ejected</b> 170:5	<b>endpoint-patients</b> 98:24	<b>eocynofil</b> 128:6	
<b>Edan's</b> 134:19; 136:16; 137:17; 200:23	<b>ejection</b> 36:10; 169:22; 251:8	<b>endpoints</b> 26:13; 56:19; 66:5, 25; 67:1, 16; 77:3, 9; 99:6; 104:6; 129:9; 143:13; 167:18, 18, 20, 23; 205:15; 210:12; 216:2, 12, 13; 217:11; 225:4, 5; 240:21; 245:23, 24; 262:25; 268:18, 18	<b>eocynofils</b> 128:4	
<b>edema--a</b> 149:23	<b>elaborate</b> 241:8; 247:1; 315:22	<b>ends</b> 8:5; 274:18	<b>eosinophils</b> 128:2	
<b>EDSS</b> 10:20; 12:21; 18:12; 43:19, 21, 23, 24; 44:1, 3, 4, 7; 46:9, 20; 47:11, 14, 16; 49:24; 50:2, 3; 51:1, 3, 4, 5; 52:24; 53:1, 3, 4, 6, 7, 9, 13, 16, 17, 18; 54:25; 55:9; 61:20, 23; 66:4; 71:11, 17, 20, 21; 72:15; 76:20; 77:18, 20; 80:6, 16; 91:6, 16, 17, 22; 92:14; 93:14, 14; 94:4, 10, 18, 24; 96:17, 20; 97:3; 99:7; 103:5, 18, 21; 104:2; 106:16, 25; 107:1, 2, 15, 21, 25; 108:6; 109:7, 7, 10, 18; 110:8, 9, 17, 23, 25; 111:2; 113:11, 15; 114:6, 11, 13; 115:24; 117:4, 6; 119:13, 14, 22; 121:2, 24; 122:4, 6; 131:21; 132:13, 17, 22, 25; 133:9, 12, 14, 16; 134:4, 8, 11, 14; 135:4; 136:1; 138:21; 140:14; 141:15; 151:2; 176:3, 5; 205:3, 8, 13; 208:11, 17; 209:17, 18; 215:3, 11; 216:14, 25; 217:9; 218:22; 220:18, 21, 23; 230:9; 232:4; 233:10; 234:7, 9; 235:1, 15; 237:5; 238:22; 240:22; 248:9; 258:21, 23; 259:4; 269:15; 282:23; 284:21; 290:7; 297:2, 7; 302:20; 304:7; 313:4	<b>elaborating</b> 242:8	<b>energy</b> 39:16; 158:5		
<b>EDSS--and</b> 133:9	<b>elaborations</b> 242:17	<b>engineering</b> 157:25	<b>equivocation</b> 313:6	
<b>EDSS--this</b> 55:6	<b>elected</b> 108:24; 170:25; 175:25	<b>England</b> 152:21	<b>erabinocide</b> 40:10	
<b>educated</b> 204:11	<b>electrocardiogram</b>	<b>English</b> 41:17	<b>Erich</b> 35:11	
<b>education</b> 204:13, 14; 206:18; 318:2, 4, 8; 319:9	172:19	<b>enhanced</b> 283:2	<b>erratically</b> 69:10	
<b>educational</b> 199:5; 202:24; 203:10; 204:18, 20; 206:21	<b>electrocardiograms</b> 169:13	<b>enhancement</b> 23:7; 57:3; 136:25; 137:4, 6; 142:17; 144:22; 257:22; 270:17; 271:6; 275:18, 24; 281:22	<b>especially</b> 38:13; 90:1; 118:1; 226:15; 229:12; 236:19; 266:3	
<b>effect</b> 14:8; 16:6; 17:16, 20; 18:2, 4; 20:3; 21:19, 19, 21, 21, 25; 22:19; 23:6	<b>effective</b> 161:16; 199:19; 211:7; 225:13; 230:6, 10; 239:23; 240:1; 297:21	<b>enhancement</b> -- <b>and</b> 57:4	<b>especially--and</b> 295:7	
<b>efficacy</b> 34:20; 35:23; 40:18; 41:10; 42:17; 46:2, 3, 4; 48:21; 49:1, 2; 50:7, 10, 16, 19; 52:1, 17; 55:18; 67:24; 96:4; 98:20; 99:6; 101:16; 102:3, 5, 13; 104:6, 7; 129:11; 167:1, 13; 175:6; 205:14; 216:2, 4, 11; 243:23; 248:9; 254:5; 269:2; 284:4	<b>else</b> 131:7; 162:23; 194:21; 235:23; 238:4; 244:11; 245:15; 265:17; 291:1; 295:11; 306:1, 4, 5; 308:16	<b>enhancement--or</b> 57:2	<b>especially--and--</b> 102:3;	
<b>efficacy--64</b> 49:5	<b>else--Dr</b> 322:19	<b>enhancing</b> 11:11; 57:22; 58:3; 99:3; 107:21; 149:2; 221:25; 270:22	112:22; 133:13; 222:21; 225:7; 245:18; 317:22	
<b>efficacy--did</b> 102:22	<b>else--that</b> 291:19	<b>enlighten</b> 230:16	<b>established</b> 25:15; 181:11; 242:21	
<b>effort</b> 90:21; 91:18; 160:13; 175:6	<b>else--voting</b> 301:15	<b>enough</b> 16:19; 37:20; 80:12; 104:3; 162:19; 166:12; 235:16; 263:15; 272:11, 12; 277:19; 278:11; 294:11; 304:15; 320:20; 322:16, 17	<b>estimated</b> 47:3; 99:13	
<b>efforts</b> 91:13; 206:21	<b>Emeritus</b> 5:7	<b>enriched</b> 136:25	<b>et</b> 47:12; 64:16; 76:20; 86:2; 90:16; 99:11; 127:5, 25; 153:17; 277:2, 4; 278:18; 294:25; 308:12; 314:20; 319:22	

99:23; 102:2, 3; 106:21, 24; 114:1; 121:2; 122:2; 14:16, 19; 169:13; 17; 172:20; 181:24; 182:23; 198:13; 205:8, 12; 213:10, 11; 214:7; 216:13; 248:7, 10; 262:25  
**evaluations** 48:11; 65:16, 17; 98:1, 2, 12; 123:2; 216:7  
**evaluator** 132:22  
**evaluators** 45:12; 61:22; 67:25; 105:10; 268:12  
**even** 6:17; 16:22; 18:15; 78:1, 2; 85:16; 91:25; 93:1; 95:5; 103:16; 106:6, 9; 118:12; 137:7; 139:13; 143:4, 5; 145:17, 18, 22; 149:3; 155:20; 187:4, 22; 188:22; 203:17; 209:10, 23; 217:23; 221:11; 229:22; 232:22, 22; 238:15; 239:14; 251:2; 254:9; 259:25; 269:24; 272:16; 280:25; 285:21; 298:5; 301:21; 310:21; 313:10; 315:13; 321:18  
**evenly** 11:16  
**event** 7:20; 23:4; 168:13; 173:2; 176:22; 178:20; 179:6; 182:1; 188:25; 206:11; 282:3; 321:10  
**nts** 12:20; 26:2; 24; 168:21, 25; 169:1, 6, 8; 172:3, 8, 11, 13, 25; 175:20; 181:17; 183:14; 15; 189:20; 194:10; 195:19, 21; 211:3, 13; 213:24  
**eventually** 86:5; 146:8; 191:17; 266:11  
**every-3-month** 147:9; 169:14; 190:18  
**every-3-week** 190:19  
**everybody** 59:17; 159:22; 160:6; 236:12; 237:6; 274:15; 279:14; 295:23; 308:16; 316:12; 322:21, 22  
**everyone** 87:24  
**evidence** 13:8, 17, 20, 22; 14:1, 6, 7, 15, 25; 15:3, 5, 20; 19:9; 20:20; 21:2; 24:15; 26:18, 20; 27:1; 29:13; 36:7; 39:16; 42:14; 69:8; 84:4; 103:5; 142:13; 145:15; 155:8; 178:15; 186:4; 202:2; 207:5; 212:21; 213:6, 6; 216:17; 217:18; 218:4, 15; 232:17; 24; 237:21; 257:10; 258:17; 261:21; 263:21, 23, 25; 264:4; 265:21; 24:27; 277:21; 280:12, 16; 281:2; 282:4, 5; 284:12; 288:1, 1; 291:8, 8, 10; 292:18; 293:7; 294:1, 6, 7, 10; 296:21; 306:16; 307:17; 313:19; 314:17,

22  
**evident** 104:12  
**exacerbation** 263:24; 274:17  
**exacerbations** 227:1, 15, 21, 24; 229:2; 236:10; 261:1, 17; 273:24; 274:11  
**exact** 116:16; 188:2; 302:16; 306:25  
**exactly** 39:21; 65:6; 107:7; 152:19; 255:14; 276:8; 284:20; 302:8; 304:23  
**examination** 69:20; 71:4; 91:14; 213:16  
**examine** 17:19; 72:4  
**examined** 44:20; 220:16; 299:5  
**examiner** 95:1, 1  
**examiners** 29:20; 65:9, 10; 91:15  
**example** 14:16; 16:3; 21:10, 25; 46:22, 23, 23; 74:1, 24; 80:15; 123:23; 124:9; 127:24; 132:25; 149:1; 150:14; 151:19; 269:18; 287:17, 19; 293:25; 319:6  
**example-and** 23:25  
**example-this** 21:9  
**examples** 21:17; 206:23  
**exceed** 146:9; 321:7; 322:9  
**exceeds** 198:17  
**except** 89:11; 168:24; 288:13; 305:17  
**excess** 283:3  
**exclude** 7:23; 41:5; 175:2; 200:3; 250:3  
**excluded** 44:12; 231:7; 262:6  
**excluding** 34:17; 214:12; 225:14; 239:2; 306:12  
**exclusion** 7:24; 44:10; 96:23; 261:20  
**excruciatingly** 206:24  
**Excuse** 102:18  
**executed** 203:20  
**Executive** 4:20; 204:2  
**exhaustive** 21:10  
**exist** 249:13  
**existence** 207:19  
**existing** 70:17; 116:22; 200:5  
**exists** 249:21  
**expanded** 34:13; 47:10  
**expect** 80:14, 22; 83:19; 134:13; 137:2; 193:3; 202:17; 250:22; 262:24; 276:9  
**expectations** 135:24  
**expected** 124:19; 154:14; 178:11; 187:17, 19; 212:20; 226:14; 273:2  
**expecting** 156:2

**experience** 9:2; 28:21; 32:10; 40:22; 42:10, 10; 80:8; 85:8; 125:1; 138:10, 12; 139:1, 7, 8; 147:11; 161:14, 23; 179:8, 13; 180:25; 193:15, 19; 194:22; 198:9, 17; 200:14, 22; 202:12; 206:3; 212:24; 225:9; 233:13; 241:19; 242:12, 18; 244:3; 305:21, 22; 315:24; 318:16, 17; 321:21; 322:8  
**experienced** 27:21; 57:14; 73:2; 91:16; 158:12; 173:24  
**experimental** 228:7  
**experimentally** 84:6  
**experiments** 38:25  
**expert** 21:2; 35:19; 91:9; 152:21; 237:20; 249:5  
**expertise** 35:17; 57:10; 249:23  
**experts** 17:4, 5; 147:25; 149:16; 153:1; 196:3; 201:17; 248:8; 286:5  
**experts--since** 271:20  
**explain** 43:11; 45:17; 55:10; 93:18; 162:22; 209:10; 282:21  
**explained** 93:7; 209:12  
**explaining** 219:23  
**explicit** 29:6  
**exploratory** 45:3; 205:22  
**explore** 71:9; 145:14; 153:10; 319:14  
**explored** 265:2  
**expose** 86:7  
**expressed** 229:3; 254:1  
**expression** 257:4  
**extant** 133:23  
**extension** 317:15  
**extension-and** 236:2  
**extensive** 179:15  
**extensively** 174:16  
**extent** 14:4; 33:3; 126:3; 127:13; 223:15; 271:21; 272:14; 289:21; 298:9  
**extra** 309:2  
**extremely** 66:4; 85:25; 88:7; 187:9; 188:25; 243:20  
**eye** 92:5

**F**

**face** 18:16; 165:25; 167:10  
**face-valid** 23:18  
**facie** 186:3  
**facilitate** 202:19  
**facing** 165:25  
**fact** 10:12; 21:20; 24:19; 28:15; 32:6; 40:2, 9; 44:11; 48:4; 63:13; 64:9; 65:2;

73:17; 79:24; 86:9; 91:7; 101:19; 103:14; 107:17; 109:2; 117:8; 123:10; 126:19; 131:20, 24; 132:4; 134:18; 142:15; 143:14; 148:16; 150:17; 152:20; 168:3; 170:21; 173:3; 176:4; 182:19; 183:14; 187:18; 191:8, 18; 194:12; 195:23; 196:17; 197:22; 200:7, 23; 201:2; 205:12; 207:19; 217:9; 222:25; 228:4; 231:4, 10, 11, 13; 232:5, 9, 10, 11, 19; 235:15; 241:16; 243:4; 247:9, 25; 250:5, 11; 254:10; 259:23; 260:19, 21; 261:1, 14; 264:19; 272:15, 20; 277:13; 279:22; 284:11; 287:16; 294:4; 296:7, 21; 297:4; 298:6; 305:5; 309:13; 314:4  
**facta** 23:24  
**factor** 170:1  
**factored** 124:16; 135:21  
**factors** 200:7; 251:9  
**facts** 263:13  
**factual-but** 270:7  
**fail** 242:21; 243:11  
**fail-and** 242:9  
**failed** 200:24; 201:6; 229:12; 248:2, 4; 256:11  
**failure** 25:19; 123:3, 5; 169:19; 176:21, 24; 177:3, 4, 9, 10; 178:16; 179:19; 180:19; 181:18; 198:18; 199:18; 213:5, 7; 266:13; 268:1, 3  
**fair** 20:3; 32:15; 154:16; 221:7; 259:2; 288:19  
**fairest** 148:15  
**fairly** 31:24; 207:20; 236:5; 243:24; 247:2; 271:1; 282:17  
**fairness** 8:2  
**faith** 287:22  
**false** 295:14  
**familiar** 29:18; 30:10, 11; 57:4; 97:20  
**family** 158:15; 164:2; 177:21; 182:12  
**far** 10:22; 19:20; 22:12; 40:7; 61:25; 90:9; 91:6; 129:13; 130:12; 144:5; 151:4, 23; 190:19; 195:6; 198:3; 207:11; 208:17; 211:5; 217:23; 237:20; 244:9; 255:12; 263:11; 277:18; 278:8, 11, 17; 282:15  
**fashion** 268:22; 271:22; 293:17  
**fast** 166:19; 253:14  
**fatal** 320:1, 2  
**fatalities** 320:21  
**fatality** 320:23

**father** 158:15  
**fatigue** 162:14  
**favor** 51:7, 15, 23; 52:11; 54:12; 94:7, 19; 129:15; 145:6  
**favor-there** 314:15  
**FDA** 4:5; 6:3; 7:1, 21; 28:15; 33:25; 34:1; 78:14; 79:21; 132:3; 134:24; 153:23; 163:14; 179:14; 182:9; 190:23; 191:21; 223:7; 302:11; 319:13  
**FDA's** 7:7; 182:23  
**FDA-in** 28:14  
**febrile** 187:10; 188:11, 25  
**feed** 166:7  
**feel** 9:11; 17:4, 6; 34:12, 23; 137:11, 17; 162:14; 199:20; 228:3; 238:2; 250:10; 263:8, 15; 289:7; 292:9; 294:2; 298:10; 307:12; 315:14  
**feeling** 92:1; 151:14; 209:14; 235:9; 239:25; 274:14; 278:16; 286:24; 301:13  
**feels** 35:1; 38:3; 155:8; 291:5; 308:16  
**feet** 157:19  
**felt** 59:23; 72:5; 106:14; 20; 278:18  
**felt-and** 63:14  
**fever** 38:2, 12; 70:23; 171:19; 190:14, 14, 17; 212:11, 12  
**few** 5:22; 8:24; 26:3; 72:16; 84:3; 121:7; 131:2; 144:25; 145:2; 154:22; 178:7; 181:3; 193:10; 210:5, 15; 249:17; 251:7; 256:2; 290:19  
**few--who** 243:10  
**fewer** 57:24; 104:10; 183:3  
**fibers** 150:8  
**fide** 19:1  
**field** 133:21; 148:2; 235:11; 248:8  
**field-is** 196:3  
**fifth** 83:20  
**Fifty** 166:7  
**fifty-four** 174:23  
**Fifty-seven** 54:3  
**figure** 74:23; 92:25; 199:17; 236:10; 285:16; 289:11  
**filed** 34:4  
**filings** 34:23; 42:7, 8; 221:15  
**fill** 219:22; 300:3  
**filled** 164:13; 220:11  
**fills** 162:23  
**final** 245:17  
**finally** 43:21; 69:6; 206:3; 224:18



**Gissey - hematologic (14)**

**Min-U-Script®**

**Food and Drug Administration  
Peripheral & Central Nervous System Drugs**

**Hearing  
January 28, 2000**

**hematology** 37:14, 16  
**hemipareses** 312:19  
**hemiparesis** 260:13  
**hemoglobin** 171:10  
**hemogram** 212:18, 19  
**hemograms** 173:22  
**herbs** 79:6  
**herd** 156:8  
**here-a** 94:24; 107:19  
**here-are** 116:11  
**here-in** 143:21  
**hesitant** 265:6  
**hesitate** 160:1  
**Hickey** 160:21  
**high** 37:20; 103:5; 184:4; 187:9; 201:24; 233:8, 12; 251:3; 269:18; 271:7  
**high-dose** 32:1; 61:10; 142:18; 316:2  
**higher** 25:23; 36:12; 47:17; 60:5; 73:21; 114:12; 133:17; 176:3; 186:23; 187:8; 188:7; 190:9; 196:10, 12; 205:4; 209:24; 210:1; 226:16; 230:9; 321:18  
**higher-that** 192:19  
**highly** 66:1; 96:17, 19; 121:3; 185:10; 218:19; 222:11  
**Hill** 35:15; 161:17  
**himself** 95:19  
**hip** 164:19, 19, 23  
**hired** 82:25; 175:4  
**Hispanic** 162:9  
**histologic** 282:4; 309:12  
**historical** 75:21  
**history** 13:24; 33:24; 49:23; 70:25; 71:2; 96:16; 103:24; 151:25; 155:3; 250:20; 321:15  
**hit** 236:5  
**hits** 162:11  
**hole** 293:20  
**home** 65:23; 73:25; 75:10; 177:7; 187:24; 219:4  
**homogeneity** 228:6  
**hope** 29:18; 30:11; 154:18, 22; 159:22; 239:23; 242:5; 252:10; 289:11; 320:4  
**hope-if** 295:9  
**hopefully** 13:2; 137:12; 199:7; 242:1; 248:19  
**hopes** 295:14  
**hoping** 317:24  
**Hopkins** 4:25  
**hormone** 31:9  
**hormone-refractory** 9:25  
**horse** 116:18  
**Hospital** 5:6; 95:22, 22; 164:6; 195:13; 319:16;

320:25  
**Hospital's** 7:13  
**hospitalization** 171:20; 190:7; 195:10, 20; 196:3, 7  
**hospitalization-and** 190:2, 4  
**hospitalizations** 195:5, 17, 18; 196:12, 17, 19, 22; 197:3, 6  
**hospitalized** 195:7, 7; 196:5, 10  
**hours** 68:24; 70:23; 87:17  
**house** 164:1, 7  
**Houston** 4:14  
**how-do** 153:9  
**Howard** 7:7; 95:18, 20; 240:11  
**huge** 182:16  
**human** 33:14  
**hundred** 48:16; 174:23; 248:15  
**Hungarian** 89:7  
**Hungary** 24:20  
**husband** 163:8, 25; 166:2, 15  
**hyperbilirubinemia** 190:24; 191:22  
**hypothesis** 46:7; 267:15; 280:17; 286:23  
**hypothetical** 282:9; 287:15

**I**

**idea** 16:1; 39:13; 86:7; 115:20; 192:8; 203:22; 279:9; 293:9; 307:22; 309:3; 316:15  
**idea-even** 236:21  
**idea-from** 236:21  
**ideal** 321:10  
**identical** 87:15; 209:5; 225:7; 245:22  
**identified** 101:14; 174:24; 178:22  
**idiosyncratically** 251:3  
**ignorance** 142:20  
**II** 32:23; 42:6; 59:3; 123:17; 281:13; 302:18  
**III** 34:2; 35:9; 42:4, 21; 104:2; 121:22; 127:16; 140:22; 146:11; 147:15; 167:17; 189:17; 215:1; 225:4; 246:8; 247:21; 281:15  
**IL-12** 257:4; 286:21  
**IL-2** 33:8; 127:17, 19  
**ill** 38:3  
**ill-defined** 12:8  
**Illinois** 5:8; 320:11, 11  
**illness** 161:24; 246:20  
**illustrate** 43:23  
**illustration** 320:9

**imagine** 45:11; 76:23; 90:4; 147:2; 173:3; 208:3; 302:2; 303:19  
**imagined** 150:23  
**imaging** 150:24, 25; 283:2, 16  
**immediately** 6:7; 144:10; 150:12  
**imminently** 222:25  
**immobility** 185:23  
**immune** 257:3, 24; 286:23; 294:3  
**Immunex** 6:1; 7:17; 9:14; 41:1; 42:7; 69:5; 128:11; 160:5; 179:10; 180:22; 181:3; 195:4; 203:1; 215:18; 316:21  
**immunologic** 124:20; 126:6; 128:3, 9; 228:2; 257:7  
**immunologically** 257:2  
**immunology** 127:1  
**immunomodulator** 289:8  
**immunomodulatory** 33:2, 5; 129:21; 138:24; 242:4; 243:11; 286:15  
**immunosuppressive** 124:21; 138:24  
**impact** 38:17; 145:5; 160:3; 295:18  
**impair** 104:3  
**impaired** 185:16  
**impairment** 44:4; 47:17; 23, 25; 121:1; 152:12; 165:13; 191:5; 259:10  
**impairment-that** 61:20  
**imperfect** 155:20; 288:6  
**imperfectly** 288:9  
**implication** 291:18; 309:11  
**implies** 17:16; 292:2  
**implore** 163:14  
**imply** 257:6; 320:4  
**importance** 154:9  
**important** 7:2; 9:19; 13:4; 15:2; 25:2; 71:17; 83:23; 93:17; 111:11, 19; 124:17; 129:18; 130:15; 148:21; 151:17; 200:13; 203:14; 211:19; 228:1; 236:13; 265:15, 15; 266:17; 279:1; 282:3; 283:12; 284:25; 290:8, 11, 12; 292:15; 307:21; 315:12  
**importantly** 276:23  
**imposed** 27:17; 50:4  
**impossible** 118:11; 162:18; 212:11; 322:14  
**impressed** 224:9; 296:21  
**impression** 136:18; 138:5; 185:9, 11; 186:6; 241:21; 245:8; 263:17; 319:24  
**impressive** 298:8

**improve** 138:20; 142:1; 281:7; 299:19  
**improved** 53:3, 20; 107:1; 118:15; 119:14, 22; 208:25; 295:25; 299:18  
**improvement** 51:6, 21; 93:15; 123:4, 23; 145:18; 227:3, 4; 264:14  
**improving** 124:15; 264:16  
**inactive** 91:8  
**inadequate** 288:23  
**inappropriately** 305:15  
**inaudible** 72:19; 91:1  
**inch** 259:15  
**incidence** 36:19; 40:5, 8; 179:18, 20; 181:23; 186:23; 188:1, 7; 201:1; 266:13; 270:19  
**incidentally** 29:15  
**include** 20:19; 43:7; 49:1, 2; 59:25; 233:4, 6; 248:6; 311:4; 317:24  
**included** 48:13, 21; 106:3, 5; 107:6; 136:24; 139:22; 180:10; 216:13; 230:2, 17; 237:2; 254:1; 258:14  
**includes** 93:23; 179:25; 189:24; 194:11  
**including** 10:19; 13:11; 62:10; 179:13; 212:16; 216:13; 226:13; 240:22; 319:3  
**inclusion** 12:13; 43:6, 18; 96:14  
**incomplete** 128:23; 227:4, 5; 228:16  
**incorporated** 82:17  
**incorporates** 13:14  
**incorporating** 313:17  
**incorrect** 12:12  
**increase** 12:10; 36:13; 53:8; 70:15; 81:12; 110:9; 111:2; 116:21; 143:6; 186:1, 17; 191:14; 320:2  
**increased** 49:25; 53:4, 18; 58:17; 128:2; 143:22; 181:23; 184:25; 191:7; 195:11; 200:16; 201:1; 224:11; 232:4; 257:18, 19; 258:23  
**Increased-you** 185:1  
**increases** 51:4  
**increasing** 25:16; 199:21  
**increment** 48:7; 70:7  
**increments** 47:23; 48:7  
**increments-so** 47:12  
**Indeed** 74:16, 17; 102:24; 106:13; 140:8; 141:18; 144:25; 146:17; 151:1, 6, 14; 153:17; 186:19; 188:5, 7; 191:2; 205:6; 216:24; 218:1; 241:6  
**independent** 13:14; 14:23; 206:1, 2; 228:18; 254:4  
**independently** 100:21  
**Index** 10:21; 46:9; 47:20, 24; 51:12; 54:25; 55:8, 9; 61:21; 91:19; 121:25; 122:6; 133:9, 16; 151:3; 209:4, 4; 240:22; 269:15  
**indicate** 38:7; 69:19; 128:3; 182:1; 204:6  
**indicated** 30:23; 36:12; 42:1; 214:19; 219:12; 245:1; 265:24; 316:22  
**indicates** 44:4; 47:24; 51:5, 6, 20, 20; 215:15; 217:11  
**indicating** 81:4  
**indication** 9:16, 24; 16:21, 22, 22; 17:16; 26:19; 27:2, 3, 7; 31:1, 18; 34:13, 21; 37:12; 53:10; 60:21; 141:1; 206:6; 244:7, 20; 245:9; 261:23; 306:17; 308:9; 314:18, 18  
**indications** 31:7; 269:7  
**indicative** 170:6  
**indirectly** 33:6  
**individual** 17:1; 28:25; 29:1, 20; 66:13; 82:21; 94:24; 107:19; 142:3; 213:21; 214:4; 259:10; 320:23  
**individually** 50:24  
**individuals** 149:3  
**induction** 31:7, 21, 24; 138:14, 20, 23; 139:2; 141:8; 146:19, 24; 147:3; 243:8  
**industry** 161:10  
**inelegance** 312:13  
**ineligible** 48:18  
**infection** 38:3; 171:21; 181:23; 183:1, 15, 18; 184:5, 14; 185:6, 10, 21; 186:4; 187:21, 22; 188:4; 189:14, 22, 23; 190:10, 16, 20; 196:17; 198:1; 212:22  
**infection-really** 189:24  
**infections** 177:24; 182:22; 183:3, 5, 9, 15, 16, 23; 184:6, 9, 12, 23; 185:12, 17; 186:2; 190:1, 1  
**infinitesimally** 200:10  
**inflammatory** 58:9, 21; 98:17; 149:20; 222:6; 282:2  
**influence** 67:5; 118:25; 183:24; 271:23; 274:13  
**influenced** 206:11  
**influx** 277:22  
**inform** 8:8; 93:10  
**informally** 8:6  
**information** 6:19; 15:20; 24:13; 38:16; 40:21; 64:4; 74:11; 75:21; 80:1; 100:1; 115:13; 125:9; 128:6; 130:13, 14, 22; 132:2;

135:7; 150:2; 155:21;  
162:6; 168:7; 174:13;  
175:9; 177:18, 20, 20;  
179:7, 9, 16; 180:15, 17;  
181:9; 184:4; 193:25;  
202:23; 203:1, 20; 206:1,  
2; 207:14, 24, 25; 226:3;  
241:4; 248:17, 19; 249:7;  
250:25; 290:21; 304:15;  
318:1  
**information--there**  
170:20  
**informed** 203:18  
**informing** 207:6  
**infusion** 29:10; 63:22,  
22; 86:15; 246:9  
**infusions** 44:18  
**ingredient** 200:1  
**inherently** 149:13  
**inhibit** 58:21  
**inhibiting** 32:20  
**inhibition** 32:22  
**inhibitor** 123:4, 15; 268:2  
**inhibitors** 123:18  
**inhibits** 58:23; 123:10  
**initial** 28:22; 31:13;  
82:22; 154:18; 245:4  
**initially** 16:3; 86:18;  
243:2, 10  
**initials** 101:14  
**immediate** 277:22  
**implied** 247:12  
**initiation** 202:8  
**injection** 118:17; 126:19;  
199:17  
**Innovative** 4:16  
**insert** 36:22; 38:7, 9;  
181:11; 191:4; 199:1, 5;  
202:18, 23; 203:9; 214:19;  
307:4; 316:14; 321:23;  
322:4, 10  
**inside** 161:17  
**insight** 277:18  
**inspiration** 167:11  
**instance** 220:18; 268:20  
**instances** 72:16; 194:23;  
269:18  
**instigation** 74:15  
**Institute** 5:11, 15  
**instructed** 91:15  
**insufficiency** 178:25;  
182:15  
**insurance** 300:14  
**int** 63:9  
**intend** 247:9  
**intended** 71:7; 207:23,  
24  
**intending** 127:16  
**intensity** 36:18; 172:12;  
200:7; 311:2  
**intensive--and** 300:24  
**intent** 178:4  
**intention** 207:15  
**intentionally** 177:17

**intentioned** 229:10  
**interacted** 208:6; 280:13  
**interaction** 21:11; 202:2  
**interactions** 33:24  
**interacts** 21:14  
**intercalation** 32:22  
**intercurrent** 134:10  
**Interest** 6:14, 16, 23, 25;  
7:22; 8:2; 21:4, 20; 148:13;  
151:22; 152:4; 173:18;  
176:22; 245:1  
**interest--what** 189:21  
**interested** 22:14; 23:2;  
68:17; 78:8; 240:5; 249:3;  
269:22; 303:20  
**interesting** 22:23; 29:23;  
60:19; 71:9; 78:6; 141:10;  
148:8; 243:20; 266:21;  
303:21; 323:10  
**interests** 6:21; 7:8  
**interfere** 280:11  
**interfered** 280:13  
**Interferon** 84:11, 14;  
127:4, 17, 20, 25; 146:21;  
21; 152:6; 200:15, 24;  
201:2, 6, 13, 17; 229:13;  
248:5; 286:11  
**Interferon--please**  
201:18  
**Interferon-Gamma** 33:9;  
257:4  
**Interferon-naive** 200:20  
**Interferons** 248:2, 3;  
255:13; 286:18  
**intermediate** 268:9  
**intermittent** 44:6; 260:20  
**international** 161:1  
**internists** 319:3  
**interpret** 307:14; 308:8  
**interpretation** 26:15;  
45:7; 187:2; 219:8; 267:5;  
310:20  
**interpreted** 13:12;  
287:24  
**interrupt** 59:4; 182:7;  
216:19  
**interval** 44:24; 175:18  
**intervals** 41:19  
**intervene** 232:25  
**into** 12:24; 20:5; 40:17;  
60:8, 10; 67:17; 71:20;  
77:9; 83:10; 97:11;  
111:10, 23; 122:23;  
124:16; 125:11, 11, 13;  
126:23; 131:9; 137:1, 14;  
148:1; 149:25; 163:3;  
164:16; 165:4, 19, 23;  
166:12; 175:19; 195:18;  
223:1, 10; 226:18; 227:14;  
229:24, 25; 235:1, 16, 18;  
237:6; 240:7, 18, 23;  
243:20; 246:12; 250:23;  
257:18; 261:5; 276:10;  
277:18, 22, 24; 285:4;  
313:2; 318:25  
**intolerance** 172:16, 22

**intracerebral** 125:11  
**intranuclear** 272:6  
**intravenous** 32:19;  
126:19; 246:9  
**intravenously** 44:17;  
97:6, 17  
**introduce** 4:5, 6; 5:16;  
6:13; 30:1, 14, 15, 20;  
35:22; 95:18; 112:17  
**introduced** 82:22  
**introduction** 41:2; 144:6;  
215:19  
**introductions** 29:25  
**introductory** 5:19  
**investigate** 147:1  
**investigation** 13:13  
**investigational** 16:13;  
63:17  
**investigations** 13:11, 12  
**investigator** 7:5, 18;  
35:8, 10; 147:2  
**investigators** 30:20;  
35:6; 57:14; 69:23; 93:7;  
10; 119:5; 146:7, 17, 25;  
173:1; 201:5; 219:14, 18;  
221:13; 235:10; 247:13;  
271:1  
**invite** 189:9  
**invited** 7:7; 8:24  
**involve** 7:20; 17:21;  
68:11  
**involved** 33:6, 41:17;  
45:15; 174:20; 250:8;  
291:14  
**involvement** 7:2, 24; 8:3;  
36:14  
**involves** 33:1  
**irregular** 192:18  
**irrespective** 282:11  
**irreversible** 14:9;  
233:10; 283:20  
**is--and** 150:6  
**is--as** 108:13  
**isn't--I** 219:20  
**issue** 6:16; 19:5; 24:8, 17;  
28:17; 29:5; 41:2; 59:14;  
63:15; 72:3; 84:20;  
107:13; 111:14; 116:11;  
120:2; 123:1, 20; 129:18;  
134:11; 136:20; 148:11,  
12; 149:15; 192:1; 197:18;  
218:2; 245:11; 259:19;  
263:22; 266:17; 268:4, 23;  
282:14; 283:6, 13; 284:20;  
293:8; 296:4, 24; 317:16  
**issues** 6:6, 7; 9:6, 9, 11;  
12:24; 13:5; 15:4, 7; 21:6;  
26:8; 28:4, 11; 30:6;  
136:15; 154:9; 204:20;  
224:18; 240:10; 252:1;  
253:18; 262:9; 280:11;  
284:5; 322:22  
**it--and** 18:11  
**it--is** 257:1  
**it--it** 274:18

**it-tell** 309:7  
**it--that** 88:7  
**it--the** 275:22  
**it--there** 187:16  
**it--they** 68:23  
**it--was** 11:3  
**it--we** 262:16  
**it--where** 108:6  
**Italy** 132:8; 146:18

## J

**Jerry** 5:1; 7:8; 111:22;  
257:12; 292:5  
**Jim** 4:13; 297:24  
**job** 158:20, 23; 315:8  
**John** 209:9  
**Johns** 4:25  
**joined** 95:18  
**Journal** 39:1  
**journals** 41:17  
**judge** 83:22  
**judging** 155:18  
**judgment** 68:13; 124:14;  
155:19; 237:22; 238:1  
**judgments** 263:19  
**July** 43:3  
**June** 9:14; 34:4; 43:2  
**just--and** 294:19  
**justify** 266:7, 16

## K

**Kaplan-Meyer** 55:20;  
76:4; 231:17  
**Kapos** 71:14; 270:25  
**Katz** 4:8, 9, 9; 6:5; 8:19;  
21; 28:12, 18, 19; 30:10;  
34:22; 36:12; 41:2; 46:5;  
59:5; 81:8, 10; 82:1, 6;  
83:4, 7; 91:21; 92:9;  
108:13; 114:14, 15, 22;  
115:8, 11; 116:1, 5, 6, 18;  
121:11; 122:11, 12;  
133:22; 135:13, 18, 19;  
150:6; 151:16, 17; 173:7;  
186:9; 204:23; 205:7;  
206:14, 15; 207:17;  
215:19, 23; 216:16;  
217:13, 14; 224:19;  
231:20, 21; 232:8, 16, 19;  
233:5; 238:8; 244:5, 6;  
245:12, 13; 247:9; 248:13;  
251:20, 24; 252:15, 20, 25;  
253:18; 254:13, 14, 20;  
255:6; 258:3, 5; 262:10,  
11, 21; 265:3, 4, 18; 266:2;  
267:6, 7; 269:4, 5; 270:7;  
271:18; 273:1, 21, 22;  
275:6; 276:12, 13; 278:9;  
281:18; 284:2, 7; 285:11,  
12; 291:1, 3, 9, 13; 292:14;  
298:2, 3, 13; 299:23, 25;  
300:20; 301:3, 16; 305:2,  
5; 306:4, 6; 310:19; 313:8,

9; 314:9; 317:13; 321:9;  
322:16, 17, 19, 20; 323:9  
**KAWAS** 4:24, 24; 62:7, 8;  
102:19, 20; 103:9; 132:20;  
182:8; 193:4, 5, 19; 194:4;  
285:24, 25; 287:9, 13;  
301:18, 19; 306:19;  
307:10; 308:4, 14; 314:2;  
315:11; 316:1, 4; 317:14,  
15; 318:21, 22; 320:17, 19;  
322:24

**keep** 9:19; 55:8; 64:4;  
74:22; 106:15; 156:3;  
161:21; 167:25; 264:22;  
280:9; 296:4

**keeping** 254:17

**kept** 93:10; 119:4  
**key** 141:4; 150:5; 260:17;  
277:11  
**key--it** 285:7  
**kids** 166:15  
**kill** 302:12; 321:2  
**kind** 72:22; 76:16; 91:3;  
137:11; 141:10; 151:25;  
154:7; 157:15; 158:6, 25;  
162:19; 166:3; 173:12;  
184:5; 240:14, 14; 242:13;  
14; 243:7; 246:2; 275:10;  
289:5; 316:13; 319:5, 21  
**kinds** 76:18; 79:11;  
80:21; 155:16; 230:16;  
242:3

**knew** 12:22; 18:24;  
45:22; 62:12, 13; 63:7;  
64:2, 3; 89:13, 14; 90:10,  
19; 93:8; 103:3; 130:6;  
146:7; 187:19  
**know--and** 88:6  
**know--Dr** 83:15  
**know--I** 116:6  
**knowing** 173:19; 176:21;  
22; 218:20; 250:6; 262:14;  
303:20; 316:11  
**knowledge** 64:16; 67:4;  
84:3; 161:11; 162:7;  
271:22; 318:8

**known** 9:15; 28:16;  
39:18; 40:5; 85:8; 93:2;  
169:10; 202:2; 214:22;  
302:6  
**known--at** 93:9  
**knows** 153:9; 155:21;  
249:6; 279:14; 289:22;  
316:12  
**Kurtzke** 12:10; 47:10;  
71:12; 81:13; 116:21;  
260:12; 280:4, 6  
**Kurtzke's** 71:23

## L

**lab** 64:16  
**label** 214:21; 239:16;  
271:22  
**labeled** 265:16; 290:1  
**labeling** 27:12; 206:24;

231:13; 262:17; 285:14; 289:15; 292:15; 310:21	learned 11:23; 162:13; 248:7; 259:13; 269:5	lesions--so 107:20 less 22:21; 33:3; 46:17; 50:18, 22; 53:19; 55:3; 56:16, 21; 105:6; 107:2; 108:7; 121:24; 122:4; 124:12; 129:20; 139:2; 145:23; 168:23; 170:6, 13, 18, 19; 110:6, 9, 14, 15; 116:19, 21; 122:15; 132:4; 136:23; 142:9; 143:8; 144:5; 146:12; 147:15; 148:23; 155:8; 174:21; 176:25; 188:25; 191:6; 192:15; 198:12, 21; 204:20; 206:12; 208:13; 209:2; 212:22; 227:18; 230:25; 233:7, 11; 235:13; 243:6, 24; 252:1; 257:17; 260:22; 270:16; 273:10; 274:10, 12, 14; 275:22; 282:3; 285:22; 289:22; 302:6; 304:14; 315:11; 322:25	303:16; 304:22 linkages 287:19; 288:3, 4	long-term 28:2; 32:12; 37:6; 39:7; 134:22; 142:22; 143:4; 174:13; 181:25; 182:4; 211:3; 248:15, 17; 288:2; 315:23
laboratory 171:23 LACEY 5:7, 7; 202:13, 14; 203:6, 24; 306:19; 320:6, 7, 14	least 12:9; 13:9; 16:5; 18:13; 19:8; 41:1; 43:19; 56:3; 69:7; 70:16, 22; 81:14; 93:9; 94:9; 96:18, 18; 103:15; 108:5; 109:10, 18, 19; 110:6, 9, 14, 15; 116:19, 21; 122:15; 132:4; 136:23; 142:9; 143:8; 144:5; 146:12; 147:15; 148:23; 155:8; 174:21; 176:25; 188:25; 191:6; 192:15; 198:12, 21; 204:20; 206:12; 208:13; 209:2; 212:22; 227:18; 230:25; 233:7, 11; 235:13; 243:6, 24; 252:1; 257:17; 260:22; 270:16; 273:10; 274:10, 12, 14; 275:22; 282:3; 285:22; 289:22; 302:6; 304:14; 315:11; 322:25	lesioned 228:11; 277:10 lesser 127:13; 284:16 letting 27:6; 160:9 leukemia 9:23; 31:8, 19; 39:23; 180:25; 182:3 leukocyte 171:13, 14, 16; 184:2, 4, 20, 22, 24; 186:22; 187:18, 20; 189:21; 203:19; 212:20 leukopenia 173:25; 174:3, 4; 187:5; 212:5, 8 level 66:2; 73:19; 111:1; 121:17; 138:21; 139:4; 155:8; 233:9; 239:15; 272:16; 277:17, 25; 289:16; 309:12 levels 73:22; 126:17, 18, 20, 20; 127:4; 149:3, 9; 233:9 license 317:21 life 29:7; 115:23; 117:4, 6; 157:17; 158:9, 10; 159:10, 11; 161:6; 166:1, 10; 195:6; 199:15 life-threatening 173:9; 300:18 lifelong 266:16 lifetime 29:12, 15 light 117:3; 254:7; 273:3 like--and 74:25 liked 285:3; 295:7 likelihood 201:13; 271:6; 300:11 likely 20:23, 25; 21:1, 3, 7; 37:24; 80:5; 129:20; 162:18; 186:25; 190:18; 193:16, 20; 196:13; 284:23; 300:6, 8 limit 29:8; 44:5; 249:12; 320:4 limitation 36:2; 50:4; 264:20 limitations 221:23; 320:5; 322:4 limited 41:8; 211:11; 228:8; 255:11 limited--and 127:15 limiting 315:8; 320:7 limits 185:2; 301:13 Lindamide 71:15 line 76:2; 85:22; 141:20; 162:16; 165:18; 234:25; 235:3; 237:2, 6; 238:11, 11, 12, 23, 25; 239:1, 1; 240:1, 2, 9; 244:10, 13 lines 236:9; 240:8; 241:5	list 77:21; 83:13; 98:9 list--but 21:10 listed 43:6; 44:10; 45:9; 46:19; 47:13; 48:10; 51:8, 16; 52:7; 96:14, 23; 172:13; 176:17; 180:7 listed--EDSS 129:10 listed--the 79:15 listening 279:1 lists 88:23; 195:5 lists--one 89:4 literature 25:17, 22; 149:7; 161:8; 179:13; 181:8 little 10:10; 14:13; 23:15; 28:19; 45:17; 55:5; 76:16; 86:10; 92:18; 112:16; 117:20; 118:22; 122:25; 124:8, 12; 135:23; 149:24; 154:17; 159:14; 163:23; 167:12; 172:21; 190:6; 219:23; 234:23; 242:8; 247:1; 258:6; 265:4; 274:18; 286:1; 300:6; 308:24; 311:20; 315:22; 319:2 live 157:9; 162:13; 293:9, 23; 320:9, 24 liver 191:1, 3, 5; 212:16 lives 160:4; 173:13; 247:3 living 158:13; 159:4; 160:6; 164:19 load 58:12, 15, 17; 143:1; 149:8; 153:13 loading 145:21 lobbying 161:16 local 68:5; 71:4; 72:18; 74:10, 16, 18; 162:9; 188:10 locally 76:5 located 283:7 location 150:4 lock 240:18 log 210:18 logical 63:6 London 98:2; 101:1; 119:5; 153:10 long 31:25; 82:12; 129:23; 130:1; 135:9; 145:21, 23; 157:21; 201:25; 204:24; 221:5; 233:2; 249:6; 266:19; 293:13; 294:20; 296:5; 301:9; 315:16, 20; 316:2, 3; 322:21 long-lasting 145:16	look--again 287:17 looked 53:17; 65:10; 68:13; 75:9; 76:23; 77:2; 79:1; 82:7, 16; 87:15; 94:17; 108:3, 6, 6; 114:19, 23; 115:12; 128:5; 134:21; 137:24; 143:2, 3, 144:4; 185:8; 186:20; 189:16, 17; 190:12; 194:2; 197:2, 5, 19, 20, 24; 199:16; 205:13; 212:7; 223:25, 25; 240:21; 262:13; 285:22 looking 22:25; 55:19; 59:13; 64:24, 25; 65:3; 78:8; 100:20; 105:14; 108:18; 120:6; 125:20; 126:17; 133:22; 142:16; 147:6; 149:17; 152:9; 155:12; 171:13; 193:23; 196:21; 203:5; 208:15, 16; 209:13; 229:24; 238:3; 240:16, 25; 249:3; 257:1; 263:14; 286:10; 289:2; 315:21 looks 39:12; 54:9; 65:20, 24; 74:25; 75:2; 76:17; 105:7; 113:7; 119:12; 143:20, 24; 145:24; 146:18; 209:2; 228:24; 305:16; 315:18, 19 lose 303:15 loss 90:4; 194:18; 272:24; 312:19 loss--alopecia--I 194:14 lost 163:19 lot 28:16; 62:8; 67:3; 90:10; 95:6; 108:25; 127:9; 131:3; 138:21;
later--I 59:15 later--were 45:17 Latin 161:8; 162:8 Latimeris 84:11, 14 latter 72:10; 214:16; 228:19 law 13:1, 9, 10, 19, 24; 161:9, 11; 162:8 lawyer 321:24 lay 306:22 lead 33:3; 225:19 lead-in 97:4 leads 145:22 league 116:13 leaning 208:12; 303:12 leap 268:24	legislative 13:24 lends 218:24 length 185:4; 192:22; 246:1 lens 172:22 lenses 172:16 lesson 58:11, 15, 17; 100:8; 114:11, 12; 116:21; 126:5; 143:1, 8, 22; 149:8; 150:4, 5; 7, 11, 13; 151:12; 153:12; 219:25; 224:15; 277:2, 4, 22; 280:14; 282:3, 6; 283:4, 7 lesion--and 107:21 lesions 11:11; 22:17; 23:1; 57:22, 24; 58:3, 9, 13; 59:7, 10, 18, 21, 23; 97:9, 14; 98:17, 22, 25; 99:3, 5, 14, 17, 24; 100:6; 104:9, 11, 18, 24; 105:3, 8; 107:16; 108:1, 8; 111:18; 114:7, 7; 118:18; 121:1; 124:25; 125:5; 126:8, 10; 143:15, 16, 16, 17, 19, 24; 149:2, 18, 20, 21; 151:1, 4; 153:19; 215:6, 14; 221:25, 25; 223:11, 12, 16, 16, 19; 224:1, 5, 7, 8, 14; 264:1; 270:19, 22; 271:12; 278:2, 18; 280:9; 282:4, 22; 288:5, 7	lock 240:18 log 210:18 logical 63:6 London 98:2; 101:1; 119:5; 153:10 long 31:25; 82:12; 129:23; 130:1; 135:9; 145:21, 23; 157:21; 201:25; 204:24; 221:5; 233:2; 249:6; 266:19; 293:13; 294:20; 296:5; 301:9; 315:16, 20; 316:2, 3; 322:21 long-lasting 145:16	Min-U-Script®	(17) laboratory - lot



250:1, 21; 296:22; 297:4;  
 298:18; 299:1; 300:17;  
 321:9  
**methodological** 10:10;  
 100:10, 19  
**methodology** 153:4, 5  
**methods** 147:14  
**Methylene** 45:10, 91:3;  
 247:24  
**methylprednisolone**  
 11:5, 5; 97:6, 8, 16, 18;  
 102:8, 9, 10; 103:1, 2;  
 104:16, 20; 107:3, 6;  
 113:13, 20; 116:15, 17;  
 117:14; 118:13, 15, 16, 17,  
 19; 119:18, 21; 120:5, 5,  
 15, 24; 143:23; 144:7, 9,  
 12, 14; 145:1, 3, 6; 304:13  
**methylprednisolone--corticosteroid-500**  
 61:11  
**methylprednisolone-alone** 223:13  
**methyltrexate** 138:25  
**Meyer-Kaplan** 131:6  
**mg** 10:16, 16; 11:4; 25:19,  
 21; 31:19, 22; 32:3; 36:8;  
 37:3, 8; 41:19, 23; 44:15,  
 16; 45:2; 46:14; 49:6, 7,  
 13, 14; 50:9, 12, 13; 51:8,  
 15, 23; 52:5, 11, 18; 53:12,  
 22; 54:4, 12; 55:2, 25;  
 56:4, 15, 17; 57:19, 25;  
 58:3, 16; 59:8, 9, 19, 21;  
 60:4, 5; 61:11; 75:4; 79:23;  
 85:2; 87:4, 12, 13; 97:19,  
 21, 22; 129:4, 16; 133:4;  
 141:6; 147:3, 4; 168:14,  
 15; 170:15; 171:1; 175:15;  
 177:5; 178:13; 179:18;  
 181:19; 182:12, 13;  
 188:22; 189:18; 190:8;  
 195:9, 9, 11; 197:23;  
 198:6, 15, 18, 20; 200:9;  
 205:1, 9, 10, 18, 22, 24,  
 25; 206:3, 4, 8, 17; 209:15;  
 211:13; 213:5, 11, 17;  
 214:11; 224:21; 225:3, 7,  
 8; 246:10; 250:1, 21;  
 296:22; 297:4; 298:17;  
 299:1, 13; 300:17; 302:21,  
 22; 316:18, 18; 321:7, 8, 9  
**Michael** 5:12  
**Michigan** 4:23  
**micro** 309:11  
**microphone** 78:10  
**mid-portion** 259:3  
**middle** 151:9  
**might** 14:5, 14, 23; 28:1;  
 29:14; 67:5; 68:8; 71:13,  
 13; 80:16; 82:22; 83:11;  
 84:17; 90:21; 93:3;  
 111:12; 127:25; 129:23;  
 130:3; 142:22; 144:18;  
 147:21; 154:19; 193:6, 11;  
 208:14; 221:12; 232:12,  
 25; 243:18; 246:2; 248:23;  
 267:1, 2, 19, 20; 274:3;

279:6, 10; 285:4, 4; 287:4;  
 294:4; 296:23; 298:5  
**migration** 286:21  
**Mike** 209:19  
**mild** 14:20; 44:2; 115:6,  
 24; 169:8; 172:12; 173:1,  
 11; 181:17; 211:17;  
 272:13  
**mill** 158:7  
**Miller** 57:6; 98:2, 7; 99:11;  
 101:1  
**million** 157:12  
**mimic** 45:10  
**mind** 9:19; 55:9; 167:25;  
 235:13; 242:7; 243:24;  
 245:23; 257:18; 276:25;  
 277:8; 289:6; 290:9;  
 295:1, 5; 318:6  
**minds** 41:6; 204:17  
**minerals** 79:6  
**mini** 229:2  
**minimal** 50:5; 125:12  
**minimally** 321:18  
**minimized** 91:20  
**minimum** 56:5  
**minor** 80:3; 116:12;  
 190:5  
**minority** 74:21; 273:20  
**minus** 164:2  
**Minus-1** 223:20  
**minute** 218:11  
**minutes** 95:14; 253:9, 15  
**misery** 166:14  
**misleading** 21:18  
**miss** 323:6, 6, 7  
**missing** 105:18; 188:10;  
 236:25; 264:2  
**mistake** 209:1; 318:22  
**misunderstanding**  
 76:11  
**misuse** 322:1  
**Mito** 304:12  
**Mito-12** 209:7; 304:10  
**Mito-5** 209:2, 7; 302:23  
**mitochondria** 39:16  
**Mitoxantrone** 9:15;  
 30:19, 23; 31:2, 6, 15, 17;  
 32:1, 18, 25; 33:10; 34:13,  
 14; 35:1, 20, 24; 38:1;  
 39:12; 40:21, 24; 41:4, 10,  
 18, 22; 42:10, 13; 44:15,  
 16; 45:11; 49:6, 6, 12, 14;  
 50:9; 51:8, 15, 23; 52:5,  
 11, 18; 53:3, 12, 22, 24;  
 54:4, 12; 55:2, 6, 16, 22,  
 25; 56:4, 8, 15, 17, 22;  
 57:19, 24; 58:3, 8, 16;  
 63:21; 65:25; 67:8; 75:5;  
 77:17, 17; 78:18; 85:7;  
 86:20; 87:10, 12, 17, 19;  
 89:14; 91:5; 92:24; 93:15;  
 94:7, 14, 19; 97:18, 19;  
 102:8; 104:10, 16; 105:4;  
 106:25; 108:23; 113:15;  
 117:16; 119:18, 19; 120:4,

12, 19, 24; 121:6, 24;  
 125:10, 19, 24; 126:2, 5, 8,  
 15, 18; 127:6; 128:5;  
 129:4, 5, 16; 132:11, 12;  
 134:21; 138:13, 19;  
 139:20; 140:1, 5, 11, 17,  
 25; 141:6; 142:1, 2; 143:9,  
 21; 146:14, 19, 20; 147:1,  
 13; 168:11, 14, 22; 169:9;  
 170:12, 15; 171:1, 3, 17;  
 172:6; 173:22, 24; 174:5,  
 6, 14, 16, 21, 24, 25;  
 175:14; 176:10, 16; 177:1,  
 2, 5, 7, 9, 16; 178:2, 4, 13,  
 23; 179:1, 2, 4, 5, 6, 9, 21,  
 23; 180:14, 16; 181:15;  
 182:2, 11; 188:5, 20;  
 189:15, 18; 190:9, 25;  
 191:3, 6, 15; 193:14, 15,  
 17; 194:11, 13, 16; 195:14,  
 21; 196:11; 198:4; 200:7,  
 17, 24; 201:6, 14; 202:7,  
 15; 204:19; 205:16, 17;  
 211:1, 4, 7, 13, 22; 214:10,  
 20, 25; 215:2, 10, 16;  
 216:17; 217:8; 218:5, 17;  
 219:4; 222:5, 17; 224:12;  
 225:12; 230:6, 11; 233:15;  
 236:4; 239:10; 241:2;  
 242:6; 243:3, 7; 246:5, 9,  
 14; 248:16, 18, 18; 249:19;  
 250:22; 277:20; 286:19;  
 287:4; 290:15; 295:2, 12;  
 296:6; 302:21; 22; 303:25  
**Mitoxantrone's** 42:15;  
 58:21; 211:9  
**Mitoxantrone-and**  
 135:2  
**Mitoxantrone-plus-methylprednisolone**  
 223:14  
**mitral** 178:25  
**mix** 313:3  
**mixed** 289:21  
**mls** 283:3  
**mobile** 202:17; 203:21  
**mobility** 185:16  
**model** 33:11, 11  
**models** 41:10; 127:9, 10  
**moderate** 44:1; 115:6,  
 24; 116:6, 9, 14; 143:18,  
 24; 169:8; 172:12; 173:11;  
 179:20; 181:17; 211:17;  
 245:7; 294:7  
**moderately** 263:8;  
 274:12; 289:17  
**modest** 154:23; 256:6  
**modification** 310:24  
**modified** 294:4; 314:19  
**modifier** 310:20  
**modify** 289:10  
**moment** 55:5; 63:15;  
 113:22; 198:3; 243:17;  
 255:25; 276:21; 289:22  
**moment--let's** 276:21  
**moment--were** 45:14  
**monitor** 211:6

**monitoring** 28:1; 32:16;  
 37:13, 14; 68:6; 178:11;  
 215:16; 247:4; 316:24, 25  
**monotherapy** 16:14  
**month** 44:20, 22; 48:25;  
 51:2, 13, 21; 53:2, 2;  
 54:17; 55:13, 15, 15, 25;  
 56:12; 62:25; 64:7; 94:6;  
 97:7, 17; 98:23, 23; 99:5,  
 5, 18, 23, 25; 100:3, 5, 6,  
 22; 101:17; 102:12, 12;  
 104:12, 15, 24, 24; 105:5,  
 5, 7; 106:2; 107:2, 2, 9, 21;  
 113:14; 120:24; 121:25;  
 122:4, 22; 131:13, 24;  
 132:14, 16, 25; 133:2, 2, 8;  
 143:17; 144:13, 15, 18;  
 145:13; 168:17; 170:10,  
 11, 13, 14, 17, 17; 172:19;  
 181:24; 192:5, 13; 223:10,  
 20, 20; 224:8, 8, 10, 10;  
 233:11; 236:21, 22;  
 282:21, 21; 298:9; 299:18;  
 301:3  
**month-to-month** 109:23  
**monthly** 11:6; 97:23;  
 98:1, 18, 23; 99:5, 18;  
 121:1; 132:12; 138:13;  
 142:18; 144:22; 146:19;  
 172:7, 20; 173:23; 188:6,  
 14; 198:20; 225:6; 233:15;  
 304:23  
**monthly--I** 118:2  
**months** 10:17; 11:6;  
 29:12, 12; 37:6; 41:20;  
 43:20; 44:18, 19, 24;  
 49:25; 53:8, 9, 14; 54:21;  
 56:3, 5; 60:22; 62:21; 63:1;  
 90:15; 94:6, 11, 11, 12, 12;  
 96:19; 99:19; 102:6;  
 103:16, 22; 104:9, 18;  
 105:22; 107:5; 110:7, 16,  
 24; 111:3; 113:12; 120:14,  
 25; 122:18; 133:14;  
 138:13; 139:2, 20; 140:1;  
 141:5, 16, 22, 23, 24;  
 146:4, 6, 10; 147:4;  
 160:19; 164:2; 173:23, 25;  
 175:16; 176:7; 178:7;  
 182:13; 188:2; 191:25;  
 194:17; 202:11, 11;  
 211:23; 224:25; 233:7, 22;  
 237:4; 246:10; 275:24;  
 290:8, 11; 297:16; 298:9,  
 19, 20; 299:1, 11, 13, 21,  
 22; 303:14; 304:24  
**months--does** 276:22  
**months--that** 123:16  
**Moorehouse** 4:19  
**morbidity** 14:9  
**more** 6:9; 10:6; 13:13;  
 14:10; 22:22; 27:18;  
 28:20; 31:15; 36:16; 37:8;  
 39:6; 48:7; 53:19; 59:22;  
 68:24, 24; 70:17; 78:19;  
 80:2; 81:3, 4; 92:6, 7, 18;  
 94:8; 95:3, 3; 105:6, 12;  
 106:9; 107:2; 109:1;  
 112:3; 114:5, 24; 117:25;

136:23; 140:15; 142:21;  
144:7, 10, 11, 11, 14, 20;  
15:1; 148:4, 15, 24;  
19:23; 151:6, 14, 23;  
152:7; 153:1, 22; 154:5, 9;  
155:9, 15; 167:19, 23;  
215:7; 216:7; 217:6;  
221:14, 19, 20; 222:4, 11,  
13; 223:5, 16, 17, 22;  
224:6, 7, 8, 11, 15, 15;  
245:24, 25; 248:7; 256:5,  
10; 257:20; 263:25; 264:1,  
6; 265:19, 21, 22, 24, 25;  
268:21; 270:17, 20; 271:2,  
9; 272:1, 19; 273:23;  
274:15; 275:4, 7, 15;  
276:8, 9, 23; 277:1, 2, 9,  
13, 18, 21, 25; 278:7, 12,  
15, 21, 23; 279:2, 5; 280:9;  
281:16, 20; 282:13, 22;  
283:24; 284:8; 288:5;  
292:25; 293:19; 294:9;  
298:7; 300:22; 302:23  
**MRI-based** 99:11;  
167:22; 216:12; 222:10  
**MRI-enhancing** 111:18  
**MRLs** 12:18; 98:3, 9;  
100:20, 21, 23; 118:7, 24;  
119:4; 137:1; 221:17;  
271:2; 277:4  
**MS-half** 15:14  
**MS-how** 108:15  
-related 196:20  
much 6:9; 8:23; 10:6;  
17:7; 20:5; 27:6; 28:7;  
36:16; 39:6; 40:14; 59:11,  
22; 60:5; 62:17; 78:19;  
92:1; 94:14; 105:14;  
108:3; 125:10, 13, 15;  
135:15; 146:9; 151:20;  
154:8; 163:8, 17; 166:2,  
14, 20; 180:16; 187:8, 8;  
207:18; 223:12; 224:16;  
226:5; 236:1; 240:5;  
244:6; 259:17; 267:4;  
268:8; 272:13; 274:13;  
275:21; 283:10; 298:12;  
299:14; 300:5, 6, 7; 301:4;  
304:19; 305:9; 311:6;  
322:23; 323:5, 7  
**multi-center** 14:15  
**multinational** 137:6;  
139:15  
**multiple** 6:1; 9:18; 31:3;  
33:12, 15, 18; 37:5; 40:18,  
25; 41:5, 24; 42:1, 11, 16;  
43:8, 10, 12, 16; 44:1;  
45:4; 46:3; 56:10; 58:9, 22,  
24; 63:4, 10; 67:10; 73:3;  
95:21; 98:6; 103:14;  
108:16; 121:4, 6; 124:20;  
127:6; 140:11, 18; 150:4;  
7:9, 11, 22; 159:14, 20,  
160:1, 7; 161:22;  
163:22; 165:3, 5, 17, 20;  
166:13; 174:14; 176:19;  
177:21; 181:16; 182:2;  
189:15; 197:3, 6; 201:24;  
211:1, 8, 11; 213:2, 8;

## N

**nadir** 187:6, 20; 188:3,  
23, 24; 212:13, 20  
**nadir-in** 187:18  
**nadirs** 188:24  
**name** 4:2; 95:20; 157:7;  
158:11; 163:21; 256:3;  
313:25  
**named** 229:23  
**namely** 221:9; 280:14  
**narrative** 6:5; 28:12;  
30:10; 59:5, 6; 121:13;  
177:12; 182:23; 238:7  
**narrative-if** 150:7  
**National** 5:11, 15;  
157:11; 159:5; 160:22, 22  
**natural** 151:25; 155:3  
**nature** 15:4; 82:1, 2;  
115:1, 3; 133:25; 134:4;  
155:2  
**nausea** 84:25; 85:2, 4, 9,  
17, 21; 86:4, 9; 87:22, 22;  
89:22; 90:9, 10, 16;  
168:24; 169:1; 173:11;  
211:17; 269:19, 19;  
272:23  
**nausea-I** 85:16  
**nausea-that** 85:18  
**nauseated** 86:12, 22  
**NCI** 173:17  
**NDA** 5:25; 9:10, 13; 34:4  
**near** 73:25; 75:10; 177:7;  
219:4; 249:12  
**nearly** 163:4; 176:7;

214:17; 215:1; 222:6, 17;  
224:23, 24; 225:14, 17, 20;  
226:10, 12, 17, 21; 227:2;  
228:3; 229:1; 242:6;  
244:22; 245:20; 246:7, 13;  
249:18; 253:25; 254:2, 3,  
25, 255:7; 260:15; 261:24;  
271:10; 278:7; 281:15;  
294:21; 295:14; 306:12,  
13; 308:7, 13; 309:5, 23;  
310:7, 11  
**multivariate** 10:18;  
28:24; 46:6, 16; 67:17;  
82:9, 10, 16; 83:10  
**muscle** 268:6  
**music** 161:10  
**must** 22:21; 48:11; 54:19;  
90:2; 92:23; 166:3;  
171:15; 274:20; 302:9  
**mutual** 313:16  
**myelodysplasia** 182:4  
**myelogenous** 31:8, 19  
**myeloma** 201:24  
**myocardial** 170:7  
**myorelaxant** 80:2  
**myorelaxants** 80:5  
**myself** 148:1; 159:1;  
160:2; 163:23; 166:1;  
265:5; 307:9; 311:7  
**neurology** 27:19; 71:24;  
148:2  
**neurons** 24:2  
**neuropathology** 148:17;  
149:12  
**Neuropharmacological**  
4:10, 12  
**neuropsychological**  
150:16  
**neurosurgeon** 5:5;  
152:9  
**neurosurgeons** 317:25  
**neutropenia** 187:10;  
188:3, 7, 12, 25; 212:12  
**neutropenic** 171:19;  
190:14, 14, 17; 212:11, 12  
**neutropenia** 183:19  
**Nevertheless** 64:18;  
95:5; 150:3  
**New** 5:6, 23; 11:10; 13:3;  
58:2; 63:17; 68:23; 69:19;  
70:4, 7, 10, 21; 81:12;  
98:22; 24:99:2, 4, 14, 17,  
20, 21; 100:4, 7; 104:8, 10,  
17, 23; 105:3, 7; 107:25;  
109:16; 116:20; 133:21;  
140:19; 150:4; 161:10;  
166:14; 180:16; 224:7, 11;  
225:20; 270:19; 277:22,  
22, 23; 280:17; 308:9  
**newer** 140:5  
**newlywed** 161:21  
**next** 37:20; 49:18; 56:24;  
72:2; 84:17; 114:2;  
119:12; 124:22; 138:21;  
160:15; 162:16; 165:6;  
168:20; 169:4; 193:10;  
207:8; 214:6; 221:14;  
239:20; 242:8; 262:19;  
265:24; 275:4; 280:4;  
281:19; 282:9; 290:24;  
313:25  
**nice** 28:8; 123:8; 159:17  
**NIH** 150:21; 191:13  
**Nili** 132:7  
**nine** 178:5; 197:13  
**nineties** 45:1; 57:6; 67:7;  
94:2; 146:6; 175:17  
**ninety-four** 48:16  
**no-I'm** 137:23  
**No-there** 303:10  
**No-they** 111:2  
**No-you** 298:15  
**nobody** 316:7  
**nomenclature** 246:12  
**nominal** 208:9, 15; 221:2  
**nominally** 82:13; 208:17  
**non** 13:7; 210:2, 8; 236:8  
**non-Hodgkins** 202:1  
**non-lymphocytic** 9:23  
**non-MS** 196:24  
**non-significant** 210:4  
**non-voting** 252:4  
**nonclinical** 19:21; 20:14  
**nondividing** 32:20

**none** 84:5, 12; 133:25;  
231:4; 251:6; 284:2  
**nonetheless** 10:11; 14:3;  
18:15; 19:16; 20:8; 22:17;  
270:8  
**nonprofit** 162:4  
**nonresponders** 243:12  
**nonspecific** 124:25;  
142:19  
**nor** 13:24; 320:13; 322:9  
**normal** 37:17, 24; 170:4;  
171:4, 7, 24; 178:6; 185:1;  
192:13; 199:15; 237:8  
**normal-there** 260:13  
**normally** 88:16; 187:7  
**not-but** 250:19  
**not-in** 14:11  
**not-maybe** 144:20  
**not-was** 66:10  
**note** 6:24; 81:11; 167:6;  
281:6  
**noted** 7:24; 18:8  
**notes** 165:13  
**noticed** 60:13; 142:24;  
157:18; 196:2  
**noticing** 89:23  
**notion** 153:22; 292:10;  
317:11; 318:25  
**notorious** 40:11  
**Notwithstanding** 142:8  
**Novantrone** 5:25; 6:25;  
7:5; 9:15; 25:17; 36:5;  
38:25; 39:3; 40:2, 8; 135:8;  
159:23; 163:12; 180:24;  
186:2; 203:16; 253:23  
**Novantrone-if** 159:18  
**Novantrone/Mitoxantrone** 181:10  
**November** 13:19; 34:2;  
174:22  
**now-and** 90:2  
**now-are** 109:11  
**now-there** 220:11  
**number** 6:5; 10:24;  
19:22; 20:18; 41:12; 45:6;  
46:12; 47:2; 51:5, 6, 13,  
20, 20; 52:5, 6; 53:7; 59:7,  
10, 18, 21; 60:6; 66:9;  
68:17; 73:5, 13, 18; 74:9,  
14, 15, 17, 21; 77:4; 80:11;  
84:4, 8; 85:3; 89:1, 8;  
98:22; 99:2, 9, 14, 17;  
101:9; 103:5; 104:8, 23;  
105:3, 7, 24; 107:16, 20,  
25; 108:4, 9; 109:18;  
110:10, 20; 113:24;  
116:16; 117:9, 10; 118:18;  
122:20, 21; 127:21; 128:2,  
15; 129:9; 146:3, 4, 15;  
148:25; 149:22; 152:6;  
155:13; 171:6, 10; 177:22;  
192:10; 196:9, 11, 16;  
197:21; 205:16; 206:23;  
207:21; 211:21; 215:5, 13;  
217:4, 5, 7; 218:17; 221:7,  
24, 25; 223:11, 19; 224:1,

Food and Drug Administration  
Peripheral & Central Nervous System Drugs

Hearing  
January 28, 2000

5, 10, 13; 238:23; 250:24; 256:8; 261:6; 275:13; 280:8; 282:22; 287:20; 288:3; 290:6; 295:24; 304:8; 307:23, 24; 312:19; 318:4	number--66 75:19 <b>numbers</b> 73:6; 98:9; 108:14; 112:10, 14; 113:10; 115:10; 143:6; 290:14	<b>number--good--let's</b> 255:4	18; 285:13 <b>Odansitron</b> 87:15, 19; 88:5, 7; 92:12 <b>of--that's</b> 311:19 <b>off</b> 6:9; 96:3; 119:5; 123:9; 124:2; 166:24; 167:5, 13; 198:19; 253:10; 261:3; 276:22; 323:1 <b>off-handedly</b> 158:10 <b>off-site</b> 175:9; 177:15 <b>off-therapy</b> 124:4 <b>offer</b> 113:4; 241:25 <b>offers</b> 162:17 <b>Office</b> 30:3; 161:2; 164:15 <b>often</b> 14:11; 185:6; 192:3; 273:14, 16; 296:12; 320:11 <b>older</b> 180:1; 193:16, 20; 200:6; 250:4; 251:4; 266:11, 13
---	---	-------------------------------------	---

5; 302:14; 315:25; 316:1, 5  
**Overall** 49:10; 83:18;  
30:11; 172:8; 176:7;  
11:9; 256:11; 258:12;  
293:12  
**overjoyed** 302:14  
**oversee** 241:15  
**overview** 9:6; 28:8; 30:19  
**overwhelming** 290:22  
**own** 29:2; 68:12; 72:8;  
127:16; 134:19; 142:20;  
147:21; 151:14; 161:23;  
163:6; 164:25; 219:14;  
235:13; 256:14; 277:8;  
289:6; 294:20; 295:1  
**own--you** 219:13

## P

**p** 14:18; 46:17, 24; 50:11,  
18, 21; 51:8, 15, 23; 52:7,  
12; 53:14, 25; 54:8; 60:14;  
77:13; 83:19; 101:18;  
104:25; 105:8; 143:25;  
168:23  
**p-value** 104:24; 105:7;  
107:9; 114:10; 119:21;  
120:15, 21; 195:12  
**p-values** 208:9  
**p-values--these** 241:1  
    m 156:11, 12; 157:2;  
    23:13  
**package** 12:25; 36:22;  
38:6, 9; 168:3; 181:11;  
191:4; 199:1, 4; 202:18,  
23; 203:9; 214:19; 307:4;  
316:14; 321:23; 322:4, 10  
**packaging** 319:22  
**page** 59:6; 128:10; 182:9,  
23, 24; 186:12; 195:4;  
223:6  
**paid** 158:23  
**pain** 9:25; 31:10; 164:19,  
19  
**pair** 160:20; 173:5  
**palliation** 31:10  
**panel** 5:24, 24; 6:10;  
12:19; 68:17; 134:7;  
163:10; 166:21, 25; 226:8;  
286:6  
**Panitch** 35:15; 80:7, 9;  
91:9, 12, 24; 94:21, 22;  
148:6  
**paper** 71:24; 130:5;  
132:23  
**paperwork** 164:13;  
319:8, 9  
**papulation** 239:24  
**paradigm** 122:15  
    *iragraph* 182:10  
**parallel** 121:18; 210:17;  
263:2  
**parallelism** 122:16  
**parameter** 22:24  
**parameters** 37:15; 171:7

**paraphrase** 284:11  
**paraplegic** 165:7  
**parentheses** 309:7  
**parenthesis--was**  
109:16  
**parents** 158:16  
**park** 301:2  
**Parkinson's** 16:10, 12,  
13  
**part** 6:17; 22:16; 40:23;  
62:14; 82:17; 97:12;  
101:24; 130:10; 144:3;  
150:1; 151:17; 158:10;  
175:1; 186:21; 191:3;  
201:11; 206:12; 227:4;  
291:12, 13, 22; 292:24;  
311:11; 320:11, 19  
**part-time** 158:20; 159:11  
**partial** 16:4, 6; 228:10  
**participant** 7:22  
**participant's** 7:2  
**participants** 6:20; 7:9,  
22; 8:1  
**participate** 92:22;  
252:11, 12  
**participated** 7:4; 71:3  
**participating** 7:14; 74:7  
**participation** 7:3; 91:23,  
25  
**particular** 15:23; 18:16;  
22:15, 24; 24:9, 15; 25:8;  
26:13, 21; 27:1, 24; 28:17;  
83:12; 152:22; 153:22;  
206:25; 209:17; 247:2;  
265:6; 271:6; 288:18;  
290:23; 296:14; 320:3  
**particularly** 8:24; 9:1;  
21:16; 85:1; 87:22;  
125:19; 127:14; 136:14;  
193:17; 194:17; 217:19;  
218:14; 237:9; 275:17;  
277:19; 322:24  
**particularly--although**  
266:8  
**parts** 40:17; 146:3;  
240:20; 241:14; 283:17,  
18; 308:4  
**parts--to** 308:1  
**pass** 78:10; 85:23;  
160:16; 308:21  
**passport** 203:15, 16, 17;  
207:4, 8, 13, 18, 19; 208:6  
**past** 16:2; 134:7; 159:9  
**Pat** 163:18  
**patchy** 195:1  
**path** 161:9  
**pathologic** 282:5  
**pathologically** 17:6  
**pathology** 17:17; 22:10,  
14, 19, 21, 22, 24; 148:5,  
8, 18; 151:15, 20; 262:23;  
276:21; 281:21; 293:2;  
295:3  
**pathophysiologic** 21:1  
**pathophysiologically**  
21:14; 255:9; 258:9  
**pathophysiology** 17:17;  
292:17  
**pathways** 283:8; 286:16  
**patient** 23:25; 24:4; 29:7,  
11, 14; 34:25; 37:1; 38:2,  
12; 44:6, 8; 45:15, 23;  
48:15; 49:10, 18, 20, 22,  
22; 50:3; 61:7, 7; 63:18;  
64:13; 66:19, 21; 68:22;  
69:19; 70:3; 71:2, 5, 25;  
72:4; 79:25; 80:1, 17;  
81:20; 87:21, 22; 90:6;  
91:6, 23; 92:1, 5, 7; 94:25;  
98:9, 11; 99:4; 101:22;  
103:23, 24, 25; 105:21, 23;  
106:1, 21; 107:22; 113:21;  
114:4, 5; 115:16; 117:7,  
18, 22; 118:12; 119:19;  
129:14; 138:20; 150:8;  
170:15, 24; 171:1; 174:20;  
176:2, 23, 25; 177:4, 8, 17,  
19, 20, 21; 178:25; 179:2,  
4; 182:10, 17; 183:19;  
184:1; 187:20; 189:1, 8;  
190:17; 191:14, 15, 18;  
192:16; 196:8; 197:10;  
200:3; 202:11, 11, 17, 18;  
203:16, 18; 204:13; 207:4,  
6, 7, 10, 11, 15; 208:6;  
212:21; 213:11, 22, 22;  
214:5, 23; 218:2; 220:9;  
221:5; 222:23; 223:2;  
225:18; 228:20; 236:4, 22;  
238:18; 239:3; 241:5;  
242:13, 14; 243:7; 246:2;  
248:4; 249:20; 258:10;  
259:10, 22; 260:9, 12;  
272:23; 277:3; 283:22;  
289:3; 290:14; 301:20;  
306:11; 312:22; 313:3;  
316:17, 23; 320:24; 321:6,  
8  
**patient's** 29:15; 62:2;  
81:23; 89:8, 24; 113:23;  
182:12  
**patient--and** 107:18  
**patient--if** 80:17  
**patient--is** 276:10  
**patients** 9:18; 10:7, 8, 9;  
11:6, 10, 14, 17; 12:7, 14,  
18; 15:12, 13, 17; 17:1, 3,  
23, 25; 18:5; 25:4, 5, 6, 6,  
22; 31:3, 14, 15; 34:16;  
35:3, 12, 17; 36:1, 5, 5, 9;  
37:8; 39:24; 40:22, 25;  
41:4, 18, 24; 42:1, 13, 15,  
23; 43:2, 7, 13, 16, 25;  
44:11, 14, 19; 45:4, 12, 19,  
22; 47:2, 3; 48:16, 17, 19,  
23; 49:1, 2, 4, 7, 11, 12, 13;  
53:7, 13, 18, 23; 54:4, 7,  
16, 20; 55:2, 4, 21, 23;  
56:10; 57:9, 9, 16, 21, 24;  
58:2, 4; 60:7, 19; 61:18,  
25; 62:1, 5, 12, 12, 15;  
63:7, 8, 16, 19; 67:10;  
68:4, 25; 69:10; 71:13, 18,  
19; 72:17, 24; 73:3; 74:10,  
14; 76:17, 18, 21; 77:9, 10,

18; 78:16, 17, 23; 79:5, 11;  
80:8, 12; 81:3; 82:7; 84:5,  
12, 21, 23; 85:2, 3, 5, 10,  
13, 18, 20, 24; 86:4, 7, 9,  
21, 21, 24, 24; 87:1, 4, 5, 9,  
12, 14; 88:1, 4, 5, 8, 14;  
89:1, 9, 21; 90:10, 18, 24;  
91:12, 17; 92:21; 93:5, 8,  
23; 94:9, 13; 96:8, 11, 15;  
97:1, 9, 12, 15; 98:1, 6, 8,  
13, 22; 99:9, 12, 14; 100:5,  
11; 101:11, 14, 23, 25;  
102:2, 4, 6, 7, 8, 9, 13, 20,  
24; 103:2, 7, 8, 13, 16, 19;  
104:8, 10, 15, 17, 19, 21,  
23; 105:16, 25; 106:5, 7;  
107:3, 5, 7, 18, 19, 23;  
108:5, 6, 9, 14, 21, 23, 24,  
25; 109:2, 3, 6, 8, 9, 12, 17,  
22, 25; 110:4, 5, 8, 11, 12,  
13; 111:4, 15, 15, 16, 21;  
112:2, 10, 21, 23, 24;  
113:12, 20; 114:8, 23;  
115:21; 116:8, 14, 16;  
117:2, 9, 12, 15, 16; 118:1,  
9, 14; 119:18, 22; 120:11,  
17, 19; 121:3, 6, 15, 23;  
122:1, 3, 5; 125:1; 126:21;  
127:6, 9, 11, 21; 128:5, 13,  
14, 17, 18, 21, 22, 24;  
129:18, 22, 23; 130:1, 18,  
20; 131:18, 21; 132:9, 11,  
14; 133:11; 134:19, 22, 22;  
135:3, 5, 8, 10; 136:15, 17,  
24; 137:2, 7, 12, 14, 17,  
24, 25; 138:1, 2, 3, 6, 12,  
14, 15, 16, 17, 22; 139:10,  
19, 22, 24; 140:1, 5, 11,  
18, 23; 141:12, 18, 25;  
142:1, 3, 4, 18; 144:13, 17,  
25; 145:3, 18; 146:23;  
147:11; 150:22, 22;  
151:24; 154:1; 155:14;  
156:3; 167:9; 168:11, 14,  
15, 16, 25; 169:1, 7, 18;  
170:10, 12, 17:1, 6, 10, 14,  
14, 14; 173:16, 24; 174:14,  
23, 24; 175:2, 7, 19, 21,  
22, 24; 176:5, 8, 9, 10, 16,  
17, 18, 21, 23; 177:19;  
178:3, 11, 14, 22, 22;  
179:1, 9, 21; 180:1, 11, 11,  
23; 182:2, 4, 25; 183:22,  
24; 184:6, 22, 24; 185:10,  
13, 13; 186:2, 3, 9, 15, 18,  
22, 25; 187:23, 25; 188:1,  
6, 9, 15; 189:14; 190:7, 12,  
20, 24; 191:4, 7; 192:2, 4,  
15, 20; 193:2, 2; 194:7, 13,  
16, 20, 25; 195:6, 7; 196:1,  
4, 5, 9; 197:12, 12, 16, 21,  
22, 24, 25, 25; 198:4, 9,  
11, 14; 200:2, 15, 20, 24;  
201:6, 13, 23; 202:4, 6, 19,  
22; 203:2, 15, 21, 21, 23;  
204:7, 8, 10; 206:4;  
207:19; 209:14; 211:1, 8,  
10, 15, 18; 212:3, 6, 15,  
24; 213:2, 7, 8; 214:2, 17,  
20; 215:1, 13; 216:8;  
217:20; 218:20; 219:11;

**patients--29** 192:12  
**patients--and** 127:3;  
243:9  
**patients--is** 180:20  
**patients--that** 41:23;  
74:2  
**Patricia** 163:21  
**Patrick** 161:1, 19; 162:1,  
19  
**pattern** 230:1  
**pay** 322:2  
**Pediatrics** 164:6, 14  
**PENIX** 4:18, 18; 37:11,  
12; 38:6; 65:5, 6; 66:7;  
84:19, 20; 85:16; 87:1;  
88:10; 147:16; 197:7, 8;  
198:25; 244:17, 18;  
261:18, 19; 306:19;  
310:24; 316:20, 21;  
318:12, 13; 319:24;  
320:13; 321:5, 20; 322:6, 7  
**PENN** 5:5, 5; 126:25;  
127:1; 130:25; 131:1;  
134:17; 135:14; 147:16,  
17; 148:7; 152:5; 172:21;  
173:5; 243:15, 16; 263:7,  
8; 291:7, 12; 293:18, 19;  
299:21; 302:11; 306:19;  
308:15; 317:23, 24  
**people** 4:5; 14:20, 20;  
23:2; 62:11; 77:24; 94:10;  
111:9, 12; 115:12; 123:2,  
9, 14; 124:4; 135:23;  
154:16; 157:4, 12; 158:10,  
22; 159:6, 8, 24; 160:1;





**proper** 32:16; 260:23  
**proportion** 11:10; 53:12, 23; 94:13; 120:21; 230:20; 237:23  
**proposal** 6:1; 36:21  
**propose** 38:11; 141:1; 202:14; 224:21; 238:24; 246:16; 297:21  
**proposed** 9:16; 15:10, 12, 22; 17:11, 11, 16; 26:19, 22; 32:25; 33:13; 39:11; 224:23; 225:18; 237:14; 244:19; 247:8; 285:14; 291:11; 300:1; 306:17; 312:2; 314:18, 18  
**proposing** 24:9, 14; 27:2; 38:8; 140:16; 225:2  
**prospective** 96:6  
**prospectively** 12:3; 19:14; 86:14, 19; 186:17; 216:3, 7; 249:8  
**prospectively-defined** 216:1, 11  
**prostate** 9:25; 31:9; 32:8; 60:21; 180:25; 266:12; 273:11  
**protect** 85:10  
**protectant** 248:22  
**protected** 68:4  
**protection** 161:12  
**protocol** 12:8; 19:6; 46:2, 13, 19; 50:8, 20; 52:17; 54:19; 57:1; 61:5, 12; 62:25; 68:20; 75:15; 82:9; 87:16; 93:7; 96:17, 23; 98:21; 99:21; 100:15; 115:5, 18; 131:17; 143:12; 144:17; 172:23; 187:16; 233:1; 238:21  
**protocol--they** 63:25  
**protocol-defined** 144:4  
**protocols** 75:20  
**proud** 160:20  
**proven** 228:5; 229:5; 230:9; 284:4  
**provide** 30:18; 31:10; 40:20; 42:14; 162:6; 174:13; 222:16; 241:4; 243:6; 246:17; 248:19; 249:7; 272:16  
**provided** 6:20; 15:9; 29:3; 35:12; 47:3; 59:5; 128:11; 145:15  
**provides** 14:4; 219:7; 228:10; 230:11; 289:9; 307:19; 308:9  
**providing** 41:1  
**provision** 20:19  
**provisions** 20:18  
**prudent** 78:5  
**pseudo** 70:24  
**public** 7:9; 95:15; 156:6; 255:25  
**publication** 117:7; 132:6, 15, 19  
**publications** 179:12;

180:8, 13; 203:10  
**publicly** 256:8; 322:24; 323:5  
**published** 39:1; 41:16; 44:25; 57:6; 98:5; 99:10; 130:6; 132:9; 139:17; 146:6; 151:10; 175:17; 180:9; 203:11; 226:21; 255:25; 256:9  
**pulled** 164:23  
**punctuated** 227:20  
**purposes** 23:7; 300:20  
**pursue** 248:24  
**push** 265:1  
**put** 6:8; 50:12; 59:24; 60:14; 64:12; 77:12; 90:1; 95:6; 120:7; 133:24; 157:16; 167:14; 180:14; 208:21; 239:5; 240:6; 292:1; 293:21; 295:9, 19; 309:6; 321:3, 22; 322:3, 10  
**putative** 154:19, 24; 278:6  
**puts** 318:3  
**putting** 151:11; 166:18; 204:5; 283:21

## **Q**

**qua** 13:7  
**quadriplegic** 165:8  
**qualified** 164:13  
**qualify** 235:23; 239:12  
**quality** 155:20; 195:6  
**quantitative** 150:25; 279:9  
**question--and** 72:2  
**question--the** 216:25  
**questionable** 116:12  
**quick** 60:17, 18; 88:21; 93:13; 100:10; 102:20; 282:20; 290:5  
**quicker** 159:15  
**quickly** 108:22; 184:9; 236:5; 263:3  
**quite** 10:13; 29:1; 32:12, 15; 39:4; 60:4; 79:23; 138:21; 139:23; 190:25; 192:18; 202:17; 203:18; 217:4; 272:21; 284:10; 304:16  
**quote** 272:13

## **R**

**R** 151:8  
**radiation** 200:4; 214:15; 250:4; 251:7  
**radiation--and** 179:24  
**radical** 39:13  
**radiographic** 14:23; 19:25; 23:23  
**radiologic** 228:2  
**raft** 264:25

**raise** 127:2; 145:20; 314:22; 317:4  
**raised** 6:6; 13:6; 15:4; 41:2; 108:13; 205:7; 215:19; 216:16; 224:19; 252:2; 317:10  
**raises** 145:13  
**raising** 83:8, 14; 153:23; 275:20  
**ran** 263:2  
**randomization** 48:18; 59:22; 78:20; 88:22, 23, 24; 89:4, 6, 11; 101:8  
**randomize** 249:13  
**randomized** 10:5, 15; 11:4; 17:22; 40:18; 41:12; 16; 42:3, 5, 6, 18, 21; 44:14; 49:11, 12, 13; 54:4, 7; 55:2, 4, 21, 23; 57:16; 58:5; 60:8; 78:23; 85:20; 86:19; 87:12, 14; 88:2; 96:6; 97:11, 12, 15, 23; 101:24, 24; 102:7, 9, 10; 104:16, 19; 107:3; 109:3; 119:18; 120:19, 20; 122:3, 5; 132:9, 10; 141:15; 167:16, 17; 168:8, 14, 15, 16; 169:7, 18; 170:25; 171:1; 176:4, 13; 181:12, 20; 189:16; 200:19; 211:15; 212:10; 213:3; 215:25; 216:10; 218:21; 220:13; 221:18; 229:8; 246:5  
**range** 37:24; 78:17; 176:12; 223:12; 230:9; 251:1; 259:4; 269:21  
**ranged** 192:16  
**ranging** 41:18; 43:21  
**ranked** 210:18  
**rapid** 110:17; 145:22; 302:21; 310:17, 17  
**rapidly** 96:20; 121:3; 243:5; 310:16, 20; 311:3  
**rare** 188:25; 214:17  
**rarely** 40:3  
**rate** 9:18; 19:3; 34:16; 36:13; 54:9; 55:13, 14; 56:9; 60:22; 120:6, 9, 11, 12; 121:2; 124:1; 209:22; 215:12; 218:5; 227:25; 228:11; 230:7; 244:21; 253:24; 256:5, 10; 270:14; 272:19; 306:11; 308:3; 309:21; 310:5; 312:5  
**rate--and** 246:12  
**rated** 68:14; 206:10  
**rater** 12:5; 61:16; 67:1; 89:23; 100:23; 101:7; 206:10  
**rates** 173:1; 271:3  
**rather** 29:22; 126:13; 137:8; 205:4; 229:1; 268:17; 276:3; 285:5; 303:24; 306:25  
**rating** 172:24  
**ratings** 67:3, 4

**rationale** 88:1; 108:19; 225:2, 18  
**rationales** 146:4  
**raw** 132:18  
**reach** 198:14; 224:16; 256:11; 290:15  
**reached** 55:25; 56:2; 178:13; 233:8; 289:4; 290:16; 299:2  
**reaches** 213:11, 16; 214:11  
**reaction** 172:22; 173:9, 10, 12  
**read** 6:14; 12:18; 30:9; 51:3; 68:22, 23, 25; 92:5; 114:22; 130:5; 152:21; 154:10; 162:12; 166:9; 189:3; 190:5; 238:7; 303:14; 309:18  
**readily** 109:1  
**reading** 19:8; 196:2; 268:21  
**reads** 38:10  
**ready** 205:7; 246:21; 284:4; 317:1  
**real** 81:6; 86:24; 94:9; 126:17; 153:3; 155:5; 240:13; 250:13  
**realize** 159:15; 204:7; 236:14; 312:12  
**really** 9:6; 13:13; 14:11; 19:18; 21:12, 16; 23:11; 36:11; 38:24; 47:17, 23; 49:19; 50:13; 65:12, 25; 66:5; 69:1; 79:3, 6; 80:1; 81:2, 7; 88:18; 89:3; 90:3, 5, 7; 91:2; 94:8; 99:24; 105:22; 108:18, 21; 109:14; 110:11; 111:13, 20; 123:18; 125:8; 126:23; 136:8, 13; 137:12; 140:21; 145:20, 23; 147:24; 152:22; 155:11, 12, 12; 158:14; 162:21, 22; 165:10; 166:16; 180:6, 8, 14; 181:10; 187:9; 190:5; 191:12, 14; 192:19; 196:1, 8, 13, 19; 198:19; 199:9, 15, 18; 217:24; 221:11; 235:14; 236:12; 237:1; 239:2, 22, 25; 245:18; 248:6; 249:5; 251:9; 263:13; 264:16; 265:9; 268:4; 278:25; 279:21; 289:22; 293:3; 294:10; 300:4, 20; 302:7, 15; 304:18; 305:18; 307:23; 310:20; 312:2; 318:7; 322:22  
**realm** 255:25  
**reason** 103:20; 139:24; 155:19; 161:6; 168:17; 176:11; 183:25; 188:21; 190:7; 198:16; 200:14; 201:12, 16; 224:6; 250:10; 320:20  
**reasonable** 27:3; 230:11; 235:23; 302:4; 313:19  
**recommendation** 36:4; 37:5; 198:2; 199:11, 14; 203:25; 212:23; 213:9; 245:5  
**recommendations** 37:1, 13, 21; 197:8; 198:23, 25  
**recommended** 226:8; 298:11; 300:10, 11; 316:6, 7; 322:9  
**recommended--that**

285:5	registered 203:17	16, 16, 17, 18, 23, 24;	relief 78:16	reported 6:21; 7:8; 76:5;
<b>recommending</b> 198:20; 9:15 convene 95:14; 156:12	registration 34:1	74:4, 6, 8, 10, 15, 18, 21;	religiously 234:25	89:21, 22; 163:11; 168:14;
record 6:17; 7:25; 81:24, 24; 175:5, 12; 180:22; 183:17, 21; 191:24; 208:6; 220:9; 297:25	registry 208:3; 248:14; 319:6	75:9, 14, 20; 76:1, 12; 77:25; 81:17; 84:4, 8;	reluctant 281:14	170:22; 172:3, 9, 9, 17;
<b>recorded</b> 169:6; 220:18	regular 192:12; 193:3; 256:24; 320:25	96:18; 97:3; 99:8; 103:16; 104:1; 108:25; 109:18;	rely 13:25; 91:16; 194:25; 265:12	176:15; 181:8, 18; 182:4, 25; 191:23; 194:10; 245:2;
<b>records</b> 62:1	regulate 322:14	110:6, 7, 10, 12, 15;	relying 82:20	255:19
recovered 184:12; 192:15	regulated 6:21	111:10, 13, 16; 115:1, 3, 9, 21; 116:15, 24; 117:3, 11,	<b>remain</b> 112:9; 161:19	<b>reported-I</b> 191:21
recovers 283:16	regulation 276:14	23; 118:1, 3, 5, 10; 134:10, 11; 140:24; 151:4; 215:5;	remained 53:19; 84:15; 107:2, 8; 119:15; 120:17;	<b>reporting</b> 180:4; 255:21;
recovery 128:23; 228:16	regulations 20:17; 64:19; 148:19	216:6; 220:7, 16; 227:21; 228:18; 231:12; 233:8;	131:21; 195:10	322:13
recreation 158:22; 159:10	regulatory 42:25; 243:21	234:7, 9; 237:4; 239:14; 240:3; 241:17, 22; 256:24;	<b>remaining</b> 104:13; 169:1; 178:8	<b>reports</b> 181:3; 187:10
recur 303:17, 18	regulatory-type 127:5	240:3; 241:17, 22; 256:24;	<b>remains</b> 60:20; 150:3	<b>represent</b> 42:12; 165:15;
Redondo 163:18, 19, 21; 166:20	rehabilitate 196:8	270:3, 9, 18; 271:12, 16;	<b>remarkable</b> 204:17	170:3; 176:8; 257:8
reduce 9:17; 34:15; 45:6; 244:21; 253:24; 289:15; 306:11; 309:21; 310:5; 311:15	rehabilitation 162:2; 195:17; 196:6, 14	274:1; 288:13; 291:14; 293:16; 297:8	<b>remarks</b> 5:22; 225:16	<b>representative</b> 5:9
reduced 120:25; 246:11	reiterate 64:11; 79:14; 249:24; 301:6	<b>relapses-and</b> 66:9	<b>represents</b> 316:21	<b>representatives</b> 316:21
reduces 58:8; 292:10	relapse 9:18; 10:24; 11:19, 24, 25; 12:3, 11; 18:19, 22; 19:1, 3, 15; 34:16; 46:12; 52:10; 54:6, 9; 55:13, 14, 14, 19, 20, 22, 24; 56:3, 9; 60:25;	<b>relapses-in</b> 76:6	<b>representing</b> 150:15	<b>representing</b> 15:22; 225:16
reducing 230:7; 308:2	61:6, 6, 8, 9, 13; 62:6, 11; 63:4, 9; 64:20, 20, 21, 25; 65:11, 12, 16, 23; 66:3, 4, 7, 9, 10, 14, 15, 16, 19, 20; 67:9, 11; 68:20; 69:2, 9, 11, 12; 71:1; 72:4, 7, 9, 11, 14, 18; 74:14; 75:8, 21, 25; 77:9, 11, 18, 19; 79:8;	<b>relapses-is</b> 72:3	<b>remember</b> 15:3, 11; 60:8; 118:13; 130:19; 152:7; 191:21; 233:9; 266:9; 299:11	<b>reproduced</b> 52:15
reduction 52:4; 53:11; 215:4; 221:24; 224:7; 228:10; 256:5, 5; 270:19; 288:21; 293:9	80:6; 81:5, 11, 21, 23; 82:3, 4; 98:13; 103:5, 17; 110:1, 23; 115:6, 16, 20, 22, 23; 116:20; 117:4, 5, 10, 13, 21; 118:24, 25; 120:2, 6, 9, 11, 12, 18; 121:2; 128:24; 132:13; 140:14; 144:18; 145:4; 210:7; 215:12; 216:14; 217:1, 10; 218:5, 11, 13, 14, 16, 18, 24; 219:1, 2, 2, 2, 3, 7, 8, 12; 220:8, 12, 15, 19, 20; 228:10; 230:7; 233:11, 22; 237:9; 244:21; 246:11; 253:24; 256:10;	<b>relapses-were</b> 74:2	<b>remembering</b> 245:15	<b>request</b> 108:15; 291:20
refined 48:7	269:25; 270:2, 14, 22; 271:3, 21, 23; 272:1, 2, 4, 4, 19; 287:23; 297:8; 306:11; 307:5; 308:3; 309:21; 310:5	<b>relapsing</b> 11:15; 12:15; 15:15, 17; 34:9; 43:13; 103:14, 17; 108:14; 109:6, 13, 15, 22; 110:4, 13, 19, 21, 22; 112:2, 3, 5, 6, 10, 23; 128:19, 22; 132:10; 136:19; 137:2, 25; 138:15; 140:23; 150:22; 160:25;	<b>remind</b> 114:15; 122:21; 297:19	<b>requested</b> 47:5; 170:23; 304:20; 305:4
reflect 22:20; 126:11; 151:6, 15; 278:18	162:24; 163:3; 165:4, 15, 24; 222:19; 226:1, 9, 11, 12, 14, 25; 227:8, 10, 16, 19; 228:9, 9, 15; 229:19, 22; 230:20, 21, 22, 25;	<b>reminded</b> 182:8	<b>requesting</b> 34:14; 269:7	<b>requesting</b> 34:14; 269:7
reflected 282:11; 288:13; 296:25	231:6, 15, 22; 232:2, 5, 11, 20, 22; 233:12, 15, 18, 24; 234:1, 17, 20, 21; 235:3, 6, 19, 22; 237:7; 238:9, 15, 20; 239:11, 15, 19; 240:1, 24; 254:2, 10; 255:6, 11; 256:16, 22; 257:6; 258:11, 19, 20; 260:10, 11; 261:21; 285:6, 9; 289:20; 295:8;	<b>remission</b> 31:8, 21, 24, 25	<b>requests</b> 146:25; 306:9	<b>require</b> 65:1; 70:3, 10; 71:24; 91:23, 24; 163:5; 197:10
reflection 22:13, 18; 159:5; 276:20	309:9, 22, 24; 310:6, 9, 11, 15	<b>remissions</b> 239:14; 293:13	<b>require-my</b> 320:3	<b>require</b> 49:9, 15; 50:5;
reflective 134:8; 148:16, 18, 23; 153:2	<b>relate</b> 15:4	<b>remitting</b> 12:15; 15:17; 43:9, 12, 13; 76:25; 103:14, 18; 108:14; 109:6, 12, 13, 22, 24; 110:20, 22; 112:2, 4, 5, 7, 11, 23;	<b>requirement</b> 24:22; 187:17	71:13; 72:4; 82:9; 99:9; 162:3; 171:11; 187:15, 22; 218:14
reflects 22:10, 25; 23:24; 136:2, 2; 142:20; 281:20	<b>related</b> 6:25; 9:25; 10:23; 121:8; 126:4, 6; 128:10; 169:11; 176:16; 191:22; 244:8	128:13, 17, 19, 21, 23; 132:10; 136:19; 137:2, 25; 138:15; 140:23; 150:22;	<b>requires</b> 44:6, 8; 92:5	<b>rescue</b> 243:9
reflexes 91:25	<b>relates</b> 128:10; 150:20; 155:3	160:25; 162:24; 163:3; 165:4, 15, 24; 222:20; 226:1, 10, 11, 14; 227:1, 8, 10, 16; 228:9, 16; 229:19;	<b>Research</b> 4:17; 6:22; 226:20; 250:2	<b>Research</b> 4:17; 6:22;
refractory 31:9	<b>relapse"-not</b> 70:19	230:21, 22, 23, 25; 231:6, 15, 22; 232:2, 5, 11, 20, 22; 233:15, 18, 24; 234:17;	<b>reservations</b> 145:20	226:20; 250:2
refrain 156:4	<b>relapse--but</b> 271:7	235:4, 6, 19, 22; 237:7;	<b>reserved</b> 156:7	<b>residency</b> 164:6
regard 6:16; 37:12; 62:8, 15; 269:6, 11, 21; 316:24, 25	<b>relapse--but</b> 271:7	238:9, 15, 20; 239:11, 19;	<b>residents-I</b> 164:13	<b>residents-I</b> 164:13
regarding 180:3; 223:5; 252:5; 253:22	<b>relapse--but</b> 271:7	240:1, 25; 254:2, 10;	<b>residual</b> 43:14; 189:5	<b>residual</b> 43:14; 189:5
regardless 266:6	<b>relapse--but</b> 271:7	255:7, 11; 256:17, 23;	<b>remove</b> 291:18	<b>remove</b> 211:21; 212:9
gimen 11:7; 24:9, 10, 16; 26:21; 61:10; 146:19, 24; 299:1, 8; 300:2, 10, 25; 301:1	<b>relapse--but</b> 271:7	257:6, 258:12; 260:11;	<b>removed</b> 18:4	<b>resolved</b> 90:17; 231:23
regimens 24:11; 32:2; 298:7; 316:11, 17	<b>relapse--but</b> 271:7	261:21; 289:20; 295:8;	<b>removes</b> 212:3	<b>resolved</b> 90:17; 231:23
region 150:10	<b>relapse--but</b> 271:7	309:9, 24; 310:7, 9, 11, 15	<b>respect</b> 7:7; 8:1; 89:19; 129:7; 150:5; 223:9; 272:22; 283:7, 9	<b>respectable</b> 289:8

209:22; 210:12, 15;  
217:16; 223:17; 240:8;  
255:3; 258:2; 275:2;  
276:23; 280:21; 284:1;  
305:23; 314:14  
**responses** 255:9; 294:3  
**responsible** 45:20, 23;  
98:10; 177:3; 318:18  
**responsive** 242:3  
**rest** 159:3, 10, 11; 281:3;  
315:4  
**restrict** 29:14; 207:22;  
318:1  
**restricted** 27:23; 207:20;  
320:15  
**restriction** 319:4, 6  
**restrictions** 27:17;  
317:17; 318:19  
**result** 42:3; 49:4; 50:19;  
82:18; 83:12; 142:5;  
169:11; 174:6; 224:13;  
312:3  
**resulted** 178:5  
**results** 10:4, 19; 14:18;  
25:7; 26:12, 15; 42:18;  
45:8; 50:7, 10; 52:16, 21,  
23; 56:25; 57:18, 18;  
58:20, 25; 65:25; 80:20;  
83:11; 96:4; 101:16;  
114:6; 118:15; 124:2;  
132:13; 139:3, 23; 144:7;  
145:5; 154:20, 21; 163:10;  
167:13, 19, 24; 169:17;  
171:23; 172:5; 205:9;  
210:9, 10; 217:2, 6;  
218:23, 25; 219:4; 222:1,  
11, 13, 13; 223:6, 18;  
224:9; 225:12; 255:23;  
283:24; 301:11; 305:9  
**resume** 95:25; 156:9;  
166:24  
**retarded** 312:7, 7  
**reticular** 39:15  
**retrospect** 68:8  
**retrospective** 10:9;  
40:20; 147:10; 168:10;  
174:20; 175:10; 178:21;  
180:20; 186:14; 197:21  
**retrospectively** 103:13;  
130:23; 174:15; 223:24  
**return** 111:1; 234:18;  
237:8; 258:25; 260:13  
**returned** 121:17; 162:1;  
235:20  
**returns** 136:6  
**revascularize** 164:25  
**reversible** 171:17; 172:3;  
181:18, 21; 183:23; 192:4  
**review** 9:10; 13:2; 26:11;  
34:6; 47:5; 57:12; 68:12;  
69:5; 78:15; 79:21; 98:7;  
167:12; 180:20; 182:9;  
190:23; 223:7; 288:17  
**review--were** 191:22  
**reviewed** 12:15, 19; 34:5;  
98:2, 9; 101:1; 175:11;  
183:20

**Reviewer** 4:11; 12:20  
**reviewing** 57:14; 179:10  
**revisiting** 152:5  
**rials** 63:9  
**Richard** 4:15; 5:5; 34:20;  
35:22  
**rid** 245:6; 311:3  
**right** 8:16; 27:19; 28:18;  
30:9; 36:25; 38:9; 54:19;  
60:5, 7; 75:11; 77:15; 82:5;  
90:2; 100:4; 101:5;  
106:20; 112:17; 152:11;  
157:9; 159:18; 164:2, 10;  
165:9; 167:4; 171:16, 18;  
191:2; 197:4; 198:3;  
199:21; 200:25; 201:7;  
205:8; 208:12; 210:22;  
219:16, 18; 234:10;  
235:17, 21; 242:19;  
245:11, 16; 249:7; 251:12,  
21; 252:13, 17; 254:23;  
255:14; 261:13, 13;  
262:19; 267:15; 268:9;  
270:1; 274:10, 22; 275:3;  
283:23; 284:2, 10; 286:5;  
290:24; 292:8; 298:3;  
301:5, 5; 303:18; 304:16;  
305:1; 306:8; 307:14;  
309:25; 310:1, 2; 311:10;  
313:25; 314:12, 20; 317:2;  
322:12  
**rightfully** 202:20  
**rightly** 278:20  
**rigorous** 123:24; 139:14;  
272:5  
**rigorously** 265:2  
**rises** 25:20  
**rising** 236:11  
**risk** 25:18, 20; 45:7;  
182:5; 198:18; 199:9;  
200:6, 16; 210:22, 25;  
212:10; 213:3, 6, 22, 23;  
251:8; 283:22; 296:20  
**risk--whether** 271:3  
**risks** 25:16; 26:2; 211:10;  
271:4; 279:11  
**road** 276:18  
**robust** 217:2, 11; 218:11;  
224:14; 230:6  
**robustly** 268:20  
**robustness** 66:3;  
218:24; 219:7  
**role** 140:25; 147:1;  
245:19; 250:13  
**roll** 302:3  
**romance** 161:7  
**room** 156:7; 288:19;  
298:1  
**rotating** 323:1  
**roughly** 50:2; 75:4;  
304:14  
**routinely** 13:12; 20:1  
**row** 120:7, 9  
**rule--a** 51:12, 19  
**ruled** 177:10; 178:24  
**rules** 13:4; 46:21

**run** 145:21, 23; 226:22;  
315:16, 20  
**running** 162:15; 164:7;  
302:14  
**Russ** 4:9; 278:4

---

**S**

---

**safe** 198:15  
**safeguard** 322:1  
**safeguards** 300:11  
**safely** 32:15  
**safely--even** 318:5  
**safer** 298:1  
**safest** 188:20  
**Safety** 4:11; 10:7; 24:18;  
25:11; 26:9; 27:10, 11;  
34:21; 35:12, 23; 40:19,  
21; 42:15; 45:24; 48:21;  
49:3; 63:16; 64:12; 78:14;  
88:5; 91:1; 98:12; 121:5;  
167:2; 168:5, 7; 170:20;  
172:5; 174:13; 175:6;  
181:2, 25; 182:9, 24;  
190:22; 201:8, 8; 203:1;  
225:9; 243:23; 248:6, 16,  
19; 315:3, 16, 23; 317:4, 9,  
16; 320:20  
**safety--alopecia** 90:3  
**safety-related** 27:13  
**saint** 166:2  
**sake** 82:15; 83:9  
**salute** 167:9  
**same** 14:16, 21; 38:25;  
41:22; 51:12, 19; 61:3, 4;  
66:13; 72:24; 77:21;  
79:25; 85:1; 88:11; 89:4;  
91:3; 94:12, 18; 95:1;  
97:16, 18; 118:18; 139:14;  
143:2; 152:18, 20; 154:5;  
156:12; 167:20, 24;  
182:23; 208:19; 217:10;  
246:1; 248:24; 255:13;  
260:8; 272:20; 285:25;  
288:22; 297:15; 301:10;  
305:8, 9; 312:13, 13; 314:7  
**same--admittedly** 304:4  
**San** 5:13  
**Sandra** 5:10; 6:13; 7:4  
**Sandy** 4:20  
**sarcoplasmic** 39:15  
**saving** 166:14  
**saw** 76:12; 177:13; 221:7;  
224:9; 241:11; 271:17;  
272:13  
**saying** 83:17; 109:11;  
123:24; 124:6; 137:23;  
155:7; 193:1; 221:1;  
234:2; 259:15, 18; 274:5;  
279:2; 297:25; 311:19;  
313:2; 318:6; 323:3  
**saying--you** 323:3  
**says--I** 74:19  
**scale** 10:20, 21; 29:17;  
43:24, 25; 46:9, 9; 47:11,

11, 11, 19, 20, 21, 22;  
48:1, 2, 6, 11; 51:3, 4, 5,  
11, 18; 55:10; 58:14; 70:9;  
99:7; 216:5, 14; 280:4, 7;  
305:18  
**scales** 10:19; 45:13;  
47:6, 7; 48:8; 54:2, 24;  
55:1, 9; 61:19; 77:21;  
81:15; 148:17; 263:23;  
268:20; 305:16, 16  
**scales--the** 46:9  
**scan** 22:11; 57:2, 12;  
98:17; 100:12, 16; 105:18;  
111:16; 113:23; 125:3;  
126:9, 10; 144:20; 148:24;  
215:7; 270:20; 271:6;  
280:14; 293:21  
**scanned** 144:13  
**scanning** 59:6; 268:10;  
282:16  
**scans** 57:5, 6, 11, 13, 14,  
22; 58:12, 13; 60:9; 98:5,  
18, 23; 99:5; 100:24;  
101:1, 7; 105:13; 113:14,  
14, 16, 17, 21; 121:1;  
293:23  
**scans--and** 45:16  
**scants** 97:10  
**scenarios** 243:4  
**schedule** 97:16; 140:13;  
146:3, 13; 147:5, 9, 15;  
190:18, 19; 213:13, 18;  
224:24; 246:14  
**schedules** 31:18; 146:17  
**scholarship** 162:2  
**School** 4:19, 25; 95:23;  
164:15  
**Schwab** 180:10  
**scientific** 13:14  
**sclerosis** 6:1; 9:19; 31:4;  
33:12, 15, 18; 40:19, 25;  
41:5, 25; 42:1, 11, 16;  
43:8, 10, 12, 17; 44:1;  
45:4; 56:11; 58:9, 22, 24;  
63:4, 10; 67:10, 73:3;  
95:21; 98:6; 103:14;  
108:17; 121:4, 6; 124:20;  
127:6; 140:12, 19; 150:4;  
157:9, 12, 22; 159:14, 20,  
25; 160:2, 7; 161:22;  
163:22; 165:4, 5, 17, 20;  
166:13; 174:15; 176:19;  
181:16; 182:3; 189:15;  
197:3, 6; 211:1, 8, 11;  
213:2, 8; 214:17; 215:1;  
222:7, 17; 224:23, 24;  
225:14, 18, 20; 226:10, 12,  
17, 21; 227:2; 228:3;  
242:6; 244:22; 245:20;  
246:7, 13; 249:18; 253:25;  
254:2, 3, 25; 255:7;  
261:24; 271:10; 278:7;  
281:15; 294:22; 295:14;  
306:12, 13; 308:7, 13;  
309:5, 23; 310:7, 12  
**seemingly** 124:13; 155:9;  
237:16; 248:23; 257:4;  
268:19; 299:14; 312:5, 8  
**seemed** 15:15; 114:11,  
13; 146:10; 157:18;  
275:18

**seems** 39:14; 68:16;  
113:18; 123:20; 155:4;  
9:19; 195:6; 236:11;  
8:25; 279:2; 281:7;  
299:14; 312:6, 24  
**sees** 296:3  
**segregate** 111:23  
**seizure** 23:17  
**seizures** 16:4, 7, 8  
**select** 110:11  
**selected** 110:6, 13;  
136:24; 146:3  
**semantic** 259:19  
**semantics** 244:19;  
259:25  
**Senator** 161:15  
**Senior** 30:14; 157:18;  
204:2  
**sense** 91:22; 116:10;  
136:4; 146:11; 232:22;  
260:2, 15; 264:13; 268:11;  
269:7; 276:16, 17; 291:4,  
5; 294:3; 300:2; 301:11;  
313:9, 13, 14  
**sense—I** 313:14  
**sensitive** 23:22; 24:2;  
210:19, 21  
**sensitivity** 282:12; 318:8  
**sensoring** 210:19  
**sensory** 92:6; 283:8  
ent 69:5, 7; 100:25;  
1:10  
**sentence** 194:15; 220:5;  
311:11; 312:14  
**separate** 93:25; 141:25;  
142:3, 6  
**separated** 115:24;  
307:25  
**separately** 307:7  
**separates** 141:21  
**September** 174:22  
**sequelae** 110:7, 16;  
233:8, 16; 238:22  
**sequence** 296:13  
**sequentially** 46:18; 47:1;  
50:20; 67:19; 82:11;  
296:11  
**serial** 199:19; 271:2;  
283:2  
**series** 56:24; 69:13;  
100:22; 101:11, 12;  
107:22; 112:13; 176:15;  
251:24; 253:18; 272:25  
**serious** 14:9; 64:15;  
173:9; 208:4; 246:20;  
274:11; 300:18; 312:17  
**Sermin** 273:11, 11  
**serum** 171:24; 174:9;  
21:15  
**serve** 14:24; 42:7; 155:4;  
21:2; 295:12  
**served** 7:16; 45:11  
**serves** 157:13; 277:13  
**session** 72:22  
**sessions** 73:2

**set** 29:8; 72:8; 264:6;  
281:19; 282:16; 293:15;  
316:23  
**sets** 58:7; 132:2; 168:8;  
218:7; 280:17; 289:3  
**setting** 14:8, 25; 16:9, 14;  
24:6; 183:6; 213:19;  
215:17; 250:2; 271:24  
**seven** 47:13; 117:18;  
176:9; 178:22; 314:16  
**seventies** 127:10  
**several** 10:19; 66:25;  
161:10; 197:14; 207:11;  
226:18; 248:15  
**severe** 12:8; 61:5, 6, 8, 9,  
9, 13; 64:20; 65:22; 68:20;  
70:13, 14, 15, 20; 72:18;  
75:15; 76:13; 81:4, 11, 17,  
20; 82:3, 4; 104:3; 115:7,  
25; 116:7, 9, 14, 20;  
117:12; 171:21; 172:13,  
15, 22; 173:1, 2, 3, 11, 12,  
13, 17; 179:20; 181:23;  
190:1; 191:5; 194:7;  
196:17; 198:1; 212:1, 5;  
218:14; 219:2; 220:8, 19,  
20; 245:7; 272:10  
**severely** 295:15  
**severity** 117:21; 172:24;  
183:5, 8; 184:8  
**SGOT** 191:14  
**shaking** 236:17  
**Shall** 291:7; 314:13  
**shape** 159:7  
**share** 132:19; 247:15  
**shed** 226:3  
**sheets** 251:23  
**shift** 97:21; 127:25  
**shift—with** 127:23  
**shipped** 119:5  
**shock** 182:14  
**short** 22:1; 32:12; 44:17;  
95:16; 154:3; 157:21;  
246:9; 253:7, 8, 12; 294:24  
**short-lived** 267:19  
**short-term** 28:2  
**shorter** 301:4  
**shortly** 161:1; 253:10  
**show** 49:19; 50:23;  
55:18; 56:18; 65:15;  
77:12; 103:11; 106:21;  
112:24; 113:4; 115:17;  
120:4; 123:8; 124:2;  
127:11; 131:6; 138:7;  
140:10; 145:12; 148:20;  
149:1; 154:11; 160:3;  
188:1; 208:16; 219:4;  
221:2; 229:16; 241:2;  
246:5; 254:15; 256:4, 9,  
12; 262:20; 267:13; 269:1;  
278:12; 281:16; 283:1;  
300:9; 314:23; 317:6  
**showed** 38:23; 24:39:1;  
55:1, 21; 56:7; 106:12;  
114:18; 134:25; 146:6;  
147:9; 181:16; 196:15;  
212:10; 217:15; 254:8;

275:23; 278:11; 288:25;  
290:7; 303:14, 16  
**showing** 16:6; 115:17;  
149:11; 153:18; 155:14;  
254:10; 260:19; 299:17  
**shown** 20:20, 21, 23;  
32:11; 33:10; 39:19, 20;  
41:13; 49:7; 52:12, 12;  
54:14; 59:19; 84:4; 96:24;  
97:5; 107:8; 121:12;  
122:2; 134:24; 143:21;  
176:2, 4; 178:22; 215:3;  
225:13; 235:2; 275:7;  
277:8; 285:10; 287:6;  
288:8; 297:15; 309:13, 13,  
314:5  
**shows** 21:15; 51:1; 53:1;  
55:19; 56:20; 57:21;  
58:11; 60:22; 65:16;  
68:18; 73:8; 74:13; 77:8;  
106:9; 120:23; 125:12;  
127:12; 138:10; 169:21;  
173:15; 191:8; 199:18;  
215:2, 10; 262:22; 277:9;  
281:23; 290:6; 293:19, 20  
**Sid** 4:2; 111:6; 255:15  
**side** 31:11; 32:11; 64:15;  
85:14; 86:8; 92:23; 93:4;  
195:19; 198:16; 273:3, 12,  
16; 320:16; 321:22; 322:3  
**sides** 258:4  
**sign** 116:23  
**signal** 6:10  
**signed** 92:21  
**significance** 286:11;  
289:5; 290:16  
**significant** 14:17; 23:19;  
29:2; 31:2; 46:16, 23, 25;  
50:21; 51:7, 14, 22; 52:10,  
21, 22; 53:23; 54:12;  
56:18; 66:1; 67:22; 68:1;  
79:18; 80:13; 82:11, 13,  
13; 83:22; 85:3; 93:19;  
94:7, 25; 95:7; 103:11;  
106:9; 114:10; 117:6;  
119:24; 120:4, 10, 21;  
127:12; 129:14; 143:25;  
169:25; 178:21; 195:12;  
205:11; 208:11; 209:17;  
20, 23; 210:3, 5, 8, 9;  
218:19; 222:11; 270:18;  
279:12; 288:24; 290:13;  
297:7, 9, 10  
**significant—AI** 208:17  
**significant—this** 142:25  
**significantly** 56:8, 16;  
60:3; 94:14, 19; 120:25;  
168:21; 188:23; 205:15,  
17, 20; 215:10; 225:5  
**signs** 178:15; 212:22  
**silence** 161:23  
**silent** 151:8; 271:15  
**similar** 16:2, 18, 19;  
97:22; 139:23; 172:9;  
189:24; 191:13; 192:18;  
205:25; 212:23; 221:6;  
222:2, 14; 230:1; 256:7,  
10; 265:18; 286:10, 16, 20;

287:1; 289:1  
**similar—in** 217:9  
**similarities** 137:13  
**Similarly** 16:10  
**simpler** 108:3  
**simply** 18:3; 303:9; 313:3  
**simply—that** 293:21  
**Sinai** 5:6  
**sincerely** 242:4  
**sine** 13:7  
**single** 13:21; 14:1, 6;  
16:9; 29:10; 32:4; 40:3;  
42:10; 46:6; 48:23;  
174:15; 176:24; 177:1, 2;  
188:22; 194:13, 16;  
320:12  
**single-arm** 248:1  
**single-center** 40:20;  
42:9; 168:9  
**sinusitis** 183:4  
**sisters** 158:16  
**sit** 308:11  
**site** 74:7, 15; 75:6; 88:25;  
119:5; 134:19; 188:15  
**sites** 25:8; 57:10; 69:7;  
72:12, 13, 22, 25; 73:6  
**sitting** 313:25  
**situation** 16:1; 165:11;  
213:25; 243:25; 250:8;  
282:9  
**situations** 66:12; 110:15;  
192:3; 221:4; 268:8  
**six** 97:24; 102:11; 117:16;  
119:20; 146:19, 20; 172:7;  
176:9, 11; 178:5; 190:23;  
197:20, 22, 22, 25; 276:22;  
299:21, 22; 304:24; 317:7  
**size** 23:15; 143:18; 216:2;  
288:22  
**size—the** 24:5  
**sized** 205:23; 221:20  
**sizes** 269:16, 20  
**Slide** 9:4, 21; 10:3, 14;  
11:1, 2, 13; 12:6, 23;  
13:18, 23; 14:2; 15:6, 18;  
16:24; 17:9; 18:18; 19:4;  
20:12; 21:5; 22:6; 24:7, 18;  
25:10; 26:7, 16, 24; 27:8;  
30:22; 31:5, 12; 32:17, 24;  
33:17, 23; 34:10, 18; 35:4,  
14; 41:9, 13, 14; 42:2, 20;  
43:5, 22; 44:9, 13; 45:5;  
46:1; 47:9, 18; 48:14;  
49:17, 18; 50:6, 15, 24, 25;  
51:1, 10, 17, 25; 52:8, 14,  
15, 25; 53:5, 15; 54:1, 14,  
15, 23; 55:5, 12, 17, 18;  
56:6, 23; 57:20, 21; 58:6,  
15, 19; 59:2, 16; 60:14;  
65:15, 18, 19; 68:18, 19;  
69:15; 70:14; 73:8, 9; 74:8,  
13, 19, 22; 76:14; 77:6, 7,  
8; 79:24; 96:5, 13, 15, 22,  
24, 25; 97:25; 98:15;  
101:21; 102:15; 104:5, 12,  
14; 105:1; 106:23; 108:1;  
113:6, 7, 9; 114:2, 3, 18,



186:13, 16; 187:5, 8, 11, 13, 14; 188:5, 8, 8, 9, 13; 9:4, 17; 190:13, 16; 9:9; 193:20; 194:10; 196:16; 197:11, 19, 20; 201:5; 205:2, 24; 212:6; 215:1, 2, 9, 10, 15, 25; 216:2, 8, 10, 21, 24; 217:11; 218:9; 221:17, 18, 20; 222:1, 3, 9, 13, 14, 14; 223:10, 21, 23; 224:2; 225:4, 7, 12, 25; 231:8, 9, 22; 232:23; 233:2, 14; 235:1, 18; 237:2, 11, 16, 21, 24; 238:9; 240:24; 241:10; 245:14; 246:8; 247:1, 4, 13, 15, 20, 21; 254:1; 261:19; 263:10, 14; 265:11; 266:9; 268:11, 21, 21; 270:20; 271:11, 17; 272:17; 273:3, 23; 277:8, 16; 278:4, 6; 279:3, 24; 282:17, 23; 283:5; 284:17, 18; 288:14, 23; 293:12; 294:9; 297:17, 21; 298:10; 299:13, 19; 301:9; 302:24; 304:25; 305:13, 16  
**study--and** 47:7; 61:3; 248:11  
**study--indicates** 44:5  
**study--is** 137:6  
**study--just** 109:15  
**udy--looking** 127:16  
**udy--patients** 140:22  
**study--rather** 120:14  
**study--the** 137:5  
**study--whereas** 120:14  
**studying** 161:24  
**stuff** 155:16  
**subgroup** 76:19; 238:4  
**subgroups** 14:19; 130:1; 256:13  
**subject** 82:22; 101:9; 182:10; 293:14  
**subjected** 229:6  
**subjects** 200:8; 223:15  
**submit** 24:22  
**submitted** 6:19; 9:14; 10:12; 26:18, 25; 47:8; 132:3; 134:24; 137:19, 22; 181:3; 306:16; 314:16, 21; 315:2; 317:3, 9  
**subsequent** 82:21; 161:3; 200:16; 265:16; 271:7  
**subsequently** 84:7; 110:25; 226:8  
**subset** 12:18; 28:3; 57:8; 60:13, 15; 76:23, 24; 77:13; 78:1, 3; 136:16; 8:25; 211:7; 216:8; 1:17; 241:1; 280:10, 23; 281:19; 286:14  
**subsets** 129:14  
**substantial** 13:8, 16, 20; 15:3, 5, 20; 20:20; 24:15; 26:18, 20; 27:1; 152:8;

217:18; 246:18; 282:18; 291:8, 10; 306:16; 313:19; 314:17  
**substitute** 309:6  
**substitutes** 154:15  
**subtype** 228:4; 261:25  
**subtypes** 226:18; 309:7  
**success** 164:24; 207:17  
**successful** 204:21; 207:5; 275:14  
**successfully** 165:2  
**successive** 228:17  
**succinctly** 252:1  
**suffer** 81:20  
**suffering** 165:12; 246:20  
**Suffice** 257:15  
**sufficient** 15:20; 24:13; 264:4; 315:2; 317:4, 8; 322:5  
**sufficiently** 17:2  
**suggest** 21:2; 58:8; 123:6; 126:2, 7; 222:5; 319:4  
**suggested** 288:21; 292:5  
**suggesting** 78:18; 135:8; 212:22; 263:4  
**suggestion** 195:12; 248:22; 287:3  
**suggestion--but** 312:24  
**suggestive** 178:16; 187:22; 188:4  
**suggests** 25:18  
**summarize** 62:19  
**summary** 34:25; 35:2; 179:17; 297:6  
**summed** 229:1  
**superimposed** 227:15; 241:22  
**superior** 205:3  
**support** 16:21; 26:18; 27:4, 11; 30:25; 58:25; 163:11; 166:16; 193:9; 222:16; 232:24; 275:18; 279:3, 6, 13; 291:10; 300:13; 306:16; 311:4; 314:3, 6, 17  
**supported** 245:24  
**supporting** 34:21; 35:10; 229:8; 253:22  
**supportive** 166:2, 5; 223:3; 276:4  
**supports** 34:13, 23; 56:21; 131:5; 215:9  
**Suppose** 273:23  
**supposed** 154:12; 193:7; 251:7  
**supposedly** 219:12  
**suppression** 181:21  
**supraspinal** 48:11  
**sure** 37:19, 23; 38:4; 68:8; 72:23; 78:7; 84:5; 90:25; 92:20, 22, 24; 100:15; 114:22; 131:1; 141:12, 17; 149:15; 159:3, 21; 164:7, 10; 166:17;

186:7; 204:10; 221:11; 235:14; 245:10; 251:6; 264:9; 274:9; 279:14; 284:20; 293:11; 294:14; 297:15; 302:5, 5, 12, 13, 14; 304:25; 313:16; 319:4  
**surgery** 293:24  
**surprised** 286:1  
**surprises** 137:9  
**surprising** 60:11  
**surrogate** 20:13, 21, 21; 21:8, 19, 22; 22:1, 8; 23:6, 8, 14; 147:19, 19, 23; 148:5, 7; 151:18, 24; 152:3, 17; 153:23, 25; 154:18, 19, 24; 155:4, 6, 12, 20; 263:25; 265:19, 21; 275:4; 276:3, 3, 8, 14, 17, 20; 277:1, 14; 278:15, 21; 279:8, 13; 280:24; 281:1, 6; 282:10; 283:24  
**surrogates** 21:18; 22:5; 154:14; 281:12  
**surrounding** 125:13  
**survey** 226:19  
**survival** 60:22; 204:24  
**susceptible** 186:24; 247:4; 251:4  
**suspect** 38:14; 319:13  
**suspicion** 90:20  
**suspicious** 280:13  
**sustained** 53:8; 134:11  
**SWAIN** 5:10, 10; 7:4; 9:1; 39:9; 78:12, 13; 79:21; 80:24; 81:1; 88:15; 89:10; 125:7, 23; 126:1; 180:2, 3, 18; 181:5; 187:3, 4; 188:9; 190:21, 22; 191:3, 20; 192:1, 23; 199:12, 13; 212:17; 249:5; 250:18, 24; 273:6  
**Swain's** 199:24  
**sympathetic** 235:9  
**symptom** 81:14; 86:17; 149:5; 157:14  
**symptomatic** 17:18; 18:4; 78:16, 19, 25; 79:4, 19; 86:13, 22; 92:13; 102:14; 123:23; 124:1, 14, 19; 134:1, 2; 135:23; 144:19; 150:9; 263:4, 4; 267:11  
**symptomatically** 80:10; 185:13  
**symptoms** 16:19; 68:24; 70:17, 22; 81:4; 123:10, 12; 124:16; 134:5; 152:14; 162:14, 21; 178:15; 212:22; 238:16; 264:16; 267:16; 283:5  
**syndication** 199:6  
**synthesis** 32:20  
**synthetic** 32:18  
**system** 21:15; 39:15; 44:2; 58:10; 101:15; 126:13; 165:16; 207:18; 208:3; 257:3, 24; 300:5

**systemic** 125:23; 190:16  
**systems** 44:3; 47:13; 48:9; 189:5; 313:2

## T

**T-2-weighted** 277:23  
**T-cells** 33:4  
**T-helper** 127:14  
**T-lymphocytes** 127:14  
**T1-weighted** 57:2  
**T2** 57:4; 58:12; 142:21; 149:8, 21; 151:1, 3, 11; 153:2, 18; 271:13; 283:4; 288:7  
**T2-weighted** 58:12, 13, 17; 143:1, 8, 15, 16; 153:12  
**table** 4:4; 29:25; 88:7; 108:8; 147:25; 195:5; 209:1; 223:6; 253:4; 270:6; 278:10; 295:22; 304:3, 3; 305:20; 308:18; 318:24  
**tables** 304:21  
**tachycardia** 179:3  
**tailored** 159:24  
**tainted** 90:21  
**talk** 5:19; 9:8; 10:10; 23:13; 28:19; 54:2; 62:2; 66:20; 75:25; 80:6; 90:3; 94:10; 99:17; 135:22, 23; 138:3; 157:16; 158:24; 160:14; 168:5; 177:23; 208:7; 217:23; 239:24; 242:11; 257:1; 276:15; 298:5; 308:2, 2; 318:11  
**talked** 15:13; 122:16; 189:5; 276:19  
**alking** 22:16; 23:1, 22; 60:13; 76:1; 95:2, 2; 99:4; 116:11, 13; 122:13; 129:13; 135:20; 137:18; 196:2; 199:25; 204:25; 213:1; 242:17; 244:3; 259:22, 23; 267:4; 271:25; 285:17; 286:6; 287:17; 292:3  
**talks** 14:13; 20:25; 151:24; 276:14  
**target** 126:1; 223:1; 224:19  
**task** 82:25; 236:12, 23; 274:20  
**team** 5:17; 26:11; 30:16  
**Tech** 157:24  
**technical** 154:10  
**Technically** 20:9, 63:20  
**technique** 23:23  
**techniques** 19:25  
**television** 166:9  
**telling** 238:13; 277:18; 298:23, 24  
**tells** 190:6; 232:4  
**Temple** 30:1, 3, 3; 38:15, TH-2 128:1



274:23; 275:16; 278:11;  
288:12, 20, 25; 289:4  
*l-and* 123:17  
*al-in* 14:19  
**trials** 8:12; 10:5, 8, 21;  
13:10; 16:6, 11; 17:1; 18:7,  
17, 20, 21; 24:10, 11;  
33:15; 34:1; 40:18, 19;  
41:7, 25; 42:18; 80:11;  
86:11; 87:7; 137:14;  
160:3; 167:16, 23; 168:8;  
174:25; 176:4, 13; 180:5,  
12, 24; 181:13; 198:6;  
200:19; 211:15; 212:10;  
213:3; 217:21; 222:10;  
228:5; 229:9; 230:20;  
246:5; 253:22; 254:4, 7;  
262:20; 266:12; 268:11;  
269:1, 2; 271:20; 274:23;  
275:13, 14; 279:19; 281:3,  
11; 287:18; 288:12;  
310:15, 18, 21  
**tried** 111:23; 125:8;  
130:18; 177:17; 208:5;  
245:21; 290:2  
**tripping** 157:19  
**trivial** 235:8  
**trouble** 157:14; 244:4  
**troubling** 229:12  
**true** 11:23; 59:21; 61:4,  
14; 65:3; 67:15; 72:10;  
84:16; 122:5, 14; 134:9;  
17:9; 219:17, 22; 287:6;  
295:12; 297:2, 3, 4  
**truly** 152:11; 228:25  
**trust** 41:3; 219:14, 18;  
221:12  
**trusting** 81:7  
**truth** 136:13  
**try** 71:8; 134:11; 203:1;  
204:6, 9; 207:10, 12;  
209:10; 236:10; 248:8;  
249:20; 262:17; 274:16;  
302:17; 303:23; 304:2;  
321:14  
**trying** 13:5; 65:13; 75:24;  
116:10, 25; 124:6; 130:23;  
133:24; 137:11; 199:17;  
204:5; 232:21, 23; 235:7,  
11; 289:10; 291:4; 304:9  
**tumor** 19:24  
**tumors** 31:21; 125:11, 13  
**turn** 28:5; 50:7; 51:18;  
59:3; 104:6; 105:2;  
106:24; 121:5; 163:3;  
182:5; 214:25; 245:16;  
265:24; 278:3; 280:10  
**turns** 63:22; 71:8, 11;  
160:24; 161:4; 244:15  
**Twelve** 32:10  
**venty** 176:16  
*ice* 312:13  
**twins** 160:21  
**twists** 161:4  
**two** 7:17; 10:4, 8, 23;  
11:16; 12:9, 11; 13:9; 16:5,  
11, 25; 24:11, 19; 31:6

---

**U**

**Ulm** 174:18  
**ultimate** 155:11; 296:3  
**ultimately** 152:4; 270:11;  
286:16, 20, 25; 288:9;  
321:11  
**ultrasound** 189:6, 11  
**unmasked** 218:9  
**unable** 72:17; 177:14;  
194:23  
**unanimous** 314:24;  
318:20  
**unblinded** 11:25; 12:4,  
22; 18:23; 19:10, 17; 62:6,  
14, 20, 22, 24; 63:12; 67:2;  
114:17; 135:21; 186:24;  
206:10; 216:21; 217:12;  
268:11; 269:11; 270:14;  
274:1, 6, 23; 303:7; 305:15  
**unblinded-or** 273:8  
**unblinded-l** 122:22  
**unblinding** 19:13; 62:9,  
17; 83:3, 20, 21; 93:4;  
268:14; 269:24; 305:14  
**uncertain** 159:16  
**unchanged** 58:15;  
105:6; 107:3; 120:15  
**unclear** 67:8, 12; 228:21  
**uncomfortable** 92:20;  
137:18; 253:12; 307:12;  
308:24  
**under** 9:3; 20:17; 24:12;  
136:6, 18; 174:18; 221:18;  
228:14; 230:1; 232:2, 4;  
233:7; 237:3, 5; 238:23;  
239:18; 240:8, 20; 241:14;  
243:4; 244:25; 245:22;  
246:4; 247:16; 248:1, 3;  
254:4, 7, 15; 256:13;  
257:10; 258:4, 10; 261:5;  
262:20; 263:3; 268:7, 15,  
25; 269:7; 276:1, 18;  
279:25; 280:4; 281:3;  
285:13; 286:5; 288:12;  
290:19; 297:12; 298:6;  
299:13; 303:10; 304:3, 5,  
21; 307:5; 308:1, 4; 309:7;  
310:9; 316:17; 320:23;  
321:2  
**two-thirds** 211:18  
**type** 22:8; 49:21; 65:20;  
66:14; 81:22; 114:7;  
128:12; 134:14, 15;  
137:15; 172:8; 189:24;  
222:24; 242:1; 257:8;  
266:16  
**types** 10:2; 17:1; 131:7;  
226:23; 228:3; 256:23  
**typical** 23:16, 21; 24:6;  
25:6; 49:22; 87:7; 103:23;  
115:16; 167:22; 176:18;  
216:12; 222:10

**U.S.** 47:21; 48:12; 161:2;  
202:21; 249:17  
**U.S.-and** 196:1

**universal** 257:16  
**universally** 80:10  
**University** 4:14, 23; 5:2,  
4, 8, 13; 34:24; 35:18;  
162:3; 164:5; 174:18  
**unknown** 28:15, 20;  
183:4; 184:6  
**unless** 162:16; 282:15;  
290:25; 321:25  
**unlikely** 85:25; 177:2;  
178:25; 179:5; 190:2;  
218:19  
**unmask** 64:9  
**unmasked** 62:22; 66:16;  
67:16; 98:13; 103:3;  
131:18; 187:19; 217:1;  
218:6  
**unmasking** 54:20; 217:2;  
218:10  
**unmet** 41:4  
**unparsimonious** 281:8  
**unpredictable** 162:13  
**unreliable** 19:12; 83:12  
**unsuccessful** 275:14  
**unsympathetic** 219:21  
**untreated** 145:18;  
150:23; 163:9  
**unusual** 29:22  
**up** 24:2; 25:19; 27:14;  
32:3; 34:23; 38:1; 43:14;  
70:4; 109:2; 113:4; 118:4;  
122:1; 123:1; 126:20;  
130:7; 133:24; 139:9;  
144:3; 149:16; 150:9;  
165:22; 167:5; 181:19;  
191:8; 195:18; 198:6;  
208:21; 213:5; 216:24;  
231:16; 240:15; 251:16;  
254:16; 258:16; 259:14;  
14, 15, 15; 261:11; 282:1,  
6, 23; 283:18; 298:4, 22;  
299:2, 3, 8, 9, 15; 309:17  
**upon** 8:4; 14:8; 36:19;  
126:12; 153:3; 162:3;  
207:18; 208:4; 262:23;  
265:22, 23; 283:7; 318:8  
**upper** 44:5; 183:3, 16  
**urgency** 258:6  
**urinary** 183:3, 15, 22;  
184:8, 23; 185:6, 10, 12,  
21; 186:1, 4; 190:10  
**urine** 63:22; 184:11;  
189:5  
**us-l** 277:18  
**usage** 79:19; 316:2  
**use** 7:5; 17:15; 18:15;  
22:5, 7; 23:13, 17; 24:11;  
27:17, 21, 22, 23; 32:19;  
34:14; 35:19; 40:24;  
71:21, 23; 72:8; 79:11;  
121:6; 140:4, 5, 16; 141:8;  
145:14; 147:14; 148:17;  
149:25; 152:11; 154:12;  
161:23; 165:9, 9, 10;  
171:16; 172:23; 174:14;  
179:8; 206:17, 22; 207:4;  
211:1; 215:16; 237:21;

---

**V**

**valid** 153:18; 207:23  
**validated** 20:23; 29:17;  
275:6  
**validation** 305:18  
**validity** 29:19; 118:20  
**valuable** 151:24; 209:18;  
281:5  
**value** 54:8; 60:12; 83:19;  
106:2, 5; 107:7, 25; 287:21  
**value--sorry--so** 208:15  
**values** 14:18; 50:11;  
54:13; 60:14; 77:13, 15,  
16; 101:18; 107:23; 144:1;  
151:8; 208:16  
**valve** 178:25  
**VAN** 5:3, 3; 83:15, 17;  
107:12, 13; 204:23

**Food and Drug Administration  
Peripheral & Central Nervous System Drugs**

**Hearing  
January 28, 2000**

208:18, 19, 24; 209:16; 253:6, 7, 8; 306:19	<b>vomiting</b> 272:24	<b>weeks--so</b> 187:25	<b>who--I</b> 68:22	<b>women</b> 92:25; 170:23; 175:23; 192:10, 13, 17; 193:7, 9, 13, 20
<b>Vanik</b> 157:5, 6, 7, 8; 160:12	<b>vomiting--or</b> 269:19	<b>weigh</b> 279:11	<b>whole</b> 100:22; 103:25;	<b>Women's</b> 7:13; 95:21
<b>variability</b> 93:18	<b>vote</b> 9:7; 27:15; 252:13, 14; 253:2; 291:7; 294:19; 306:18, 22, 24; 307:22; 308:20; 313:10, 18, 20; 314:8, 13; 317:1; 320:3; 322:15	<b>weighing</b> 213:22	<b>112:20; 136:12; 149:23;</b>	<b>wonder</b> 35:25; 59:13; 87:6; 108:12; 121:7;
<b>Variable</b> 46:23, 24, 24; 77:12; 91:13, 18; 209:21; 227:25	<b>voted</b> 320:20	<b>weight</b> 92:7; 294:10	<b>264:25</b>	<b>195:17; 207:5; 230:15;</b>
<b>variables</b> 46:7, 7, 11, 17; 50:19, 21, 23; 52:2, 17, 19; 56:17; 67:14, 18, 19, 24; 77:2, 14; 206:8, 10; 216:4	<b>votes--the</b> 314:16	<b>weighted</b> 48:10; 57:5; 58:13	<b>232:25</b>	<b>236:15; 248:25; 256:19;</b>
<b>variant</b> 17:21	<b>voting</b> 251:22; 252:7, 12, 18, 21; 298:14, 15; 299:25; 301:12, 12; 306:15; 307:11; 314:8; 317:4	<b>Weiner</b> 7:8, 11; 95:18, 20, 20, 24; 111:8; 112:21; 124:22; 126:25; 127:19, 22; 128:8; 129:1, 9, 17; 130:5, 24; 150:19; 153:7, 8, 15; 155:7; 194:5, 6; 200:11, 12; 201:11; 239:4, 5, 7; 250:17; 252:3, 4, 13, 17, 22; 256:21; 259:6, 18; 260:5; 270:23; 271:8, 25; 272:3; 275:11; 276:6, 7, 24; 278:3, 14; 281:9; 282:7; 283:11; 285:2; 286:13; 287:11, 15; 294:19; 303:22; 306:2; 311:18; 313:24; 314:3; 315:6	<b>wide</b> 243:2	<b>262:2; 274:25</b>
<b>variation</b> 71:14; 224:5	<b>VP-16</b> 40:10	<b>Weiner's</b> 7:13; 240:19	<b>widely</b> 24:11; 298:6	<b>wondered</b> 59:12; 143:2
<b>variations</b> 71:16, 17		<b>welcome</b> 5:23; 8:22; 252:8, 19	<b>Wilcoxin</b> 210:20	<b>wonderful</b> 159:3, 21;
<b>various</b> 10:2; 14:19; 71:11; 79:20; 130:17; 178:23; 204:10; 256:17; 288:17		<b>well-is</b> 149:16	<b>willing</b> 248:14; 249:9; 263:18	<b>160:4, 10</b>
<b>vary</b> 92:1; 263:18		<b>well--the</b> 207:7	<b>window</b> 38:13; 212:9	<b>wondering</b> 29:9, 23;
<b>vascular</b> 164:21		<b>well--they</b> 238:21	<b>wiping</b> 152:13	<b>60:24; 81:16; 82:14, 18;</b>
<b>vast</b> 15:16		<b>well-characterized</b> 211:4, 14; 216:5	<b>wisdom</b> 231:2	<b>115:14; 116:8; 147:20;</b>
<b>vein</b> 285:25		<b>well-conducted--Study</b> 167:16	<b>wisely</b> 289:11	<b>223:15; 300:21, 24</b>
<b>veins</b> 162:15		<b>well-controlled</b> 13:10, 11, 21; 16:6; 215:24; 268:25	<b>wish</b> 6:11; 8:4; 68:8; 108:10; 122:7; 248:20; 249:10; 253:4	<b>word</b> 17:15; 68:11;
<b>ventricular</b> 36:10; 37:2; 169:22		<b>well-defined</b> 20:25; 27:3; 62:24; 211:7; 217:19; 218:15; 274:11	<b>wishes</b> 307:8	<b>150:19; 240:12; 285:12;</b>
<b>verified</b> 64:22		<b>well-designed</b> 229:8; 246:4; 305:13	<b>withdraw</b> 102:21; 103:7	<b>16, 18; 287:11; 291:25;</b>
<b>versus</b> 11:5; 50:12; 52:7; 53:24; 55:6; 58:1; 75:19; 81:18; 86:5; 89:14; 119:20, 25; 120:16, 20; 125:23; 129:5; 130:3; 143:17; 210:10, 11; 304:13, 24		<b>well-evaluated</b> 213:3	<b>withdrawal</b> 17:22, 24;	<b>312:13; 314:11</b>
<b>very,k</b> 274:2		<b>well-expected</b> 256:4	<b>223:15; 300:21, 24</b>	<b>worded</b> 307:11, 14, 21;
<b>vessels</b> 126:12		<b>well-informed</b> 207:8	<b>313:12</b>	<b>313:12</b>
<b>via</b> 228:14		<b>well-known</b> 28:14; 92:23; 273:12	<b>wording</b> 260:23; 285:4;	<b>words</b> 14:11, 20; 29:11;
<b>Vice</b> 30:14		<b>well-taken</b> 94:22	<b>withdrawn</b> 48:20	<b>70:4; 109:23; 114:10;</b>
<b>view</b> 16:17; 22:18; 25:14; 82:19; 95:3; 134:4; 148:15, 15; 149:14; 151:18; 206:20; 219:21; 245:19; 252:5; 258:5; 260:1; 265:18; 267:9; 274:10; 292:15; 294:20; 310:19, 22; 315:4		<b>well-tolerated</b> 41:24; 246:6	<b>withdrew</b> 101:25;	<b>122:19; 130:2; 131:20;</b>
<b>viewed</b> 148:4; 258:25		<b>weren't</b> 106:18; 150:1, 1; 289:17; 293:16; 297:10	<b>102:11, 12, 13; 103:4;</b>	<b>214:4; 238:24; 258:8, 24;</b>
<b>views</b> 148:4; 252:18; 253:1; 282:13; 313:17		<b>what's</b> 289:14	<b>105:16; 106:3, 7, 13; 107:5</b>	<b>260:12; 261:11; 281:21;</b>
<b>Virginia</b> 157:24		<b>what-have-you</b> 13:15	<b>within</b> 31:3; 32:22; 37:24;	<b>292:1; 311:4, 10</b>
<b>virtually</b> 209:5; 271:11		<b>whatever--and</b> 242:2	<b>53:19; 88:25; 110:6, 16,</b>	<b>words--the</b> 295:8
<b>visibility</b> 62:3		<b>whatever--if</b> 112:1	<b>23:144:10; 145:1; 158:3;</b>	<b>wordsmithing</b> 308:23;
<b>vision</b> 157:15; 162:17		<b>whatsoever</b> 274:7	<b>163:4, 6; 181:21; 185:1;</b>	<b>310:2</b>
<b>visit</b> 72:17		<b>wheelchair</b> 44:8; 158:5, 7; 163:6; 240:16	<b>233:7, 22</b>	<b>work</b> 78:21; 82:14;
<b>visits</b> 118:3, 4, 7		<b>whereas</b> 51:6; 78:17;	<b>without</b> 124:6; 184:4;	<b>146:10; 154:22; 157:25;</b>
<b>visual</b> 312:18		<b>ways</b> 16:2; 206:16; 249:3; 290:19; 315:14	<b>224:10; 227:15; 229:7;</b>	<b>158:7; 159:11, 22; 160:10,</b>
<b>vitamins</b> 79:6; 80:2		<b>weakness</b> 296:8	<b>230:21; 233:19; 265:12;</b>	<b>21:162:4, 5; 164:7; 165:3;</b>
<b>vitro</b> 33:14; 38:23		<b>weekly</b> 173:22; 212:7	<b>267:3; 271:22; 278:7;</b>	<b>166:8; 208:14; 262:15, 16;</b>
<b>vivo</b> 33:11, 14; 38:23		<b>weeks</b> 31:21, 23; 37:19; 41:20; 123:16; 181:22; 225:1	<b>279:5, 20; 296:4; 315:21;</b>	<b>294:5, 5; 295:21; 311:21;</b>
<b>volume</b> 151:1, 3, 12; 153:19; 170:4; 271:13; 283:3		<b>white</b> 37:17; 68:6; 128:3; 149:12; 150:14; 157:9; 183:7, 11; 184:13; 190:15	<b>323:3</b>	<b>313:15, 21; 323:7</b>
<b>volumes</b> 189:5; 288:8			<b>WOLINSKY</b> 5:1, 1; 7:8, 16:8; 25; 66:23; 71:6, 7; 72:2, 11, 21; 73:4, 12, 18, 21; 74:1, 25; 75:3, 23;	<b>worked</b> 161:10; 178:17;
<b>volumetric</b> 152:11			<b>76:4, 15; 78:10, 13; 89:18;</b>	<b>206:2</b>
<b>volunteered</b> 166:1			<b>92:10, 12, 18; 105:11;</b>	<b>working</b> 135:25; 158:6,

worsened 113:20, 21;  
119:15, 20; 234:8, 11;  
258:24; 304:10  
**worsening** 51:4, 5, 13,  
20; 81:13, 14; 93:14;  
94:13; 103:6, 106:16;  
108:7; 109:7; 110:7, 17,  
23; 112:25; 116:22;  
143:10; 227:12, 24;  
228:14, 15, 18, 22; 230:3;  
232:15; 234:6; 240:12, 14,  
15, 17; 260:5; 261:2, 9;  
262:8, 14; 285:6, 8, 8;  
287:12; 288:10; 289:24;  
295:8; 304:9; 308:12, 13;  
309:3, 6, 9, 22; 310:6, 10;  
311:16, 23, 25; 312:1, 12;  
313:4, 6; 314:12  
**worth** 40:21; 76:5;  
123:20; 124:6; 136:10;  
267:4; 279:2; 299:8, 12;  
323:3  
**wound** 118:3  
**wrestle** 292:7; 308:21  
**wrestling** 292:1  
**write** 166:8  
**written** 14:3; 143:12;  
154:16, 17; 233:2; 309:17  
**wrong** 11:2; 273:13, 14;  
310:8  
**wrong—are** 309:8  
**wrongly** 278:20  
**vote** 11:21  
**Wurzberg** 130:19

## X

**x-rays** 164:21  
**xanoflex** 80:15  
**Xenocar** 38:24

## Y

**year** 12:10; 29:12; 44:20;  
49:24; 54:10, 10, 17;  
55:15; 56:13; 57:7, 7, 23,  
23, 23; 58:2; 77:10, 11, 19;  
104:1; 109:8; 120:12, 13,  
13; 122:1, 2; 130:3;  
131:18; 132:12, 14, 17;  
133:7, 10; 145:19; 150:24;  
161:23; 164:12, 19;  
169:15, 15, 15, 24, 24, 24;  
170:9; 192:4, 8, 15;  
193:12; 247:12; 260:14;  
261:2, 8, 15  
**year's** 232:3  
**year-old** 103:24  
**years** 7:17; 8:11; 10:17;  
18; 25:25, 25, 25;  
26:10; 40:21; 43:4; 48:5;  
49:8, 14, 16, 23; 54:6, 10;  
60:19; 85:8; 96:16;  
103:24; 121:23; 130:3, 4,  
22; 133:11; 135:3; 138:18,  
21; 139:17, 20; 152:6

157:22; 158:1, 4, 20;  
161:10; 162:25; 163:4, 6;  
164:9, 11, 17; 165:6, 18;  
170:21; 171:8; 174:17;  
176:7, 25; 179:12; 180:17;  
181:4; 193:10; 197:11, 14;  
200:6; 213:12, 17; 233:10,  
12; 242:2, 2, 19; 246:15;  
266:5, 14; 276:1, 18;  
277:3, 5; 280:4; 294:23;  
296:3, 3, 8, 24; 299:8, 15;  
302:3; 304:25; 305:19;  
315:24, 25; 316:5  
**yellow** 52:12; 53:3;  
104:17; 105:5; 239:1  
**yes—I** 314:3  
**yesterday** 134:25;  
160:20  
**yielding** 14:17  
**York** 5:6; 161:11  
**you—and** 250:18  
**you—I** 173:3  
**young** 193:13; 197:10;  
266:10

## Z

**zero** 235:2, 4, 20; 282:21  
**zone** 126:15

## **Lawyer's Notes**

---